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CHAPTER I. INTRODUCTION. 
A drug which has entered the circulation, may be eliminated as such by 
the kidney and excreted in the urine. This depends on the lipid-solubility 
(lipophilicity) of the drug. In the kidney, lipid-soluble drugs are reabsorbed 
by the tubules, whereas water-soluble (hydrophilic) compounds cannot cross 
the tubular membrane. Upon passing through the liver some lipophilic drugs 
can be modified by conjugation with polar molecules, in order to be excreted 
in the bile or the urine, for example in the form of glucuronides. A large 
number of drugs, however, do not possess reactive groups for conjugation, 
They might tend to remain in the body, which is, in many cases, undesirable. 
In the liver, however, an enzyme system is present, which is capable of metab-
olizing these compounds by introducing polar groups with the aid of molecular 
oxygen, The metabolites produced may be excreted either directly or after 
subsequent conjugation, 
In 1958 Klingenberg (1) and Garfinkel (2) discovered a carbon-monoxide 
binding pigment in the endoplasmatic reticulum of liver cells. This pigment 
was further characterized by Omura and Sato (3,4) in 1964, and found to be 
a heme-protein, which they named cytochrome P-450. Thereafter, an increasing 
number of publications reported that cytochrome P-450-containing enzyme 
systems occur almost universally and have many different functions. High 
concentrations of cytochrome P-450 appeared to be present in the livers of 
mammals, where this heme-protein was found to catalyze the hydroxylation of 
various compounds, such as steroids, fatty acids and xenobiotics (compounds 
foreign to the body). Especially interesting is its ability to hydroxylate 
drugs, and it is because of this property that the hepatic cytochrome P-450 
system is often referred to as the drug metabolizing enzyme system. 
The magnitude and duration of the therapeutic effect of a drug is deter-
mined by various factors, apart from the properties of the drug itself. 
Important are, for example, the route of administration, and the pathway the 
drug follows through the body. From the above it is evident that the degree 
to which the drug is attacked by the cytochrome P-450 system is of great 
importance, This implies that factors which affect this system, may also in-
fluence the drug effect. Such factors are, for example, the nutritional 
status (5), disease (6), genetic variations (7), and, in some species, sex (8). 
Substances which are deleterious to the enzyme system, or the presence of 
other drugs, which compete for the same metabolizing enzyme, may lower the 
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rate of metabolism and potentiate the effect of a drug. Conversely, meta-
bolic activity may be considerably elevated by potent inducers of the enzyme 
system, such as barbiturates. This leads to a rapid inactivation of the drug, 
making higher doses necessary. 
As stated above, the cytochrome P-450 system not only metabolizes drugs, 
but a tvide variety of compounds, many of which are harmful to the organism. 
The enzymes are, therefore, often called 'detoxifying'. This is a very mis-
leading term, as it has been discovered that the metabolism of relatively 
harmless compounds sometimes yields extremely agressive intermediates. Some 
of these have been identified as the inducers of cancer (9-12). 
A study of the mechanisms of drug metabolism may, therefore, be of 
clinical importance. The unusual properties of the cytochrome P-450 molecule, 
the intricate assembly of the whole enzyme system, and its action on steroids, 
drugs and many other compounds, in fact, form an interesting research area 
to scientists from many disciplines, including biophysics, biochemistry, 
pharmacology, endocrinology, clinical medicine, and toxicology. 
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CHAPTER II. OBJECT AND FRAMEWORK OF THE INVESTIGATIONS. 
The main purpose of the studies decribed in this thesis was to investigate 
the relationships between the binding of substrates to cytochrome P-450, the 
reduction of the complex formed in this way by NADPH-cytochrome P-450 re-
ductase, and the in vitro metabolism of these substrates in mouse liver. 
Substrate binding was determined using spectrophotometric techniques, since 
the formation of characteristic difference spectra (type I spectra) is thought 
to reflect cytochrome P-450-substrate interaction, which may represent the 
formation of an enzyme-substrate complex (Chapter III,4.2). Ethylmorphine and, 
in some experiments, hexobarbital were used as model substrates, because they 
produce well-defined spectral changes. 
It was of particular interest to establish whether the reduction of cyto-
chrome P-450-substrate complex is a rate-limiting step in the reaction 
sequence, which has been suggested to be the case in rats (Chapter III,4.3). 
Such information is important, since any influence on the rate of drug 
metabolism is exerted primarily at the stage of the rate-limiting step. 
Furthermore, the measurement of the rate-determining factor might, in prin-
ciple, serve as a test of the functional capacity of the drug metabolizing 
enzyme system, which could be of clinical importance. 
In previous investigations in our laboratory mice have been shown to 
exhibit a sex difference in the duration of hexobarbital-induced narcosis 
and in the in vitro metabolism of hexobarbital (Chapter III,4.6). In this 
study sex differences were used as a tool to investigate the relationships 
between metabolism and components of the reaction chain. The effects of 
testosterone pretreatment and castration as well as the development of the 
enzyme system were studied to establish whether sex-dependent parameters are 
modified in parallel. A second tool was formed by the use of different sub-
strates. Especially interesting in this respect is the metabolism of optical 
antipodes, such as d- and !-hexobarbital. 
Chapters V-VIII concentrate on sex- and strain-dependent differences in 
the metabolism of ethylmorphine and hexobarbital and the relation of metab-
olism to type I binding and NADPH-cytochrome P-450 reductase activities. 
In Chapters IX-XI a closer examination of the type I binding capacity of 
mouse liver cytochrome P-450 is presented, thereby dealing with the role of 
tightly binding endogenous substrates and heterogeneity of cytochrome P-450. 
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CHAPTER Ill. CYTOCHROME P-450-DEPENDENT MONOOXYGENATION. 
In this chapter an introduction to the field of cytochrome P-450-catalyzed 
reactions is presented. General information on cytochrome P-450, its occur-
rence, and its role in monooxygenase reactions is contained in sections 1-3, 
In section 4 the liver microsomal cytochrome P-450 system is described in 
more detail. Only those topics which are relevant to the investigations de-
scribed in the following chapters are treated. Particular attention is paid 
to the organization of the enzyme system, cytochrome P-450-substrate inter-
action, NADPH-cytochrome P-450 reductase, the kinetics o£ the monooxygenase 
reaction, and sex differences in drug metabolism. 
I. DEFINITION AND NOMENCLATURE. 
The cytochrome P-450-dependent enzyme systems belong to a class of 
enzymes which catalyze oxidative reactions. Biological oxidations may involve 
the insertion of oxygen into the substrate molecule. This oxygen may be 
derived from Water, as in the case of 8 -oxidation of fatty acids (I): 
-2H 
For many substrates, such as apolar aliphatic or aromatic compounds, however, 
this route is energetically unfavourable. These compounds may be oxidized 
by molecular oxygen with the aid of enzymes called oxygenases (2-5). 
When the reaction requires the incorporation of both atoms of the o2-
molecule, the enzymes are called dioxygenases. The overall reaction is re-
presented by 
In many cases only one oxygen atom is utilized, whereas the other is reduced 
to water. Then the enzyme system is defined as monooxygenase, mixed-function 
oxygenase, or mixed-function oxidase. An example of such a reaction is 
RH + NADPH + H+ + o 2 + 
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Sometimes the term hydroxylase is used instead of monooxygenase, but this is 
not ideal, since several other oxidation reactions, such as epoxidations, are 
performed by these enzymes. The general equation is 
The mixed-function oxidase systems are characterized by their terminal 
oxidase. This is the component which binds and activates molecular oxygen, 
often a heme-protein, The reduction equivalents are provided by NADPH or 
NADH via electron transport chains, containing flavoproteins and, in some 
cases, non-heme iron proteins. An important group of monooxygenases contain 
cytochrome P-450 as a terminal oxidase. 
2. CYTOCHROME P-450. 
Cytochrome P-450 is a heme-protein, i.e. a protein with a porphyrin as 
a prosthetic group. The porphyrin ring contains six-coordinated iron. Four 
coordination bonds are used up by the porphyrin itself. The nature of the 
remaining two (axial) ligands is uncertain, and subject to considerable 
debate (5,6-17). One of them is probably an SH-group, belonging to a cysteinyl 
residue from the protein part of the molecule. The other ligand may be a 
nitrogenous group from the protein or an external ligand, such as H2o, or it 
may not exist at all. If it exists, it is apparently easily displaced. In the 
course of the monooxygenase reaction oxygen binds to the iron in this posi-
tion. The potent inhibitory action of carbon monoxide on monooxygenase activ-
ity is due to binding of CO at this site. Also compounds containing nucleo-
philic groups (e.g. basic amines) bind to the heme in this position. 
Cytochrome P-450 is a very unusual cytochrome in that the absorption 
spectrum of the CO-complex of the reduced form (Fe2+) displays a character-
istic peak at 450 nm (18, 19). Its name has been derived from this property. 
This absorbance peak is used for quantitation of the cyto~hrome. The in-
hibition by CO can be used as a criterion for the involvement of cytochrome 
P-450 in an oxidative reaction, since this inhibition can be reversed by 
irradiation with light of 450 nm, which dissociates CO from the cytochrome 
(20-22). Cytochrome P-450 is easily inactivated by factors such as heat, 
salts, detergents, and converted into cytochrome P-420, a form which has its 
reduced CO absorbance peak at 420 nm (18,19,23-27). 
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3. CYTOCHROME P-450-DEPENDENT MONOOXYGENASES. 
Cytochrome P-450-catalyzed reactions have been detected in so many 
species that they may be assumed to occur universally (2,5,28-31). Apart from 
mammals (including humans (32)) they have been found in birds (33,34), fish 
(35,36), insects (37-39), fungi (40), yeasts (41), bacteria (42,43) and higher 
plants (44,45) (citations refer to reviews or recent examples). The enzyme 
systems of mammals and bacteria are the ones most extensively studied, the 
latter because of the relative ease to obtain a pure cytochrome P-450 prep-
aration. 
Within the mammal cytochrome P-450 has been found (30) in such diverse 
organs or tissues as the adrenal cortex, liver, kidney cortex, lung (46), 
testis, spleen, intestinal mucosa, skin (47), pancreas, placenta, and recently 
in blood platelets (48) and aorta (49). The first reports on cytochrome P-450-
catalyzed reactions concerned C-21 hydroxylation of steroids in adrenal 
cortex microsomes (20,21). The detection of high cytochrome P-450 activity 
in the endoplasmic reticulum of liver parenchymal cells opened the way to 
the discovery of the many functions of cytochrome P-450. 
The composition of monooxygenase systems with cytochrome P-450 as the 
terminal oxidase varies to a certain extent depending on the source. Very 
schematically, cytochrome P-450-catalyzed oxidations follow the pathway 
s 02 
+ + 
P-450 (Fe 3+) 3+ 2+ inter- ) 3+ + P-450 (Fe ) -s + P-450 (Fe ) -s + (mediates + P-450(Fe ) 
t t 
+ SOH + H2o e - (I) e - (II) 
The major variations are observed in the donation of the electrons via the 
electron transport chains. In the microorganism Pseudomonas putida both 
electrons are delivered according to the pathway 
NADH + flavoprotein + iron-sulfur protein + P-450 
(putidaredoxin) 
In adrenal cortex mitochondria both electrons follow the pathway 
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NADPH + flavoprotein + iron-sulfur protein + P-450 
(adrenodoxin) 
In liver microsomes the situation is more complicated, as apparently two 
different electron transport chains are involved. The first electron is 
donated via 
NADPH + flavoprotein + 'X' + P-450 
and the second presumably via 
NADH + flavoprotein cytochrome b 5 P-450 
The Pseudomonas putida system (P-450cam) has been studied with respect 
to its activity towards camphor (2). Its components have been obtained in a 
pure form (50). Much of the known chemistry of cytochrome P-450 has been 
derived from this system (7). 
The reaction mechanisms of the adrenal cortex and liver systems are still 
far from clear, mainly as a consequence of the membrane-bound nature of these 
systems, which makes it difficult to obtain the components in a pure form. 
The system present in adrenal cortex mitochondria is mainly involved in 
steroidogenesis (51), and appears to be different from other systems with 
respect to the electron transport chain (52-55). Also cytochrome P-450 may be 
different: a subunit structure has been demonstrated, which is not known to 
exist in the liver (56-59). Interestingly, the cytochrome P-450 system present 
in adrenocortical microsomes bears much resemblance to that in liver micro-
somes, The flavoproteins involved in the donation of the first electron appear 
to be immunologically similar, and can replace each other to reconstitute 
enzymatic activity (52-55). This might indicate that the microsomal and mito-
chondrial cytochrome P-450 systems form separate classes. 
In this thesis the investigations have been confined to the liver micro-
somal system, which will be described in section 4 of this chapter. It should 
be kept in mind that the results cannot be simply extrapolated to other 
cytochrome P-450 systems. 
Cytochrome P-450 catalyzes the oxygenation of a large number of different 
substrates. Many different types of reactions can be distinguished, for 
example, aliphatic and aromatic hydroxylations, demethylations (N-and 0-), 
epoxidations, etc. (28). The substrates used in this thesis present examples 
of direct hydroxylation at a C-atom of a cyclohexenyl-ring (hexobarbital), 
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and of N-demethylation (ethylmorphine). In the latter reaction the :N-CH 3 
group is converted into :N-H by the removal of the methyl group in the form 
of HCHO. 
The idea that the metabolism of each (type of) substrate would require 
a particular cytochrome P-450 was not too appealing at first. But there is in-
creasing evidence that several types of cytochrome P-450 exist. In the adrenal 
cortex, for example, cytochrome P-450 is mainly involved in steroid hydroxyla-
tion and cholesterol side-chain cleavage (2,51). Cytochromes P-450 have been 
isolated, which show different specificities with regard to these reactions 
(56-58,60-62). 
A greater diversity of cytochromes P-450 is observed in the liver. Liver 
microsomal cytochrome P-450 has been known for some time to exist in tHo forms. 
Treatment of animals with either phenobarbital or 3-methylcholanthrene both 
appeared to elevate the cytochrome P-450 content considerably, but the meta-
bolic enzymes of the 3-methylcholanthrene-induced animals exhibited a prefer-
ence for polycyclic aromatic hydrocarbons. Furthermore, the absorbance peak 
of the reduced cytochrome P-450-CO complex had shifted to 448 nm. Hence, a 
different type of cytochrome P-450, called cytochrome P-448 (or sometimes 
P1-450 or P-446), was postulated (63-65). This was confirmed with purified 
preparations (66-68). 
Several other cytochromes P-450 have now been characterized, either from 
animals pretreated with inducers or untreated animals. These cytochromes have 
been classified according to their immunological properties, gel-electro-
phoretic mobility or catalytic specificity (69-82). The specificity is not 
confined to the nature of the substrate, but may involve the introduction of 
hydroxyl-groups at different positions of a steroid molecule (82). Thus the 
concept of one cytochrome P-450 for each type of substrate gains ground again. 
Nevertheless, it is hard to visualize why the organism would possess specific 
enzymes for the oxygenation of exogenous compounds for which there are no 
readily recognizable endogenous analogues. The answer might lie in the 
striking inducibility and adaptivity of cytochrome P-450, as indicated by the 
following considerations. 
Apart from the well-known inducers phenobarbital and 3-methylcholanthrene 
a great variety of other compounds have been demonstrated to elevate the 
level of the cytochrome, and in many instances a change in specificity is 
noticed (83), An extreme case of adaptivity is shown by a microorganism (the 
yeast Candida tropicalis), which can be forced to grow on alkanes (41,84). 
A cytochrome P-450 is developed, which attacks C-H bonds in order to transform 
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the alkanes into useful compounds. It has been speculated that cytochrome 
P-450 may be one of the oldest heme-proteins developed during evolution, and 
that it originally functioned as a scavenger of oxygen, a substance which was 
highly toxic in the primordial anaerobic milieu. Later this protein was 
retained because of its usefulness as a hydroxylating agent (85). This may 
explain the versatility of the cytochrome. During the long evolutionary path-
way it must have been exposed to various hydroxylatable substances, which 
may have led to the development of many slightly different heme-proteins and 
to a mechanism which enables the rapid induction of one specific type. 
It is evident that in analyzing drug metabolism data, one has to guard 
against misinterpretation due to a possible involvement of multiple forms of 
cytochrome P-450. Also from the investigations presented in this thesis 
evidence has been obtained for a multiplicity of cytochrome P-450. 
4. THE LIVER MICROSOMAL CYTOCHROME P-450 SYSTEM. 
The liver has a large capacity for the metabolism of xenobiotics. Cyto-
chrome P-450, in fact, may constitute about 2% of the total liver protein. 
In the early fifties the oxidative conversion of drugs had already been 
recognized, but the major knowledge about the enzymatic process involved has 
developed during the past ten years. In 1968 Lu et al. (86) succeeded in the 
solubilization and separation of the enzyme system into three components, 
which could be reconstituted to regain w-hydroxylation activity. Further 
work on the resolution of the system, which also appeared to hydroxylate 
steroids and xenobiotics, has been comprehensively reviewed by Lu and Levin 
(87). The essential factors appeared to be cytochrome P-450, a flavoprotein, 
and a lipid fraction. The flavoprotein was identified with NADPH-cytochrome c 
reductase, an enzyme already known to be present in the endoplasmic reticulum. 
The active component of the lipid fraction was demonstrated to be phospha-
tidylcholine (88). Cytochrome b5 and NADH-cytochrome b 5 reductase, which 
have been postulated to function in drug metabolism, were not necessary to 
reconstitute activity. Therefore, these factors may not be obligatory, but 
only facilitative. 
In recent years purification of cytochrome (89,90) and reductase (91-93) 
preparations to apparent homogeneity has been achieved, despite severe 
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difficulties due to the membrane-bound nature of the enzyme system (94). 
Initially an intermediate electron carrier 'X' had been postulated to explain 
some discrepancies observed (95), such by analogy to the mitochondrial and 
bacterial enzyme systems, which contain iron-sulfur proteins. No direct 
evidence for the existence of this intermediate, however, was obtained. The 
lipid fraction cannot function as such, as phosphatidylcholine does not 
possess electron-carrying properties. The function of the lipid may rather 
be of structural nature, by providing the right mode of association between 
the component proteins. Although the reconstitution of enzyme activity does 
not seem to involve the formation of membrane-like aggregates (96), a role 
of the membrane is conceivable, and is, in fact, supported by many observa-
tions (94,97-106). 
A few recent studies have provided some indirect evidence, which renewed 
the discussion about the possible intermediate carrier. (1) Mull et al. (107.) 
solubilized a cytochrome P-450 system from mouse liver microsomes and observed 
an unknown factor. (2) Careful titration of a purified cytochrome P-450 prep-
aration with the chemical reductant sodium dithionite indicated that two 
electron equivalents were needed to reduce the preparation, thus indicating 
the presence of an additional electron acceptor (108,109). A similar sugges-
tion was made by Estabrook et al. (110). (3) Some evidence has been obtained 
for the existence of an iron-sulfur centre in rat liver microsomes (111,112), 
indicating the presence of an iron-sulfur protein, as observed in the 
bacterial and adrenocortical cytochrome P-450 systems. 
Substrates of the microsomal mixed-function oxygenase (as well as many 
other compounds not yet known to be metabolized ) cause characteristic 
spectral changes when added to a microsomal suspension (113-115). This has 
been identified with shifts of the absorbance peak of the oxidized form of 
cytochrome P-450 (116). The spectral changes are measured by means of differ-
ence spectroscopy (Chapter IV,2). The magnitude of these spectral changes 
depends on the concentration of cytochrome P-450 as well as of the substrate, 
and has been attributed to binding of the substrate to the cytochrome (115). 
Several types of difference spectra can be observed, which are classified 
according to the position of the absorbance maxima and minima (Fig. III, I). 
A type I spectrum is elicited by a great variety of compounds, including 
fatty acids, steroids, and drugs (e.g. hexobarbital, ethylmorphine, amino-
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pyrine). These compounds do not seem to have anything in common, except that 
they are lipophilic and that they are metabolized (with a few exceptions (117)). 
The spectrum is presumed to reflect binding to a hydrophobic part of the 
cytochrome, which induces a conformational change affecting the physical 
properties of the heme (118,1 19). There may be a certain degree of binding 
specificity, due to the existence of different types of cytochrome P-450. It 
had already been recognized by Diehl et al. (120) that only a fraction of the 
total amount of cytochrome P-450 present is involved in type I binding. Gras-
dalen et al. (72) showed that different type I substrates may bind to differ-
ent classes of type I binding sites. Also in this thesis evidence is presented 
for this (Chapter XI), Type I spectra have also been observed with solubilized 
cytochrome P-450 (121). Results with purified preparations suggested that the 
lipid fraction is not essential for type I binding (87). Recent experiments 
with extensively purified cytochrome P-450, however, have demonstrated that 
lipid is needed to obtain maximal binding (102). This emphasizes the import-
ance of the lipophilicity of compounds which show type I binding. 
There exists some controversy as to whether the type I spectral change is 
a prerequisite for a substrate to be metabolized. Two observations seem to 
contradict this proposition, First, some substrates are metabolized despite 
the appearance of different types of spectral change. It is probable, however, 
that a type I component is hidden in such spectra (122-126). Second, treatment 
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of rnicrosomes with phospholipase C seems to destroy type I binding, whereas 
metabolism is only partly inhibited (127). This, also, may be only an apparent 
discrepancy. Phopholipase C treatment has been shown to eventually result in 
the release of free fatty acids, which competitively inhibit the metabolism of 
other type I substrates (128,129). Since they themselves elicit the type I 
spectral change, type I binding of other substrates will be hardly detectable 
in preparations containing fatty acids, despite the competitive nature of the 
inhibition. 
A type II spectrum is observed with compounds which have a nucleophilic 
group, such as basic amines (115). They react directly with the heme at the 
position of the sixth ligand, thereby interfering with oxygen binding. The 
display of such a spectral change does not preclude the metabolism of the 
substrate concerned, as examplified by aniline. As it is hard to understand 
how such substrates can be metabolized at a site where they inhibit the binding 
of oxygen, it is believed that they additionally bind to the type I site. 
A type I component may, in fact, be observed in several of these spectra (122-
126). 
A third type of difference spectrum resembles the type II spectrum to a 
certain extent, and has, therefore, been defined as 'modified type II' (1 15). 
With some substrates (phenacetin, lower alcohols) the spectrum seems to be the 
reverse of the type I spectrum (reverse type I or RI spectrum (123)), A suit-
able division into subclasses, however, is not readily made (also definitions 
such as IIA and liB have been used (130)). The nature of this third class of 
binding sites is subject to controversy. It has been proposed that the spectral 
change merely reflects the release of endogenously bound type I substrates 
(120) (this is discussed more extensively in Chapter IX). On the other hand, 
the sometimes anomalous shape of the spectrum suggested that it might be the 
result of superimposition of type I and type II spectra (118), Evidence is 
now accumulating that the spectra indeed resemble the type II spectra in that 
they are elicited by the interaction of nucleophilic substrates with the heme, 
and that a varying nucleophilicity is the cause of the variation in the 
absorbance maxima and minima (17,130, 131), The fact that such substrates bind 
directly to the heme implies that the maximal magnitude of the spectral 
change is related to the total cytochrome P-450 content, which is in contrast 
to the type I spectrum. 
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The donation of the first electron to cytochrome P-450 (see 3. 1) is an 
intriguing feature of the monooxygenase reaction chain. This electron is 
derived from NADPH and is transferred via the flavoprotein NADPH-cytochrome c 
reductase. An additional redox component may be involved, but for this no 
conclusive evidence is available yet (4. 1). The activity of the reductase is 
usually assayed with respect to cytochrome c, which is apparently an arti-
ficial substrate, since it does not occur naturally in the endoplasmic re-
ticulum. The involvement of this enzyme in the reduction of cytochrome P-450 
was evidenced by (1) the inhibition of drug metabolizing activity by cyto-
chrome cor specific antibodies against the flavoprotein (52,132,133), and 
(2) the reconstitution of enzyme activity using purified flavoprotein prep-
arations (87). NADPH-cytochrome c reductase does not show heterogeneity, as 
cytochrome P-450 does (134-136). Induction with phenobarbital or 3-methyl-
cholanthrene did not alter its specificity or immunological and gel-electro-
phoretical properties. 
The reduction of cytochrome P-450 is studied under anaerobic conditions 
in a CO-atmosphere. The addition of NADPH to the microsomal preparation 
causes the rapid appearance of the reduced cytochrome P-450-CO complex, which 
can be followed spectrophotometrically (Chapter IV,3). The kinetics of this 
reaction are intricate and not yet fully resolved. The initial rate of the 
reduction appeared to be stimulated by the presence of type I subs~rates 
(type II substrates cause a decrease in reduction rate, which is mechanistical-
ly interesting, but which is not discussed in this thesis) (138). Moreover, 
a relationship between the magnitude of this stimulation and the rate of 
ethylmorphine demethylation was observed. This led to the hypothesis that the 
reduction might represent a rate-limiting reaction (137,138). 
The reaction proceeds in two phases, a rapid and a slm.;r phase, which 
occur simultaneously. The relationship between reductase stimulation and 
ethylmorphine demethylation suggested that the observed fast phase does not 
participate in the metabolic reaction. The stimulation of reductase activity 
by type I substrates would be due to an activation of the reduction of cyto-
chrome P-450 which is reduced in the slow phase in the absence of substrate 
(138). If this endogenous rate of the slow phase is negligible with respect 
to the rate observed in the presence of substrate, the reductase stimulation 
approximates the actual rate of cytochrome P-450 reduction. Later it was 
suggested that the fast phase occurring in the absence of substrate involved 
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the reduction of cytochrome P-450 bound to endogenous substrates, and that 
the increase in ini~ial rate observed after addition of type I substrate was 
due to an increase in the amount of cytochrome P-450 being reduced in this 
fast phase as the result of the formation of a cytochrome P-450-substrate 
complex (120). Other observations, however, have indicated that the substrate-
induced stimulation of reductase activity may be the result of an increase 
in the rate constant of the fast phase rather than of the amount of cytochrome 
P-450 being involved in this phase (139), 
According to the most recent theory on the kinetics of cytochrome P-450 
reduction the two phases relate to cytochrome P-450 molecules which are 
differently located in the microsomal membrane. The fast phase would represent 
the reduction of cytochrome P-450 molecules arranged in a clus~er around a 
central flavoprotein molecule, whereas the slow phase reflects the reduction 
of cytochrome P-450 molecules which are not associa~ed with the cluster (106), 
Similar cluster models had been suggested before for the functioning of the 
cytochrome P-450 system as a whole (98,100,105). 
Several investigations have demonstrated a relationship between type I 
binding, reductase stimulation and metabolic activity. Especially in the 
case of ethylmorphine a relationship between reductase stimulation and de-
methylation in rats is consistently observed (138,140-142). This relation-
ship appears to be stoichiometrical. This strongly suggests that a cytochrome 
P-450, which is reduced at a negligible rate, is activated to take part in 
the demethylation reaction. Reductase stimula~ion might, therefore, be a 
measure of the reduction of cytochrome P-450-substrate complex. If the stimu-
lation is only due to an increase in the rate constant of the fast phase, 
this result must be fortuitous. 
The role of NADPH-cytochrome P-450 reductase is discussed further in 
Chapter XII, in particular with regard to the question, which parameter of 
reductase activity adequately reflects the reduction of cytochrome P-450-
subs~rate complex. 
Microsomes contain an electron transport chain consisting of the heme-
protein cytochrome b5 and NADH-cytochrome b5 reductase, which is ac~ive in 
fatty acid desaturation (143,144). Some observations, such as the synergistic 
effect of NADH on the NADPH-driven monooxygenase reaction (145-147), have led 
to the hypothesis that the second electron, which is needed to activate the 
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oxygen, might be provided via this system. On the other hand, cytochrome b5 
and the reductase did not appear to be essential to reconstitute an active 
enzyme system (see 4. I). The possible roles of cytochrome b 5 have been re-
viewed by Schenkman (148), and an extensive discussion of this problem is 
beyond the scope of this thesis. 
The cytochrome P-450-catalyzed monooxygenase reaction (depicted in Fig. 
111,2) has long been considered to follow simple Michaelis-Menten kinetics, 
according to the equation 
V • [S) 
max 
v 
[S) + K 
m 
in which Km would reflect the dissociation constant Ks of the enzyme-substrate 
complex. The formation of this complex is thought to be represented by the 
type I spectral change, and is determined according to the equation 
6A • [S) 
max 
The similarity between Km and Ks for some substrates led to the suggestion 
that the reaction step following the formation of the enzyme-substrate com-
plex is rate-limiting. This becomes evident from the following scheme (E = 
enzyme or cytochrome P-450, S = substrate, P = product, k = rate constant): 
E + S ES reduced E + p 
If the steps beyond k3 are very fast, Km is approximated by 
K 
m 
with K 
s 
k 3 is sometimes low, as compared with k 1 and k 2 . In that case Km is equal to 
Ks' otherwise Km will exceed K
8 
to a certain extent, 
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Fig. 111,2. Reaction scheme of cytochrome P-450-catalyzed mono-
oxygenation, including a hypothetical cycle not involving substrate. 
The reduction may be considered to be a rate-limiting step, if variations 
in reduction rate correlate with variations in the overall metabolic reaction. 
The observation that double reciprocal plots of 1/v vs. 1/S are usually 
straight lines, seems to indicate that the kinetic behaviour of the oxidation 
reaction is simple. Hayes et al. (149) observed a concentration dependent Km 
and Vmax of ethylmorphine demethylation in rats, but this was attributed to 
the presence of two separate demethylases. Pederson and Aust (!50) observed 
non-linear kinetics with aminopyrine demethylation, but this may be attributed 
to the fact that aminopyrine is demethylated at two positions. 
Some observations, however, suggest that the reaction mechanism should 
be more complicated. The finding that after phenobarbital treatment an 
oxygenated intermediate is detectable in rat liver microsomes, could imply 
that at least one other slow step occurs in the reaction sequence (1 10). Also 
the measurement of steady-state levels of oxidized cytochrome P-450 suggested 
the presence of a certain amount of intermediate forms (132). Furthermore, 
cytochrome P-450 is reduced endogenously, i.e. without the addition of 
substrate. This may be attributed to the presence of endogenous substrates, 
but this is not definitively proven. Reversible substrate complex formation 
with intermediate forms of cytochrome P-450 is difficult to establish. It has 
been suggested that this may occur, but it may be of less importance. 
Gillette et al. (132) have extensively discussed the implications of 
these considerations for the kinetic behaviour of the monooxygenase reaction, 
They demonstrated that in certain limiting cases the rate equations may yield 
linear Lineweaver-Burk plots. This linearity will be observed, if the 
substrate does not equilibrate with any of the intermediate forms of cyto-
chrome P-450. And in case these equilibria do occur, it may still be noticed, 
when the rates of the reaction steps in the absence of substrate are zero or 
equal to those in the presence of substrate. It is not unrealistic to assume 
that one of these conditions is fulfilled, at least with regard to the re-
duction by NADPH-cytochrome P-450 reductase, i.e. either the reduction rate 
of unbound cytochrome P-450 is negligible, or the rate of reduction of sub-
strate-bound cytochrome P-450 is comparable to that observed with the unbound 
form. This becomes apparent from the following considerations. 
As discussed in section 4.3, the initial rate of reduction observed with-
out added substrate (which is approximately the rate of the fast phase), may 
represent (1) the reduction of cytochrome P-450 which is not active in metabol-
ism, (2) the reduction of cytochrome P-450 bound to endogenous substrates, 
or (3) the genuine rate of reduction of unbound cytochrome P-450. In cases 
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(I) and (2) the unbound form of (catalytically active) cytochrome P-450 is 
reduced in the slow phase of reduction, and thus its reduction rate is neg-
ligible. In case (3) the reduction rates of the bound and unbound forms do 
not differ greatly, since the stimulation observed after addition of substrate 
is relatively small. On the basis of these considerations Gillerte et al. (132) 
explained the fact that often linear Lineweaver-Burk plors are observed. 
Nevertheless, it should be recognized that the curvature in such plots may 
be small and difficult to detect. 
It can be calculated that in all limiting cases Km should reflect Ks' if 
the first reduction is rate-limiting, except when the reaction sequences in 
the presence and absence of substrate have the same rate constants and, in 
addition, the intermediate forms are in equilibrium with each other. In that 
case Km reflects the dissociation constant of the active oxygen-cytochrome 
P-450-substrate complex. 
Sex-dependent drug metabolism has been reported to occur only in rats and 
mice, and not, for example, in guinea pigs, hamsters or rabbits (151). The 
sex-dependency in mice is considered to be small (151) and is not observed 
consistently (strain-dependent) (152-155). The origin of sex differences has 
been studied in detail in rats only. 
The high activity of the drug metabolzing enzyme system in male rats 
as compared with females has been attributed ro a stimulatory action of 
androgen, which becomes apparent during sexual maturation (141,151 ,156-161). 
This action is reversible, as demonstrated by castration or testosterone 
treatment (151,159,161). Estrogens do not seem to have a direct effect, but 
merely impair the action of androgen (151), The response to androgen during 
puberty seems to be imprinted by neonatal androgen (161 ,162). The degree of 
responsiveness, however, seems to vary with the substrate studied. 
A great deal of the knowledge about these hormonal mechanisms has been 
obtained from studies on the pattern of steroid metabolism (163-165). In many 
of these reactions, in particular the hydroxylations, cytochrome P-450 is 
involved, so that the results may be of significance for drug metabolism as 
well. Recent investigations have indicated that the mechanisms which regulate 
the responses to androgen in rats, may be extremely complicated. The hypo-
physis, the hypothalamus, as well as androgen receptors in liver cytosol, 
have been proposed to be involved in these processes (166-170). 
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The sex differences which we have observed in mice, are the reverse of 
those observed in rats. Yet they seem to arise through the action of androgens, 
which in this case is inhibitory (153-155). Schriefers et al. (171) have in-
dicated that the responses to androgen might be species-specific. In this 
thesis the origin of these sex differences is discussed in the light of our 
findings, although we realize that other studies would have to be performed 
to provide a full answer. 
REFERENCES, 
I. A.L. Lehninger, 'Biochemistry', Worth Publishers, Inc., New York, 1970, 
p. 418 
2. I.e. Gunsalus, T.C. Pederson and S.G. Sligar, Annu. Rev. Biochem. 44, 377 
(1975) 
3. V. Ullrich, Angew. Chern. 84, 689 (1972) 
4. Several authors, in 'Molecular mechanisms of oxygen activation', 
0. Hayaishi, ed., Acad. Press, New York, 1974 
5. V. Ullrich and W. Duppel, in 'The Enzymes', vol. XII, part B, 3rd ed. 
(P.D. Boyer, ed.), Acad. Press, New York, 1975, p. 253 
6. J.A. Peterson and B. Walker Griffin, Drug Metab. Disp. I, 14 (1973) 
7. B. Walker Griffin, J.A. Peterson, J. Werringloer and R.W. Estabrook, 
Ann. N.Y. Acad. Sci. 244, 107 (1975) 
8. J.P. Collman, T.N. Sorrell and B.M. Hoffman, J, Am. Chern. Soc. 97, 913 
(1975) 
9. S. Koch, S.C. Tang, R.H. Holm, R.B. Frankel and J.A. Ibers, J. Am. Chern. 
Soc. 97, 916 (1975) 
10. J.P. Collman, T.N. Sorrell, J.H. Dawson, J.R. Trudell, E. Bunnenberg and 
c. Djerassi, Proc. Nat. Acad. Sci. USA 73, 6 (1976) 
11. L.K. Hanson, W.A. Eaton, S.G. Sligar, I.e. Gunsalus, M. Gouterman and 
C.R. Connell, J. Am. Chern. Soc. 98, 2672 (1976) 
12. J.O. Stern and J. Peisach, FEES Lett. 62, 364 (1976) 
13. J.H. Dawson, R.H. Holm, J.R. Trudell, G. Barth, R.E. Linder, E. Bunnenberg, 
C. Djerassi and S.C. Tang, J. Am. Chern. Soc. 98, 3707 (1976) 
14. C.K. Chang and D. Dolphin, Proc. Nat, Acad. Sci. USA 73, 3338 (1976) 
15. C.K. Chang and D. Dolphin, J, Am. Chern, Soc. 98, 1607 (1976) 
16. S.C. Tang, S. Koch, G.C. Papaefthymiou, S. Foner, R.B. Frankel, J.A. Ibers 
and R. H. Holm, J. Am. Chern. Soc. 98, 2414 (1976) 
17. Y. Yoshida and H. Kumaoka, J. Biochem. 78, 455 (1975) 
18. T. Omura and R. Sato, J. Biol. Chern. 239, 2370 (1964) 
19. T. Omura and R. Sato, J, Biol, Chern. 239, 2379 (1964) 
20. R.W. Estabrook, D.Y. Cooper and 0. Rosenthal, Biochern. Z. 338, 741 (1963) 
21. D.Y. Cooper, S. Narasirnhulu, 0. Rosenthal and R.W. Estabrook, Science 147, 
400 (1965) 
22. H. Diehl, S. Capalna and V. Ullrich, FEES Lett. 4, 99 (1969) 
23. Y. Imai and R. Sate, Eur. J. Biochem. 1, 419 (1967) 
24. Y. Ichikawa, T. Yamane and H. Fujishirna, Biochim. Biophys. Acta 171, 32 
(1969) 
25. H. Ueleke, F. Schnitger and K.-H. Hellmer, Hoppe-Seyler's Z. Physiol. 
Chern. 351, 1475 (1970) 
26. M.R. Franklin, Mol. Pharmacal. 8, 711 (1972) 
29 
27. M.R. Franklin, Mol. Pharmacal. 8, 722 (1972) 
28. J.R. Gillette, D.C. Davis and H.A. Sasame, Annu. Rev. Pharmacal. 12, 57 
( 19 72) 
29. S. Orrenius and L. Ernster, see Ref. 4, p. 215 
30. R.H, Wickramasinghe, Enzyme 19, 348 (1975) 
31. A.P. Kulkarni, E. Smith and E. Hodgson, Camp. Biochern. Physiol. 54B, 509 
( 19 76) 
32. E.A, Sotaniemi, J. Ahlquist, R.O. Pelkonen, H. Pirttiaho and P.V. Luoma, 
Eur. J. clin. Pharmacal. 11, 295 (1977) 
33. H.P. Pan, J.R. Fouts and T. Devereux, Life Sci. 17, 819 (1975) 
34. J.M. Runnels and M.A.Q. Khan, Gen. Pharmacal. 6, 97 (1975) 
35. J.E. Chambers and J.D. Yarbrough, Camp. Biochem, Physiol. 55C, 77 (1976) 
36. R.H. Stanton and M.A.Q. Khan, Gen. Pharmacal. 6, 289 (1975) 
37. C.F. Wilkinson and L.B. Brattsten, Drug Metab. Rev. 1, 153 (1972) 
38. A.P. Kulkarni and E. Hodgson, Insect Biochem. 5, 679 (1975) 
39. M. Agosin, Mol. Cell. Biochern. 12, 33 (1976) 
40. J.P. Ferris, L.H. MacDonald, M.A. Patrie and M.A. Martin, Arch. Biochem. 
Biophys. 175, 443 (1976) 
41. M. Gallo, B. Roche and E. Azoulay, Biochim. Biophys. Acta 419, 425 (1976) 
42. M.J. Coon, A.P. Autor, R.F. Boyer, E.T. Lode and H.W. Strobel, in 
'Oxidases and related redox systems', Vol. 2 (T.E. King, H.S. Mason 
and M. Morrison, eds.), University Park Press, Baltimore, 1973, p. 529 
43. A. Berg, K. CarlstrOm, J.A. Gustafsson and M. Ingelman-Sundberg, Biochem, 
Biophys. Res. Commun. 66, 1414 (1975) 
44. J. McFarlane, K.M. Madyastha and C.J. Coscia, Biochem. Biophys. Res, 
Conunun. 66, 1263 (1975) 
45. K.M. Madyastha, T.D. Meehan and C.J. Coscia, Biochemistry 15, 1097 (1976) 
46. G.E.R. Hook and J.R. Bend, Life Sci. 18, 279 (1976) 
47. R.J. Pohl, R.M. Philpot and J.R. Fouts, Drug Metab, Disp. 4, 442 (1976) 
48. D.L. Cinti and M.B. Feinstein, Biochem. Biophys. Res. Commun. 73, 1 (1976) 
49. M.R. Juchau, J.A. Bond and E.P. Benditt, Proc. Nat. Acad. Sci. USA, 73, 
3723 (1976) 
SO. C.-A. Yu, I.C. Gunsalus, M. Katagiri, K. Suhara and S. Takemori, J, Biol. 
Chern. 249, 94 (1974) 
51. M. Hamberg, B. Samuelsson, I, BjOrkhem and H. Danielsson, see Ref. 4, p.29 
52. B.S. Siler Masters, J. Baron, W.E. Taylor, E.L. Isaacson and J. LoSpalluto, 
J. Biol. Chern. 246, 4143 (1971) 
53. J. Baron, W.E. Taylor and B.S. Siler Masters, Arch. Biochem. Biophys. 150, 
105 (1972) 
54. J. Baron, W.E. Taylor and B.S. Siler Masters, see Ref. 42, p. 554 
55. J. Baron, W.E. Taylor and B.S. Siler Masters, see Ref. 42, p. 559 
56. M. Shikita and P.F. Hall, J. Biol. Chern. 248, 5598 (1973) 
57. M. Shikita and P.F. Hall, J. Biol. Chern. 248, 5605 (1973) 
58. Y. Takagi, M. Shiki ta and P. F. Hall, J. Biol. Chern. 250, 8445 ( 197 5) 
59. B.E. Tilley, M. Watanuki and P.F. Hall, Biochem, Biophys. Res. Comrnun. 
70, 1303 (1976) 
60. F. Mitani and S. Rorie, J. Biochem. 68, 529 (1970) 
61. S. Isaka and P.F. Hall, Biochem. Biophys. Res. Commun. 43, 747 (1971) 
62. J. Ramseyer and B.W. Harding, Biochim. Biophys. Acta 315, 306 (1973) 
63. N.E, Sladek and G.J. Mannering, Biochem. Biophys. Res. Commun. 24, 668 
( 19 66) 
64. A.P. Alvares, G. Schilling, W. Levin and R. Kuntzman, Biochem. Biophys. 
Res. Commun. 29, 521 (1967) 
65. G.J. Mannering, Metabolism 2, 228 (1971) 
66. A.P. Alvares and P~ Siekevitz, Biochem. Biophys. Res. Cornmun. 54, 923 (1973) 
67. A.F. Welton and S.D. Aust, Biochem. Biophys. Res, Cornmun. 56, 898 (1974) 
30 
68. D. Ryan, A.Y.H. Lu, J. Kawalek, S.B. \-Jest and W. Levin, Biochem. Biophys. 
Res. Commun. 64, 1134 (1975) 
69. K. Comai and J.L. Gaylor, J. Biol. Chern. 248, 4947 (1973) 
70. R.B. Mailman, L.G. Tate, K.E. Muse, L,B. Coons and E. Hodgson, Chem.-Biol. 
Interact. 10, 215 (1975) 
71. J. Werringloer and R.W. Estabrook, Arch. Biochem. Biophys. 167, 270 (1975) 
72. H. Grasdalen, D. BackstrOm, L.E.G. Eriksson, A. Ehrenberg, P. Moldeus, 
C. von Bahr and S. Orrenius, FEES Lett. 60, 294 (1975) 
73. D.A. Haugen, T.A. Van der Hoeven and M.J. Coon, J. Biol, Chern. 250, 3567 
(1975) 
74. D. Ryan, A.Y.H. Lu, S. West and W. Levin, J. Biol. Chern. 250, 2157 (1975) 
75. A.F. Welton, F.O. O'Neal, L.C. Chaney and S.D. Aust, J. Biol. Chern. 250, 
5631 (1975) 
76. P.E. Thomas, A.Y.H. Lu, D. Ryan, S.B. West, J. Kawalek and W. Levin, 
J. Biol. Chern. 251, 1385 (1976) 
77. D.A. Haugen, M.J. Coon and D.W, Nebert, J. Biol. Chern. 251, 1817 (1976) 
78. P.E. Thomas, A.Y.H. Lu, D. Ryan, S.B. West, J. Kawalek and W. Levin, 
Mol. Pharmacal. 12, 746 (1976) 
79. R.M. Philpot and E. Arinc, Mol. Pharmacal. 12, 483 (1976) 
80. M.-T. Huang, S.B. \Vest and A.Y.H. Lu, J. Biol. Chern. 251, 4659 (1976) 
81. A.Y.H. Lu, D. Ryan, J. Kawalek, P. Thomas, S.B. West, M.T. Huang and 
W. Levin, Biochem. Soc. Trans. 4, 169 (1976) 
82. J.-R. Gustafsson and M. Ingelman-Sundberg, Eur, J. Biochem. 64, 35 (1976) 
83. D.V. Parke, in 'Enzyme induction', Basic Life Sciences, Vol. 6 
(D.V. Parke, ed.), Plenum Press, London/New York, 1975, p. 207 
84. W. Duppel, J.-M. Lebeault and M.J. Coon, Eur. J. Biochem. 36, 583 (1973) 
85. R.H. Wickramasinghe and C.A. Villee, Nature 256, 509 (1975) 
86. A.Y.H. Lu and M.J. Coon, J. Biol. Chern. 243, 1331 (1968) 
87. A.Y.H. Lu and W. Levin, Biochim. Biophys. Acta 344, 205 (1974) 
88. H.W. Strobel, A.Y.H. Lu, J, Heidema and M.J. Coon, 245, 4851 (1970) 
89. T.A. Van der Hoeven, D.A. Haugen and M.J. Coon, Biochem. Biophys. Res. 
Commun. 60, 569 (1974) 
90. T.A. Van der Hoeven and M.J. Coon, J. Biol. Chern. 249, 6302 (1974) 
91. J.L, Vermilion and M.J. Coon, Biochem. Biophys. Res. Commun. 60, 1315 
(1974) 
92. J.D. Dignam and H.W. Strobel, Biochem. Biophys. Res. Commun, 63, 845 
(1975) 
93. Y. Yasukochi and B.S. Siler Masters, J. Biol. Chern. 251, 5337 (1976) 
94. J.W. DePierre and G. Dallner, Biochim. Biophys. Acta 415, 41 I (1975) 
95. G. Dallner, P. Siekevitz and G.E. Palade, Biochem. Biophys. Res. Commun. 
20, I 35 ( 19 65) 
96. A.P. Autor, R.M. Kaschnitz, J.K. Heidema and M.J. Coon, Mol. Pharmacal. 
9, 93 (1973) 
97. T.E. Eling and R.P. DiAugustine, Biochem. J. 123, 539 (1971) 
98. M.R. Franklin and R.W. Estabrook, Arch. Biochem. Biophys. 143, 318 (1971) 
99. S. Eletr, D. Zakim and D.A. Vessey, J. Mol. Biol. 78, 351 (1973) 
100. A. Stier and E. Sackmann, Biochim. Biophys. Acta 311, 400 (1973) 
101. C.S. Yang, FEBS Lett. 54, 61 (1975) 
102. F.P. Guengerich and M.J. Coon, Fed. Proc. 34, 622 (1975) 
103. M. Ingelman-Sundberg and J.-~. Gustafsson, Biochem. Soc. Trans. 3, 977 
(1975) 
104. W. Duppel and V. Ullrich, Biochim. Biophys. Acta 426, 399 (1976) 
lOS. A. Stier, Biochem. Pharmacal. 25, 109 (1976) 
106. J.A. Peterson, R.E. Ebel, D.H. 0 1Keeffe, T. Matsubara and R.W. Estabrook, 
J, Biol. Chern. 251, 4010 (1976) 
107. R.H. Mull, M. Schaguler and K. Flemming, Biochem. Biophys. Res. Commun, 
67, 849 (1975) 
31 
108. D.P. Ballou, c. Veeger, T.A. Van der Hoeven andM.J. Coon, FEES Lett. 
38, 337 (1974) 
109. F .P. Guengerich, D.P. Ballou and M.J. Coon, J. Biol. Chern, 250, 7405 
(1975) 
110. R.W. Estabrook, A.G. Hildebrandt, J. Baron, K.J. Netter and K. Leibman, 
Biochem. Biophys. Res. Conunun. 42, 132 (1971) 
I 11. J.C. Salerno and W.J. Ingledew, Biochem, Biophys. Res. Comroun, 65, 618 
(1975) 
112. W.J. Ingledew, J.C. Salerno and T. Ohnishi, Arch. Biochem. Biophys. 174, 
298 (1976) 
113. H. Remmer, J. Schenkroan, R.W. Estabrook, H. Sasame, J. Gillette, 
S. Narasimhulu, D.Y. Cooper and 0. Rosenthal, Mol. Pharmacal. 2, 187 
(1966) 
I 14. Y. Iroai and R. Sato, Biochem. Biophys. Res. Commun. 22, 620 (1966) 
115. J.B. Schenkman, H. Remmer and R.W. Estabrook, Mol. Pharmacal. 3, 113 
( 1967) 
116. H. Remmer, J.B. Schenkman and H. Greim, in 'Microsomes and drug oxida-
tions' (J.R. Gillette, A.H. Canney, G.J. Cosmides, R.W. Estabrook, 
J.R. Fouts and G.J. Mannering, eds.), Acad, Press, New York/London, 
1969, p.37! 
117. V. Ullrich and H. Diehl, Eur. J. Biochem. 20, 509 (1971) 
118. S. Orrenius, B.J. Wilson, C. von Bahr and J.B. Schenkman, in 'Biological 
hydroxylation mechanisms' (G.S. Boyd and R.M.S. Smellie, eds.), 
Acad. Press, London/New York, 1972, p. 55 
119. G.J. Mannering, in 'Drugs and cell regulation' (E. Mihich, ed.), Acad, 
Press, London/New York, 1971, p. 197 
120. H. Diehl, J. Schadelin and V. Ullrich, Hoppe-Seyler's Z. Physiol. Chern. 
351, 1359 (1970) 
121. M.R.I. Soliman, H.D. Johnson and A.E. Wade, Drug Metab. Disp. 2, 87 (1974) 
122. J.B. Schenkman, Biochemistry 9, 2081 (1970) 
123. J.B. Schenkman, D.L. Cinti, S. Orrenius, P. Moldeus and R. Kraschnitz, 
Biochemistry 11, 4243 (1972) 
124. B.J. Wilson and S. Orrenius, Biochim. Biophys. Acta 261, 94 (1972) 
125. I. HoffstrOm and S. Orrenius, FEES Lett. 31, 205 (1973) 
126. J,W. Garrod and D.J. Temple, Chem.-Biol. Interact. 6, 203 (1973) 
127. M.D. Chaplin and G.J. Mannering, Mol. Pharmacal. 6, 631 (1970) 
128. B.R. Cater, V. Walkden and T. Hallinan, Biochem, J. 127, 37P (1972) 
129. J.W. DePierre and L. Ernster, FEBS Lett, 55, 18 (1975) 
130. R.B. Mailman, A.P. Kulkarni, R.C. Baker and E. Hodgson, Drug Metab. Disp. 
2, 301 (1974) 
131. D.H. Nebert, K. Kumaki, M. Sato and H. Kon, Hoppe-Seyler's z. Physiol. 
Chern. 357, 1044 (1976) 
132. J. Gillette, H. Sasame and B. Stripp, Drug Metab. Disp. I, 164 (1973) 
133. T. Omura, see Ref. 116, p. 160 
134. R.I. Glazer, J.B. Schenkman and A.C. Sartorelli, Mol. Pharmacal. 7, 683 
( 197 I) 
135. A.F. Welton and S.D. Aust, Biochem. Pharmacal. 24, 1641 (1975) 
136. R.A. Prough and M.D. Burke, Arch. Biochem. Biophys. 170, 160 (1975) 
137. P.L. Gigon, T.E. Gram and J.R. Gillette, Biochem. Biophys. Res. Commun. 
31, 558 (1968) 
138. P.L. Gigon, T.E. Gram and J.R. Gillette, Mol. Pharmacal. 5, 109 (1969) 
139. T. Matsubara, J, Baron, L.L. Peterson and J.A. Peterson, Arch. Biochem. 
Biophys. 172, 463 (1976) 
140. J.L. Holtzman and B.H. Rumack, Biochemistry 12, 2309 (1973) 
141. G.M. Cohen and G.J. Mannering, Drug Metab. Disp. 2, 285 (1974) 
142. J.A. Thompson and J.L. Holtzman, Drug Metab. Disp. 5, 9 (1977) 
32 
143. N. Oshino, Y. Imai and R. Sato, J. Biochem. 69, 155 (1971) 
144. N. Oshino and T. Omura, Arch. Biochem. Biophys .. 157, 395 (1973) 
145. B.S. Cohen and R.W. Estabrook, Arch. Biochem. Biophys. 143, 54 (1971) 
146. A. Correia and G.J. Mannering, Drug Metab. Disp. 1, 139 (1973) 
147. K.J. Netter and H.P.A. Illing, Xenobiotica 4, 549 (1974) 
148. J.B. Schenkman, I. Jansson and K.M. Robie-Suh, Life Sci, 19, 61 I (1976) 
149. J.R. Hayes, M.U.K. McBodile and T.C. Campbell, Biochem. Pharmacal. 22, 
1517, (1973) 
150. T.C. Pederson and S.D. Aust, Biochem. Pharmacal. 19, 2221 (1970) 
151. R. Kato, Drug Metab. Rev. 3, 1 (1974) 
152. E.S. Vesell, Ann. N.Y. Acad. Sci. 151, 900 (1968) 
153. Chr. L. RU.mke and J. Noordhoek, Arch. int. Pharmacodyn. 182, 399 (1969) 
154. J. Noordhoek and Chr. L. Ri.imke, Arch. int. Pharmacodyn. 182, 401 (1969) 
155. J. Noordhoek, FEES Lett. 24, 255 (1972) 
156. T.E. Gram, A.M. Guarino, D.H. Schroeder and J.R. Gillette, Biochem, J. 
113, 681 (1969) 
157. S.M. McLeod, K.W. Renton and N.R. Eade, J. Pharmacal. Exp. Ther. 183, 
489 (1972) 
158. S. El Defrawy El Masry, G.M. Cohen and G.J. Mannering, Drug Hetab. Disp. 
2, 267 ( 1974) 
159. S, El Defrawy El Masry and G.J. Mannering, Drug Metab. Disp. 2, 279 (1974) 
160. D.D. Shoemaker and H.E. Hamrick, Biochem. Pharmacal. 23, 2325 (1974) 
161, L.W.K. Chung, G. Raymond and S. Fox, J, Pharmacal. Exp. Ther. 193, 621 
(1975) 
162. W. Levin, D. Ryan, R. Kuntzman and A.H. Canney, Mol. Pharmacal. 11, 190 
(1975) 
163. K. Einarsson, J.-R. Gustafsson and R. Stenberg, J. Biol. Chern. 248, 4987 
(1973) 
164. J.-R. Gustafsson and R. Stenberg, J. Biol. Chern. 249, 711 (1974) 
165. J.-R. Gustafsson, Biochem. J, 144, 225 (1974) 
166. C. Denef, Enzyme 15, 254 (1973) 
167, J.-R. Gustafsson, S.A. Gustafsson, M. Ingelman-Sundberg, R. Pousette, R. Stenberg and~. Wrange, J. Steroid Biochem, 5, 855 (1974) 
168, J.-R. Gustafsson, ~. Pousette, R. Stenberg and~. Wrange, Biochemistry 
14, 3942 (1975) 
169. J.-R. Gustafsson, M. Ingelman-Sundberg and R. Stenberg, J. Steroid 
Biochem. 6, 643 ( 1975) 
170. J.-R. Gustafsson and R. Stenberg, Proc. Nat. Acad. Sci. USA 73, 1462 
( 19 76) 
171. H. Schriefers, A. Eimiller and U. Drews, Hoppe-Seyler's Z. Physiol. Chern. 
357, 95 (1976) 
33 
CHAPTER IV. METHODOLOGICAL ASPECTS. 
1, ASSAY SYSTEMS FOR DRUG METABOLIZING ENZYMES. 
In order to study the properties of the drug metabolizing enzyme system 
it is of advantage to study isolated enzymic function, thus making the meta-
bolic activity independent of factors such as blood-flow, drug uptake, drug 
transport, cofactor availability, etc .. This is accomplished by using cell 
homogenates, homogenate subfractions, or purified enzymes. 
Cell homogenates are readily prepared, but are somewhat artificial, since 
in these systems cell constituents are brought together, which are separated 
in the intact cell. Under carefully controlled conditions homogenates may be 
useful, especially when the amounts of tissue available are too low to allow 
fractionation (liver biopsy samples) (I). They have the disadvantage that 
spectral measurements are difficult to perform, because of the high turbidity 
and the presence of mitochondrial pigments. Nevertheless, a reliable measure-
ment of cytochrome P-450 contents seems to be possible (I). 
The fraction obtained after centrifugation of a homogenate at 9000 g for 
20 minutes is devoid of cell debris, nuclei, cell membranes and mitochondria. 
This system, simply called 9000 g supernatant, is often used for the assay 
of drug metabolic activity. Spectral measurements may be perturbed by the 
presence of pigments from ruptured mitochondria or hemoglobin (if the liver 
has not been perfused before homogenization). 
After further centrifugation of this supernatant at 75,000 g for 90 min. 
(or, for example, 60 min. at 105,000 g) the microsomal fraction is obtained 
in the form of a pellet, This fraction mainly represents the endoplasmic 
reticulum, which containes the drug metabolizing enzymes. A suspension of 
this pellet is the most widely used assay system for the characterization 
of drug metabolizing enzymes. Although (after adequate supply of cofactors) 
the metabolic rates obtained with this fraction sometimes equal those ob-
served with the 9000 g supernatant (2), the reaction rate is often lower. 
We have observed this with the hydroxylation of hexobarbital. It has been 
suggested that this might be due to a soluble protein which is lost during 
centrifugation (3). 
The constituent enzymes may be solubilized by means of treatment with 
detergents, separated and further purified. The availability of pure enzymes 
is essential for the establishment of their chemical properties and the 
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understanding of the modes of interaction. It may also provide insight into 
the specificity of substrate-binding. Its usefulness, however, should not 
be overestimated. The cytochrome P-450 system is embedded in the microsomal 
membrane, and its activity has been shown to be lipid-dependent. It is con-
ceivable that the membrane structure determines enzyme activity to a certain 
degree (Chapter III,4. 1). The use of a relatively crude preparation, such as 
the microsomal fraction, for determining enzyme characteristics is, therefore, 
justified, provided the limitations are recognized (4-6). 
The availability of basic knowledge about the enzymic reactions makes 
it possible to study the influence of the factors mentioned above (blood flow, 
drug transport, etc,) on the in vivo rate of metabolism. The use of isolated 
liver cells has yielded promising results in this respect (7-10). Furthermore, 
recent studies with the isolated perfused liver have demonstrated that the 
hepatic extraction ratio may be predicted from Km and Vmax values determined 
in vitro ( 1 I). 
2. THE MEASUREMENT OF DRUG-INDUCED SPECTRAL CHANGES. 
Changes in the absolute spectrum of cytochrome P-450 cannot be measured 
directly using microsomal suspensions. The large background turbidity as well 
as the magnitude of the absolute spectrum of cytochrome P-450 itself hamper 
the accurate recording of relatively small absorbance changes induced by drug 
binding. This problem can be overcome by employing the technique of difference 
spectroscopy using a spectrophotometer which is able to record the difference 
in absorbance bet•veen a sample and a reference cuvette containing turbid 
samples (12). A baseline of zero absorbance is established with the micro-
somal suspension divided between both cuvettes and then the substrate is 
added to the sample cuvette. A shift in the absorbance peak from wavelength 
A1 to A2 is then visualized as a decrease in absorbance at A1 and an increase 
at A2 (Fig. IV, I). The magnitude of the spectral change may be defined as 
either the peak-to-trough difference or the height of the peak (or trough) 
relative to an isosbestic point. An isosbestic point occurs at a wavelength 
at which the absorbance remains constant when varying concentrations of the 
drug are added. We have adopted the first method, which, in fact, is the one 
most commonly used in drug-binding studies. Differences in turbidity and 
changes in the cytochrome P-450 concentration between sample and reference 
cuvettes must be avoided, as they may give rise to spectral artifacts. This 
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is accomplished by the addition of the substrate in very small volumes, or 
by adding equivalent volumes of buffer to the reference cuvette and equally 
stirring the contents of both cuvettes after each addition. 
A second method of measuring absorbance changes can be used if one is 
familiar with the type of spectrum to be expected, and only interested in the 
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Fig. IV, 1, Type I spectrum after addition of hexobarbi-
tal (10-4M) to the microsomal preparations. Lower part 
of the picture: ------ difference spectrum of a micro-
somal suspension (~2 mg protein/ml) from livers of phe-
nobarbital-treated rats in sample and control cuvette, 
+ 10-4 M hexobarbital in sample cuvette. - - - Calcu-
lated curve from the upper part of the figure between 
the spectrum of oxidized cyt. P-450 and oxidized cyt. 
P-450 +hexobarbital (Reproduced from Remmer et al. (13)). 
magnitude of the spectral change. A spectrophotometer which is designed for 
dual wavelength measurements is employed. Two beams of light of different 
wavelengths are directed together through a single cuvette. The wavelengths 
are adjusted to the absorbance peak and trough (or isosbestic point). After 
compensating for the absorbance difference between these two wavelengths the 
substrate is added and the absorbance recorded. In this way rapid titrations 
can be performed. Changes in turbidity and cytochrome P-450 concentration 
during the measurements, however, may cause serious pitfalls in this case, 
for example, as a consequence of settling of the microsomes, or simply by 
dilution of the sample. The absorbance due to turbidity increases exponentially 
with increasing wavelength, which effect becomes prominent in the region of 
400 nm. It is our experience that the recording of type I spectral changes 
(385 vs, 420 nm) may easily yield artifacts. 
The binding of the drug to cytochrome P-450 can be quantitated using the 
laws of enzyme-substrate or drug-receptor interaction: 
6A . [S] 
max 
[S J + K 
s 
K
8 
represents the disso~iation constant of the drug, or the concentration at 
which half of the binding sites are occupied. 6Amax is the maximum spectral 
change, and is a measure of the total number of binding sites, These constants 
AA3 /-, t 1/AA / \ I \ 
.o.A2 I I -~ \ 
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Fig. IV,2. Determination of binding constants (spectral 
dissociation constant K, and maximum spectral change 6~ax), 
using a double reciproc~l plot. 
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can be calculated from a double reciprocal plot (Fig. IV,2) or by using the 
method of Wilkinson (14), which fits the data directly to the equation of a 
hyperbole after a provisional estimation of the constants by a >veighted 
linear regression analysis. We have used the latter method, as it puts less 
emphasis on the less accurate data points (at the lower substrate concentra-
tions). 
3. THE ASSAY OF NADPH-CYTOCHROME P-450 REDUCTASE ACTIVITY. 
The assay of the reduction of cytochrome P-450 by NADPH in liver micro-
somes has been described by Gigon et al. (15). This reduction should be 
examined under anaerobic conditions in a carbon monoxide atmosphere. The 
assay is based on the characteristic absorbance peak of the reduced cytochrome 
P-450-CO complex (Chapter III,2). Since CO binds only to the reduced form of 
cytochrome P-450 it is essential that the rate of CO-binding does not inter-
fere with the rate of reduction. Several investigations have indicated that 
CO-binding is indeed a very fast reaction (15-19), and that the binding 
affinity is high (20,21). 
The microsomal suspension may be made anaerobic by bubbling with CO, 
which has been passed through an alkaline dithionite solution (0.5% sodium 
dithionite and 0.05% sodium anthraquinone-2-sulfonate in 0,1 N NaOH) to 
remove traces of oxygen. For some studies an additional treatment with either 
a glucose oxidase/glucose/catalase system is needed, or alternatively a 
treatment with electron transport particles (beef heart mitochondria) sup-
plemented with succinate (in the absence of carbon monoxide). It has been 
demonstrated, however, that the initial rate of reduction was not affected 
by traces of oxygen (15,22). Therefore, bubbling with CO for 5 minutes was 
considered to be sufficient for the reductase assay (prolonged treatment 
did not yield any improvement). An instrumentation analogous to the Aminco 
anaerobic cuvette (Al-65085) was used as a reaction vessel (Fig. IV,3). 
Bubbling was performed in the cuvette, which was placed in a waterbath, 
thermostatically controlled at 30°C. The stopcock-plunger assembly containing 
the NADPH-solution as a starter was mounted on the cuvette and CO was led 
over the suspension for an additional one minute. Then the stopcock was 
turned, which closed the vessel. The cuvette was then placed in the thermo-
statically controlled (30°C) spectrophotometer (Aminco DW/2) and allowed to 
equilibrate for 1 minute. A level of zero absorbance was established. Then 
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Fig. IV,3. Anaerobic cuvette. 
Further description in the text. 
the plunger was rapidly depressed and the reaction started. Settling of 
microsomes during the tinte of equilibration did not introduce a mixing arti-
fact. This was verified by the observation that stirring (with a magnetic 
stirring rod) did not affect the reaction profile. 
The best estimate of the initial reduction rate was obtained by determin-
ing the absorption at a fixed time interval after the depression of the 
plunger (indicated by the rapid deviation from the line of zero absorbance). 
It was observed that when running a blank with only buffer in the plunger 
the absorbance arrived at a constant level after approx. 1.2 sec. The absorb-
ance at 1.5 sec after mixing was, therefore, taken as the most reliable 
estimate of the initial rate. This value was corrected for the small change 
in absorbance caused by dilution of the preparation with 50 ~1 buffer, which 
is the volume in which NADPH was added, 
When the reductase activity was measured in the presence of a type I 
substrate, which stimulates the rate of reduction, this substrate was added 
to the microsomes prior to the bubbling with CO. There has been one study 
which indicated that the addition of ethylmorphine together with NADPH 
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resulted in a much smaller stimulation as compared with prior addition to the 
microsomes (23). We did not observe this effect, which is, in fact, hard to 
understand, since the combination of type I substrates with oxidized cyto-
chrome P-450 occurs very rapidly. Half-times of 15 msec (for hexobarbital at 
4°C) (24) and 35 msec (for benzphetamine at 7°C) (25) have been reported. 
The stimulation of reductase activity (6red) was simply defined as the 
difference between the initial rates in the presence and absence of substrate, 
The NADPH concentrations used, as described in the literature, show con-
siderable variation, and the same is observed with the protein concentrations. 
A concentration of 0.48 mM NADPH was routinely used in our experiments. 
Table IV, 1 and Fig. IV,4 show that this leaves a safe margin, since the 
protein concentration \Vas always approx. 1 mg/ml ('Vl nmol P-450/mg protein). 
Some authors use NADPH-generating systems, but Gigon et al. (1) demonstrated 
that there is no essential difference between these two methods. 
Table IV,l. Effect of NADPH-concentration on the initial rate of reduction 
of cytochrome P-450 by NADPH-cytochrome P-450 reductase (female mice) . 
NADPH concentration basal reduction rate 
reduction • in the presence of (mM) rate • I mM ethylmorphine 
0.48 9.67 + 0, 13a 16.0 I + 0. 13b 
0.24 9. 41 + 0.06 15.85 + 0. 14 c 
0.096 9.02 + 0,06a 15.35 + 0.08b,c 
* Values are expressed as nmol reduced/nmol P-450, and represent means + SE 
of 3 experiments. 
a,b,c Significant differences, p<O.OS (Student's t-test). 
It is necessary to keep factors, such as temperature, ionic strength, pH, 
and buffer controlled, since considerable variation in reductase activity 
might occur (26,27), As an example we have observed that the use of Tris or 
phosphate buffer influences the stimulation produced by hexobarbital 
(Table IV,2). Interestingly, the basal activity was not affected. Although 
this is not of practical importance, this phenomenon might deserve further 
investigation, 
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nmol P-450 reduced/min/ml 
2 4 5 6 7 
nmol P-450 / ml 
Fig. IV,4. Linearity of the initial rate of cytochrome 
P 450 reduction with the concentration of microsomes 
(marked by their cytochrome P-450 content). Microsomes 
from male mice were used. Data points represent means 
of duplicate determinations. 
Table IV,2. Effect of buffer on the initial rate of reduction of cytochrome 
P-450 by NADPH-cytochrome P-450 reductase (female mice) . 
buffer 
Tris 
(0.05 M, pH 7.5) 
Phosphate 
(0.1 M, pH 7.4) 
basal 
reduction • rate 
8. 32 + 0. 15 
8.29 + 0. 15 
reduction rate reductase 
in the presence of stimulation 
I mM hexobarbital • 
13.26 + 0.25a 4.94 
12.07 + 0. 20a 3.78 
* Values are expressed as nmol reduced/nmol P-450, and represent means + SE 
• 
of 4 or 3 experiments, in the absence or presence of hexobarbital resPectively. 
a; Significantly different from each other, p<0.05 (Student's t-test). 
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CHAPTER V. SEX- AND STRAIN-DEPENDENT HEPATIC MICROSOMAL ETHYLMORPHINE 
N-DEMETHYLATION IN MICE: THE ROLES OF TYPE I BINDING AND 
NADPH-CYTOCHROME P-450 REDUCTASE. 
SUMMARY. 
The roles of type I binding and NADPH-cytochrome P-450 reductase in 
ethylmorphine demethylation were investigated in two strains of mice, using 
sex differences in these activities as a tool. In the CPB-SE strain, females 
metabolize ethylmorphine faster than males. Sex differences in cytochrome 
P-450 content and endogenous NADPH-cytochrome P-450 reductase activity were 
too small to account for this. On the other hand, the differences in the 
magnitudes of type I spectra and ethylmorphine-induced enhancement of cyto-
chrome P-450 reduction were considerably larger than those in the rates of 
demethylation. All parameters, except endogenous cytochrome P-450 reduction, 
were modified in a similar way by testosterone pretreatment: in females they 
were depressed to the male level, whereas in males they remained unchanged. 
Castration had no effect in females and enhanced the activities in males. 
The CPB-V strain exhibited little or no sex differences in ethylmorphine de-
methylation, cytochrome P-450 content and endogenous cytochrome P-450 reduc-
tion. Testosterone pretreatment had little or no influence on these activ-
ities. Type I binding and reductase stimulation, however, showed sex differ-
ences, comparable to those observed in the CPB-SE strain, which were also 
abolished by testosterone. A relationship between reductase stimulation and 
type I binding was observed, which was, apparently, independent of sex or 
strain. It is concluded that androgen primarily influences the amount of 
cytochrome P-450-substrate complex formed, but that the reduction of this 
complex is not rate-limiting in the demethylation of ethylmorphine. 
INTRODUCTION, 
The activity of the hepatic microsomal cytochrome P-450-dependent drug 
metabolizing enzyme system is sex-dependent with regard to type I substrates 
(I) in rats and mice. This sex-dependency has been extensively studied in 
rats (see 2 for review), and seems to be the result of a stimulatory action 
of androgen, which elevates the activity in males. In mice, sex differences 
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are not consistently observed (2-6) and appear to be strain-dependent (7,8). 
We have directed our attention to mice, since this species is seldomly studied 
and the sex difference appears to be opposite to that observed in rats, i.e. 
female mice metabolize hexobarbital and ethylmorphine faster than males 
(8-1 1). We have suggested, on the basis of the effects of testosterone pre-
treatment and castration, that this paradox in mice may be attributed to an 
inhibitory action of androgen (8). 
In this study the N-demethylation of ethylmorphine in mice was further 
investigated. According to the hypothetical reaction scheme (e.g. 12) the 
initial reaction steps involve the binding of substrate to cytochrome P-450 
and the subsequent reduction of the cytochrome P-450-substrate complex by 
NADPH-cytochrome P-450 reductase. The spectral change observed upon the 
addition of the substrate to microsomes is presumed to reflect the formation 
of this complex (1). The reductase step has long been considered to be rate-
determining in rats, after Gigon et al. (13) had observed a parallel between 
the stimulation of reductase activity produced by type I substrates and their 
rate of metabolism. This stimulation was presumed to represent the rate of 
reduction of the cytochrome P-450-substrate complex. 
In a previous investigation in our laboratory the cytochrome P-450 con-
tent, NADPH-cytochrome c reductase activity and magnitude of type I spectral 
interaction were shown to be unrelated to the rate of hydroxylation of hexo-
barbital in mice of the CPB-SE strain (8). Hexobarbital hydroxylation, 
however, was measured in 9000 g supernatant, whereas the other parameters 
were determined in microsomes. Furthermore, the assay of NADPH-cytochrome 
P-450 reductase was not included. 
In the present study the relationships between NADPH-cytochrome P-450 
reductase activity, type I binding, cytochrome P-450 content and ethyl-
morphine N-demethylation were investigated in liver microsomes from mice of 
the CPB-SE strain. For this purpose the existence of sex differences is a 
very useful tool. The comparison of sex differences alone, however, is not 
sufficient. It is necessary to demonstrate that different reaction steps can 
be modified in parallel. Therefore, the effects of testosterone pretreatment 
and castration were also examined. 
Previously, we have observed that the CPB-V strain, in contrast to the 
CPB-SE strain, does not exhibit a sex difference in ethylmorphine demethyl-
ation (8), but, nevertheless, a sex difference in type I binding is apparent. 
On the basis of this interesting finding the CPB-V strain was also investi-
gated further. We describe here the observations that both type I binding 
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and ethylmorphine-induced stimulation of NADPH-cytochrome P-450 reductase 
activity are sex-dependent in both strains. The significance of these findings 
with regard to the rate-limiting step in the demethylation of ethylmorphine is 
discussed. In addition, the effects of androgen are further specified. 
MATERIALS AND METHODS. 
gg,g-!!}i£§!!.£. 
Ethylmorphine was obtained from Brocacef; NADP+ (grade I), NADPH (grade I), 
glucose-6-phosphate (disodium salt), and glucose-6-phosphate dehydrogenase 
(grade I) were obtained from Boehringer, and bovine serum albumin from Poviet. 
Testosterone propionate was a generous gift from Organon. All other chemicals 
used were at least reagent grade. 
10 Week old male and female mice from both CPB-SE and CPB-V strain were 
obtained from the Central Animal Breeding Station TNO, Zeist, The Netherlands. 
They were kept in Makrolon cages with pinewood shavings, received standard 
food pellets (Hope Farms) and water ad lib., and were used within a few weeks. 
Testosterone pretreatment was carried out by subcutaneous injection of 
testosterone propionate (2.5 mg in 0. I ml arachis oil/animal) 14, 10, 7 and 
3 days before the experiments, Control animals received an equivalent volume 
of oil. Castration (orchectomy and ovariectomy) was performed under light 
ether anesthesia at least 4 weeks in advance. Control animals were sham 
operated. 
After starving overnight, the animals were killed by a blow on the head. 
Livers were homogenized in 3 volumes of 0. I M phosphate buffer (pH 7.4), 
using glass Potter tubes with a Teflon pestle. The homogenate was centrifuged 
for 20 minutes at 9000 g and the microsomal fraction was sedimented from the 
resulting supernatant by centrifuging at 75,000 g for 90 minutes, The pellet 
was suspended in 0.1 M phosphate buffer (pH 7.4). For each determination the 
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livers o-f several animals were pooled. 
Ethylmorphine demethylation was assayed by measuring the formation of 
formaldehyde. Incubations (10 minutes) were carried out at 37°C, with shaking, 
air being freely admitted. The incubation mixture contained ethylmorphine 
(BE-strain, 3 ~mol; V-strain 1.5 ~mol), NADP+ (0. 75 ~mol), glucose-6-phosphate 
(12.5 ~mol), glucose-6-phosphate dehydrogenase (1 IU), semicarbazide (12.5 
~mol), nicotinamide (5 ~mol), MgC1 2 (12.5 ~mol), and microsomes , in a total 
volume of 3 ml. The reaction was initiated by the addition of 0.5 ml of 
microsomal suspension (10 mg protein/ml) and stopped by subsequent additions 
of 0.5 ml 40% Znso4 and I ml saturated Ba(OH) 2 . After centrifugation, 2 ml of 
the supernatant were mixed with 1 ml double strength Nash reagent (14), and 
incubated at 60°C for 30 minutes. The amount of HCHO formed tvas estimated by 
determining the absorbance at 415 nm relative to that at 500 nm, and sub-
tracting the amount of Nash-positive material formed in the appropriate blank. 
Difference spectra were recorded on an Aminco-Chance dual wavelength 
spectrophotometer in the split beam mode. Cuvettes contained 3 ml of micro-
somal suspension (3 mg prot./ml). After establishing a baseline of equal 
absorbance, ethylmorphine (3 ~mol) was added to the sample cuvette and the 
difference spectrum was recorded. The peak-to-trough difference (385-420 nm) 
was taken as the magnitude of spectral interaction, and expressed in absorb-
ance units. 
NADPH-cytochrome P-450 reductase was assayed essentially as described by 
Gigon et al. (13). 2.5 ml of a microsomal suspension, containing about 1 mg 
protein/ml, were bubbled with carbon monoxide for 5 minutes at 30°C. The CO 
was passed through an alkaline dithionite solution to remove traces of oxygen. 
A stopcock-plunger assembly provided with 50 ~1 of NADPH-solution (20 mg/ml) 
was fitted to the cuvette and CO was led over the suspension for an additional 
I minute. The cuvette was then closed and placed in an Aminco DW-2 UV-VIS 
spectrophotometer, used in the dual wavelength mode. The cuvette-holder was 
thermostatically controlled at 30°C. A baseline of zero absorbance was es-
tablished. After I minute the plunger was quickly depressed and the 450 minus 
490 nm absorbance change recorded at a chart speed of 2 inch/sec. The initial 
rate of reduction was estimated by determining ~A at 1.5 sec after mixing 
and expressed as nmol cytochrome P-450 reduced/min/mg protein using 
-1 -1 91 em roM as the value of the absorption coefficient (15). Reductase 
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stimulation (D d) represents the difference between the initial rates of 
re 
reduction, with and without added ethylmorphine (2,5 ~mol), which were de-
termined in duplicate and triplicate respectively. The total amount of cyto-
chrome P-450 present was determined by completely reducing the cuvette con-
tents by adding a few crystals of sodium dithionite and allowing the reaction 
to proceed for at least 1 minute. 
Microsomal protein was assayed according to the method of Lowry et al. 
(16), using crystalline bovine serum albumin as a standard. 
Student's t-test (two-tailed) was used for statistical analysis. 
RESULTS, 
I. CPB-SE strain. 
-------------
I. 1. No treatment. 
In Fig. V,l a sex difference in ethylmorphine N-demethylation is demon-
strated. Cytochrome P-450 content and magnitude of type I spectral inter-
action showed a similar sex-dependency, although to different extents, the 
difference being smaller for cytochrome P-450 and larger for type I binding. 
NADPH-cytochrome P-450 reductase was also more active in females than in 
males, the sex difference being comparable to that found with cytochrome P-450 
content. Addition of ethylmorphine, however, caused a profound stimulation 
of reductase activity in females. The stimulation was fourfold greater than 
that observed in males. The sex differences in all parameters were quali-
tatively similar. 
1.2. Testosterone pretreatment. 
Treatment with testosterone has been shown to abolish the sex differences 
in hexobarbital hydroxylation, by depressing female values to the male level, 
leaving male values unchanged (8). The present results indicate that ethyl-
morphine demethylation is affected in a similar way (Fig. V,2). Cytochrome 
P-450 content, type I binding and reductase stimulation were also diminished 
in females and remained unaltered in males. There was no significant sex 
difference between the resulting values. No sig~ificant change was seen in 
basal reductase activity. These results strengthen the proposition that 
androgen plays a role in regulating microsomal drug metabolism in mice, 
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Fig. V, 1. Ethylmorphine N-demethylation and components 
of the mixed-function oxidase system in hepatic microsomes 
from male and female mice of the CPB-SE strain. 
All values are related to mg microsomal protein, each 
representing the mean + SE of the number of experiments 
indicated. a. SignifiCant sex difference (p<O.OOI). 
1.3. Castration. 
Castration abolished the sex difference in demethylation activity by 
enhancing the rate of metabolism in males to the level observed in females 
(Fig. V,3). In females a slight, but statistically significant decrease was 
noticed. This had not been observed in the case of hexobarbital metabolism 
(8). In males, cytochrome P-450 content, type I binding and reductase stimu-
lation underwent parallel changes as a consequence of the treatment. In 
contrast, basal reductase was not affected, Castration of males did not in 
all cases lead to complete feminization of enzyme activities. Statistically 
significant sex differences remained in basal reductase (p<0.02) and in 
48 
0 females control (oil) 
f2l females testosterone 
• males control (oil) 
(ZJ males testosterone 
l>A385-420X 103 nmol cyt. P-450 reduced/min 
nmol HCHO nmol 
formed/min 
1.5 
4 
1.0 
b 
2 
1": 
a 
0 
cyt. P-450 
12 
15 lO 
8 
lO 
6 
4 
5 
2 
0 0 
type I 
a 
basal .6.red 
11 
11 
ethylmorphine 
demethyl ati on 
(n = 6) (n = 4) 
spectral change 
(n = 6) 
NADPH-cyt. P-450 reductase 
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Fig. V,2. Effects of testosterone pretreatment on 
ethylmorphine N-demethylation and on components of the 
mixed-function oxidase system in hepatic microsomes from 
male and female mice of the CPB-SE strain, 
All values are related to mg microsomal protein, each 
representing the mean + SE of the number of experiments 
indicated, a. SignifiCant effect of treatment (p<O.OOI), 
b. id. (p<0.002). 
reductase stimulation (p<0,05). 
In order to examine the possible relationships between the various para-
meters more thoroughly, sex differences and the effects of treatments were 
expressed as percentages, which are shown in Table V,l. A suitable candidate 
for a rate-controlling factor should exhibit values similar to those obtained 
for ethylmorphine demethylation. The total amount of cytochrome P-450 as well 
as the endogenous rate of cytochrome P-450 reduction show much less variation 
than the demethylation rate. A striking correlation bett.;reen type I binding 
and reductase stimulation is revealed, suggesting that these phenomena are 
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Fig. V,3. Effects of castration on ethylmorphine 
N-demethylation and on components of the mixed-function 
oxidase system in hepatic microsomes from male and 
female mice of the CPB-SE strain. 
All values are related to rug microsomal protein, each 
representing the mean + SE of the number of experiments 
indicated. a. SignifiCant effect of treatment (p<O.OOJ), 
b. id. (p<O.OI), c. id. (p<O.OS). 
intimately associated. In view of several other reports (13,17,18) it is 
tempting to interpret this correlation as the expression of enzyme-substrate 
binding and subsequent reduction of enzyme-substrate complex. The fact that 
these parameters were more sensitive to androgen than the rate of demethyl-
ation implies that the reduction is not solely rate-limiting. 
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Table V,1. Comparison of the variations due to sex, testosterone pretreatment, and castration in ethylmorphine 
N-demethylation and components of the mixed-function oxidase system in hepatic microsomes from mice 
of the CPB-SE and CPB-V strain. 
Sex differences and effects of treatments are expressed as males/females x 100% and treated/untreated x 100%, 
respectively. Values were calculated from Figs. V, 1-5. 
strain treatment 
CPB-SE none 
testosterone 
castration 
CPB-V none 
testosterone 
M/F 
M contr./F contr. 
F test./F contr. 
M sham/F sham 
M cas tr. /M sham 
M/F 
M contr./F contr. 
F test. /F contr. 
ethyl-
morphine 
demeth. 
57 
50 
46 
46 
175 
107 
94 
106 
P-450 
81 
83 
72 
84 
115 
118 
120 
113 
type I 
spectrum 
25 
30 
29 
35 
218 
47 
50 
47 
P-450 reduction 
basal 
" red 
70 26 
74 38 
85 36 
78 33 
107 220 
108 49 
116 54 
120 56 
2. CPB-V strain. 
2. 1. No treatment. 
Fig. V,4 shows the lack of a sex difference in ethylmorphine demethylation 
in the V-strain. Male liver microsomes were slightly richer in cytochrome 
P-450. Basal reductase activities were not significantly different. A sex 
difference was present in type I binding, although less profound than that 
observed in the SE-strain. A similar pattern was found for reductase stimu-
lation. The absence of a sex difference in ethylmorphine demethylation 
suggests that in the V-strain this reaction is insensitive to androgen. 
Nevertheless, type I binding and reductase stimulation do show sex differ-
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Fig. V,4. Ethylmorphine N-demethylation and components 
of the mixed-function oxidase system in hepatic microsomes 
from male and female mice of the CPB-V strain. 
All values are related to mg microsomal protein, each 
representing the mean + SE of the number of experiments 
indicated. a. SignifiCant sex difference (p<O.OOI), 
b. id. (p<O.OS). 
ences, which indicates that they are regulated by sex hormones. It was, there-
fore, of interest to see whether testosterone pretreatment would abolish the 
sex differences in these parameters, or at least affect them in the same way, 
2.2. Testosterone pretreatment. 
As expected, testosterone did not produce any changes in ethylmorphine 
demethylation (Fig. V,S). In females, type I binding and reductase stimula-
tion were depressed to male levels. Cytochrome P-450 content was slightly 
increased in females, which is also in accordance with the slight sex differ-
ence in this strain. With basal reductase a similar effect was observed. 
D females control (oi I) 
fZZI feme les testosterone 
nmol HCHO formed/min 
6 nmol 
1.5 
4 
l.O 
2 
0.5 
0 0 
cyt. P-450 
• males control (oil) 
E:J males testosterone 
15 
a 
0 I 
type I 
nmol cyt. P-450 reduced/min 
14 
12 
c 
2 
0 
basal l:!.red 
ethylmorphine 
demethylation 
(n = 6) (n = 4) 
spectral change 
(n = 6) 
NADPH-cyt. P-450 reductase 
(n = 4) 
Fig. V,5. Effects of testosterone pretreatment on 
ethylmorphine N-demethylation and on components of the 
mixed-function oxidase system in hepatic microsomes 
from male and female mice of the CPB-V strain. 
All values are related to mg microsomal protein, each 
representing the mean + SE of the number of experiments 
indicated, a. SignifiCant effect of treatment (p<O.OOI), 
b. id (p<0.002), c. id. (p<0.02). 
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No significant alterations occurred in males, except that reductase stimu-
lation was somewhat enhanced. It is not clear what significance this might 
have. 
Examination of the relative sex differences and effects of treatment 
reveals a parallel between reductase stimulation and type I binding, as was 
observed in theSE-strain (Table V, 1). However, demethylation rates do not 
reflect changes in either parameter. This indicates that reductase stimulation 
and type I binding are not rate-controlling. 
The results with both the SE- and the V-strain suggest that a relation-
ship between reductase stimulation and type I binding exists, which is in-
dependent of sex or strain. In order to further substantiate this, a constant 
ratio Dred/DA should be demonstrated, besides concurrent variations in Dred 
and DA. In Table V,2 these ratios are listed for all groups of animals used 
throughout this study. They appear to be in reasonable agreement, as the 
relative standard errors of these ratios amount to approx. 5-10%. Three 
values in the testosterone treatment group of the V-strain are rather high. 
These might be related to the corresponding basal reduction rates, which are 
the highest measured in this study. 
Table V,2. 
cytochrome 
microsomes 
strain 
CPB-SE 
CPB-V 
• 
Relationship between ethylmorphine-induced enhancement of NADPH-
P-450 reductase activity and ethylmorphine binding in hepatic 
from male and female mice of the CPB-SE and CPB-V strain. 
treatment 
females 
control 
none 0.47 
testosterone 0.43 
castration 0.54 
none 0. 50 
testosterone 0.59 
6red/6A * 
females males 
treated control 
0.49 
0.55 0.54 
0.58 0.51 
0.51 
0. 70 0.63 
males 
treated 
0.41 
0.51 
0. 75 
Values from Figs. V,l, V,2, V,3, 
reductase stimulation (bred) vs. 
V,4 and V,S were used 
type I spectral change 
to calculate 
(DA) ratios, 
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DISCUSSION. 
The correlation between type I binding and reductase stimulation in mice 
strongly suggests that substrate binding to the type I binding site is 
directly responsible for reductase stimulation, although discrepancies between 
these parameters have been reported in rats (17,19). As it is unlikely that 
the reductase step is bypassed in the demethylation reaction, this observation 
emphasizes the importance of type I binding for this reaction. This enforces 
the general belief that type I binding represents the formation of an enzyme-
substrate complex (1,20). The lack of agreement between the sex-dependent 
differences in the magnitude of the type I spectral interaction and the de-
methylation of ethylmorphine, therefore, indicates that the reduction of this 
complex by NADPH-cytochrome P-450 reductase may not control the rate of 
demethylation. The rate-limiting character of the reductase step was orig-
inally proposed by Gigon et al. (13). This concept has found considerable 
support (17-19,21), but has also been challenged (22-24), 
A measurement of NADPH-cytochrome P-450 reductase activity can be obtained 
from the endogenous (basal) rate of reduction, the reduction rate in the 
presence of substrate (total activity), or the difference between these two 
(reductase stimulation, 6red). The endogenous rate of reduction can hardly 
be expected to control the rate of substrate oxidation, since rates of drug 
metabolism within a single enzyme preparation vary widely, depending on the 
substrate. Table V,1, in fact, demonstrates that the basal reduction rate is 
not related to the demethylation rate, which is in agreement with data 
obtained by Davies et al. (5), 
Cytochrome P-450 reduction proceeds via two superimposed phases, a rapid 
phase and a slow phase (13,18,24-26). Type I substrates enhance the initial 
rate of reduction, probably by binding to cytochrome P-450, If this enhance-
ment is the result of an increase in the amount of cytochrome P-450 which is 
reduced in the rapid phase (13,18), 6red represents the rate of reduction of 
the cytochrome P-450-substrate complex which is formed. Significant corre-
lations between 6red and substrate oxidation have been observed repeatedly 
(13,17-19,21). Our results show that 6red is not a rate-limiting factor in 
ethylmorphine demethylation in both the SE- and the V-strain. If reductase 
stimulation is due to an effect on the rate constant of the rapid phase (25), 
the measurement of the rate of reduction of the cytochrome P-450-substrate 
complex is not well-defined. The heterogeneity of cytochrome P-450 (27-32), 
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and especially the heterogeneity of type I binding sites (28), implies that 
not all the reducible cytochrome P-450 is involved in the binding of a single 
substrate. The actual rate of complex reduction will thus be lower than the 
total reduction rate, but higher than the value of 6red' As the relative sex 
differences in complex reduction will be less marked than in 6red' a rate-
limiting function of the reductase in the SE-strain thus cannot be fully re-
jected. Other work on the SE-strain, however, has revealed further discrep-
ancies (33). 
The effects of androgen on the cytochrome P-450 system in mice are in-
hibitory (in contrast to the stimulatory effects observed in rats (2)). The 
sex differences in some parameters of the enzyme system, however, mainly arise 
from increases occurring in females during sexual maturacion (33), This sug-
gests that androgen reversibly impairs developmental changes, Basal cytochrome 
P-450 reductase activity appeared to have a more permanent sex difference, 
which explains the present finding that this activity tvas not affected by 
testosterone pretreatment and castration. 
The main sice of androgen interaction appears to reside in the cytochrome 
P-450 fraction, resulting in a discrepancy between cytochrome P-450 content 
and excent of type I binding. Testosterone might cause a decrease in the 
number of a specific type of binding sites for ethylmorphine. Alternatively, 
it might introduce a high level of tightly-binding endogenous substrates, 
such as steroids, which are themselves metabolized by the cytochrome P-450 
system (34), and which possess a high affinity for cytochrome P-450 (35). 
We have obtained data which suggest that the first possibility is more 
likely (33, and Van den Berget al., to be published (Chapters IX and X)). 
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CHAPTER VI. SEX DIFFERENCES IN THE KINETIC CONSTANTS OF ETHYLMORPHINE DE-
METHYLATION AND TYPE I BINDING TO HEPATIC MICROSOMAL CYTOCHROME 
P-450 IN MICE. THE INFLUENCE OF CASTRATION A'~ TESTOSTERONE. 
SUMMARY. 
I. In the CPB-SE mouse strain sex differences were observed in the K and 
m 
Vmax of ethylmorphine demethylation and in the 6Amax of its type I binding 
to cytochrome P-450. 
2. In the CPB-V strain a small sex difference in the V of the de-
max 
methylation was found, whereas Ks and bAmax of type I binding differed 
considerably. 
3. Testosterone pretreatment of female CPB-SE mice abolished all sex 
differences, and castration of males all except that in Vmax' which was 
partially decreased. 
4, In the CPB-V strain testosterone pretreatment of females abolished 
sex differences in type I binding but had no effect on ethylmorphine de-
methylation. 
5. Km values exceeded the corresponding Ks in all cases and sex differ-
ences in 6A far exceeded those in V , 
max max 
6. It is concluded that the Km is not only determined by the Ks of 
type I binding and the reduction rate of the type I complex between ethyl-
morphine and cytochrome P-450. 
7. The larger sex differences in 6Amax as compared with Vmax may be 
attributable to type I binding of ethylmorphine to cytochrome P-450 sub-
species not involved in its demethylation. 
INTRODUCTION. 
Type I binding of substrates to hepatic microsomal cytochrome P-450 may 
be regarded as an interaction with the active site of the enzyme or, at least, 
as a facilitation of the metabolic reactions catalyzed by this cytochrome (1), 
The dissociation constants (Ks) have been compared, under various conditions, 
with the Michaelis-Menten constants (Km) of the metabolic reaction (see 
review by Mannering (2)). Although, in many cases, a large discrepancy was 
found between these constants, Km values usually exceeding Ks' in some 
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instances no differences were found (3,4). Our investigations, using the 
enantiomers of hexobarbital in mice and rats, revealed that, in mice, Km and 
Ks do not differ, whereas, in rats, Km was about five to six times higher 
thanKs (5). This could be explained by the observation that differences in 
the rates of metabolism of the enantiomers in rats were not paralleled by 
differences in the substrate-induced enhancement of NADPH-cytochrome P-450 
reductase, which is regarded as the expression of the reduction rate of the 
type I complex between the substrate and the cytochrome (6). If this reduction 
is not rate-limiting for the whole reaction, the kinetic constants of type I 
binding and metabolism are not necessarily similar. In mice, however, a 
parallel between metabolism and enhancement of cytochrome P-450 reduction was 
observed which explained the similarity between K and K for hexobarbital 
m s 
in this species. 
We previously reported a sex difference in the rate of metabolism, in 
mice, of various type I substrates including hexobarbital, ethylmorphine and 
aminopyrine (5,7). Using a single substrate concentration, we demonstrated 
that this sex difference is abolished by either castration of males or 
testosterone pretreatment of females (7). A relation between type I binding 
and metabolism was suggested by the fact that only type I substrates and, to 
a lesser extent, substrates binding to both type I and type II sites are 
metabolized faster by female mice than by males, whereas for the type II 
substrate aniline, no such sex difference could be demonstrated (5). 
However, the relationship might be complicated by the heterogeneity of 
type I binding sites in rats (8,9) a phenomenon which may also occur in mice, 
In the present work we studied the kinetics of ethylmorphine demethylation 
in male and female CPB-SE mice. In this strain, males exhibit a higher Km and 
lower Vmax for the reaction than females. Analogous sex differences were ob-
served with Ks and 6Amax for type I binding to cytochrome P-450, Ks being 
higher and 6Amax lower in males (5). 
By determining the effect of castration and testosterone pretreatment on 
these parameters other possible parallels between Ks and 
hand and K 
m 
and Vmax on the other could be investigated. 
6A 
max 
on the one 
We further studied 
these constants in the CPB-V strain, which has previously been reported to 
lack a sex difference in hexobarbital metabolism (7). The absence of this sex 
difference was further clarified by determining the effect of testosterone 
pretreatment on ethylmorphine demethylation and by measuring plasma testoster-
one levels, 
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MATERIALS AND METHODS. 
Animals. 
Male and female mice of the CPB-SE and CPB-V strain (TNO,Zeist) were used, 
which were at least 10 weeks old. They were housed in Makrolon cages on pine-
wood shavings and allowed free access to Hope Farm food pellets and tap water. 
Treatments. 
----------
Castration (orchectomy or ovariectomy) was carried out under light ether 
anesthesia, four weeks before the experiments. Control animals were sham-
operated. Testosterone pretreatment consisted of 4 subcutaneous injections 
of 2.5 rng testosterone propionate in 0.1 ml arachis oil 14, 10, 7 and 3 days 
before the experiments. Controls received arachis oil only. 
Animals, starved overnight, were killed by a blow on the head. After re-
moval of the gall bladder, livers were rapidly excised and homogenized in 3 
volumes of ice-cold 0.1 M phosphate buffer, pH 7.4, using glass Potter tubes 
with a Teflon pestle. The homogenate was centrifuged at 9000 g for 20 minutes. 
The microsomal fraction was sedimented from the supernatant by 90 minutes 
centrifugation at 75,000 g. The pellet was resuspended in the same buffer to 
a final concentration of 10 mg protein/ml. Pro~ein was determined with the 
Falin reagent (10) using bovine serum albumin as a standard. 
Ethylmorphine demethylation was determined by measuring the formation of 
formaldehyde, Incubations were carried out at 37°C for 10 minutes in a shaking 
incubator under air. The incubation mixture contained NADP+ (0.75 ~mol), 
glucose-6-phosphate (12.5 ~mol), glucose-6-phosphate dehydrogenase (1 IU), 
semicarbazide (12.5 ~mol), nicotinamide (5 ~mol), MgC1 2 (12.5 ~mol) and 
ethylmorphine in concentrations of 0.4, 0,5, 0.67, I and 2 mM in a total 
volume of 2.5 ml 0.1 M phosphate buffer, pH 7.4. The reaction was started by 
addition of 0.5 ml microsomal suspension and stopped 10 minutes afterwards 
by addition of 0.5 ml 40% Znso 4 and 1 ml saturated Ba(OH) 2 , respectively. 
After centrifugation, 2 ml of the supernatant were mixed with 1 ml double 
strength Nash reagent (1 1) and incubated for 30 minutes at 60°C. The amount 
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of formaldehyde formed was estimated from the difference in absorbance 
between 415 and 500 nm after subtraction of Nash-positive material formed in 
incubates without added substrate. 
Difference spectra due to the addition of ethylmorphine to microsomal 
suspensions (3 mg protein/ml), were recorded in an Aminco-Chance dual wave-
length spectrophotometer in the split-beam mode. The magnitude of the spectral 
interactions is given as ~A390_ 420 . 
Testosterone determination. 
--------------------------
Testosterone was determined in plasma by radioimmunoassay, as described 
by Verjans et al. (12). Blood was collected by means of orbital puncture in 
tubes containing heparin. 
Kinetic constants for ethylmorphine demethylation (Km' Vmax) and type I 
binding (Ks' 6Amax) were calculated using the method of Wilkinson (13). 
Differences between groups of data were tested using Student's t-test (two-
sided). 
f~~~~E~!~· 
Ethylmorphine-HCl was obtained from Brocacef; NADP+ (grade I) and glucose 
6-phosphate dehydrogenase (grade I, from yeast) from Boehringer and crystal-
line bovine serum albumin from Poviet. Testosterone propionate was a generous 
gift from Organon. All other chemicals used were of reagent grade purity. 
RESULTS. 
Table VI,l shows the kinetic constants of ethylmorphine demethylation and 
type I binding to cytochrome P-450 in male and female CPB-SE mice. It appears 
that, in both male and female animals, the Km for metabolism exceeds the Ks 
for type I binding. Comparing the sexes, it is evident that the values for KID 
differ far more than K8 values, which either do not differ, as also observed 
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by Van den Berg et al. (14), or differ slightly (5). The 6Amax values also 
differ much more than do V values. 
max 
Table VI, I. Kinetic constants of demethylation and type I binding of ethyl-
morphine in liver microsomes of male and female CPB-SE mice. 
K V 6A 
m 
K 
s max max 
(mH) (rnH) (nmol/min/mg prot) (6A390_420 /mg prot) 
Males 1.27 + 0.15 (9) 0.20 + 0.02 (9) 6.50 + 0.34 (9) 4.7 + 0.5 (9) 
Females 0.69 + 0.07 (9)** 0.22 + 0.01 (10) 9.18 + 0.72 (9)"' 18.5 + 0.4 (10)' 
Values represent means + SE of the number of experiments indicated in parenth-
eses. ~Significant sei difference, p<O.OOl; ** id., p<O.Ol. 
Table VI,2 summarizes the kinetic constants for ethylmorphine demethyl-
ation and type I binding in liver microsomes from orchectomized male and 
ovariectomized female CPB-SE mice and their sham-operated controls. Again, 
in all groups studied, Km values exceeded those of Ks' particularly in males. 
In females, castration did not significantly influence any kinetic parameter 
of demethylation or type I binding. In males, hotvever, Km for demethylation 
was significantly decreased, though Vmax was not influenced, despite a sig-
nificant sex difference (p<0.02) in this parameter. On the other hand, the 
V in castrated males did not differ from the V in females. The 
max max M max 
for type I binding was significantly increased by castration of male animals, 
although these values did not completely achieve female levels. Ks was not 
influenced by castration, which is in accordance with the absence of a sex 
difference in this parameter in sham-operated animals. 
Castration, thus, abolishes sex differences in the kinetic constants of 
ethylmorphine demethylation, but does not completely abolish those of type I 
binding. Moreover, Km' but not Ks' is decreased by castration of males. There-
fore, the effects of castration on the kinetic parameters of demethylation 
and type I binding of ethylmorphine are not parallel. 
Table VI,3 shows the kinetic constants for ethylmorphine demethylation 
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w 
Table VI,2. The influence of castration on the kinetic constants of demethylation and type I 
binding of ethylmorphine in liver microsomes of male and female CPB-SE mice. 
K K v 
m s max 
(mM) (mM) (nmol/min/mg prot.) 
Males sham 2.15 :':. 0.33 (12) 0.28 + 0.04 (9) 4.41 :':. 0.58 (12) 
cas tr. 1.08 + 0.10 (12) 0 0.20 + 0.02 (7) 5.36 + 0.48 (12) 
Females sham 0.79 :':. 0.05 (12) 0.30 :':. 0.02 (5) 5.84 :':. 0.18 (12) 
cas tr. 0.81 + 0.08 (12) 0.27 + 0.04 (5) 5.40 + 0.28 (12) 
Values represent means + SE of the number of experiments indicated in parentheses. 
*Significant effect of-treatment, p<O.Ol. 
t,A 
max 
("A390-420/mg prot.) 
6.2 :':. 0.6 (9) 
11.6:':_1.5(7) • 
18.7 :':. 0.9 (5) 
15.7 + 0.8 (5) 
Table VI,3. The influence of testosterone pretreatment on the kinetic constants of demethylation 
and type I binding of ethylmorphine in liver microsomes of male and female CPB-SE mice, 
K K v 
m s max 
(mM) (mM) (nmol/min/mg prot,) 
Males contr, 1.16 :':. 0.10 (10) 0.36 :':_ 0.04 (6) 4.24 :':_ 0.34 (10) 
test. 1.21 +0.10 (10) 0.35 :':_ 0.07 (5) 3.76:':_0.18 (10) 
Females contr. 0.75 :':_ 0.05 (10) 0.23 :':_ 0.02 (6) 7.24 + 0.48 (10) 
I. 16 + 0.08 (10)" •• 4.46 + 0.24 (10) 0 test. 0.54 + 0.07 (5) 
Values represent means~ SE of the number of experiments indicated in parentheses. 
~Significant effect of treatment, p<O.OOl; ** id., p<O.Ol. 
t,A 
max 
("A390-420/mg prot.) 
7.1 :':_ 0.6 (6) 
8.2 :':_ 0.6 (5) 
21.0 :':_ 1.0 (6) 
8.0 + 0.4 (5) 0 
and type I binding in testosterone-pretreated and control CPB-SE mice, 
Contrary to the results in intact and sham-operated mice, a sex difference 
inKs was observed (p<0.02) in the arachis oil-pretreated controls. The reason 
for this apparent discrepancy is not clear, although the oil pretreatment in 
itself might have exerted some influence. Testosterone had no effect on any 
kinetic parameter in male mice. In females, Km was increased and Vmax de-
creased, Parallel changes were observed in Ks and 6Amax respectively. Moreover, 
testosterone changed the female values to the male level. Values of Km' as 
in the other groups, exceeded Ks values. 
In the CPB-V strain, a previous study revealed that there was no sex 
difference in the rate of hexobarbital metabolism, using a single substrate 
concentration (7). This finding was repeated for ethylmorphine in the present 
investigation. Kinetic constants for ethylmorphine demethylation in this 
mouse strain are given in Table VI,4. No sex difference inK and a small sex 
m 
difference in Vrnax were found. Surprisingly, hm.;rever, kinetics of type I 
binding of ethylmorphine in CPB-V mice proved to be different in males and 
females. In males 6A was 
max 
(Table VI,4). In both males 
clearly show the discrepancy 
significantly lower and Ks higher than in females 
and females K exceeded 
m 
between the Ks for type 
K . These observations 
s 
I binding and the Km for 
demethylation. It seems that the CPB-V strain either does not produce suf-
ficient quantities of androgen or the demethylating enzymes are relatively 
insensitive to testosterone. 
Table VI ,4. 
morphine in 
Kinetic Constants of demethylation and type I binding of ethyl-
liver microsomes of male and female CPB-V mice. 
K 
m 
(mM) 
K 
s 
(mM) 
v bA 
max max 
(nmol/min/mg prot.) (M390-420/mg prot) 
Males 0. 76 + 0.05 (5) 0.41 + 0.02 ( 6) 13.24 + 0.26 ( 5) 8.6 + 0. 7 (6) 
Females 0.90 + 0.07 (6) o. 23 + 0.02 (6). 15.68 + 0.44 (6)** 16.2 + 0.9 (6). 
Values represent means + SE of the number of experiments indicated in parenth-
eses. *Significant seX difference, p<O.OOI; ** id., p<O,Ol. 
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As can be seen in Table VI,5, testosterone pretreatment of female CPB-V 
mice significantly increases Ks for type I binding and decreases ~Amax' 
whereas in males no effect was observed, Testosterone pretreatment also failed 
to influence ethylmorphine demethylation (15). Therefore, it seems justified 
to conclude that the activity of the demethylating enzyme system is insen-
sitive to testosterone in CPB-V mice. 
Table VI,5. The influence of testosterone pretreatment 
on the kinetic constants of ethylmorphine type I binding 
in liver microsomes of male and female CPB-V mice. 
K M 
s max 
(mM) (M390-420/mg prot.) 
Males contr. 0.35 + 0.05 9.2 
test. 0.42 + 0.05 9.9 
Females contr. 0.23 + 0.02 16.2 
test. 0.41 + 0.02 • 8.6 
Values represent means + SE of 6 experiments. 
*Significant effect of-treatment, p<O.OOl. 
+ 0.5 
+ 0.5 
+ 0.9 
+ 0.7 • 
Testosterone levels in the plasma of male and female CPB-SE and CPB-V mice 
are given in Table VI,6. In both strains a sex difference was apparent. 
Testosterone levels in male CPB-SE mice were significantly higher (p<O.OI) 
than in male CPB-V animals, 
Table VI,6. Plasma testosterone levels (!lg/100 ml) 
in male and female CBP-SE and CPB-V mice. 
Males Females 
CPB-SE 0.60 + 0.05 0.24 + 0.02 
CPB-V 0.35 + 0.03 0.26 + 0.03 
Values represent means + SE of 4 experiments. 
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DISCUSSION. 
The comparison of the kinetic constants of ethylmorphine demethylation and 
type I binding in mice of the CPB-SE and CPB-V strain revealed discrepancies 
between these constants themselves as well as between the strains, As we used 
the same ethylmorphine concentrations for both determinations, influences of 
the concentration range on the kinetic constants should not play a role (16). 
The apparent Michaelis-Menten constant Km' however, does not necessarily equal 
the dissociation constant K
5
, since Km may be determined by the velocity of 
subsequent reaction steps and the values of the dissociation constants of 
possible intermediate (oxygenated) cytochrome P-450-substrate complexes (17). 
All Km values observed in this study were, in fact, higher than the corre-
sponding Ks values. The sex-dependent modifications of Km' however, were not 
paralleled by modifications of Ks in the SE-strain, and the converse was ob-
served in the V-strain. This apparent dissociation of K
5 
and Km may indicate 
a more complex reaction mechanism or conformational changes in one of the 
intermediate forms of the complex due to hormone action. 
The discrepancy between the 
spectral change (~Amax) is more 
sex differences in V and the maximum 
max 
difficult to explain. The sex differences in 
6Amax were much larger than in Vmax in both strains. The effects of testoster-
one treatment and castration were also more pronounced on 6Amax' but this is 
evident, if the treatments merely abolish the sex differences. Vmax is deter-
mined by the total amount of enzyme-substrate complex, and by one or more 
rate constants. The small effects on Vmax with respect to 6Amax may, therefore, 
be attributable to compensatory effects on the rate constant of the rate-
limiting step. This cannot be accounted for by effects on NADPH-cytochrome 
P-450 reductase, since the basal reduction rate was shown in a previous study 
to have a slight sex difference in favour of females and to be unaffected by 
testosterone pretreatment and castration, whereas the stimulation of the 
reduction rate by ethylmorphine was directly proportional to the magnitude of 
the spectral change (15). A more realistic possibility was suggested by a 
study of the development of the ethylmorphine demethylase in the CPB-SE 
strain (14). Different forms of cytochrome P-450 may exist, which have diverg-
ing properties with respect to type I binding and demethylation. A hetero-
geneity of cytochrome P-450 has, in fact, been observed in mice (18,19). 
Grasdalen et al, (8) even observed a heterogeneity of type I binding sites 
in rats. 
The origin of the observed sex differences in ethylmorphine demethylation 
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and type I binding in the CPB-SE strain is obviously testicular testosterone, 
which exerts an inhibitory action, in contrast to the stimulatory effects 
observed in rats (20). This confirms our previously published conclusion for 
the hydroxylation of hexobarbital (7). The primary role of androgens is best 
illustrated by the effect of castration in male animals and the lack of effect 
in females. The lack of effect of castration on the Vmax suggests that the 
sex difference in this parameter is irreversible and not due to testicular 
androgen. This is supported by our observation that Vmax for ethylmorphine 
demethylation also differs in immature male and female animals (14). Castra-
tion of males did not convert 6Amax completely to the female values. We found 
no sex difference in 6A in immature animals (14), which indicates that 
max 
this sex difference is, in part, irreversible, although of androgenic origin, 
since testosterone pretreatment reduced 6Amax to the male level in females. 
Apparently, the degree of sex-dependency of type I binding and ethyl-
morphine demethylation is strain-dependent. In the V-strain type I binding of 
ethylmorphine is androgen-dependent, but the sex difference is smaller than 
in theSE-strain, due to higher 6A values in V-males. This is not likely 
max 
to be simply the effect of the lower testosterone level observed in male 
V-mice as compared with SE-mice, since testosterone pretreatment did not 
further decrease 6Amax in males. The demethylation reaction did not seem to 
be sex-dependent at all, despite the fact that males of the V-strain do pro-
duce testosterone. Only a very small sex difference in Vmax was observed, but 
testosterone pretreatment did not affect ethylmorphine demethylation in males 
or in females, when measured at a single substrate concentration (15). These 
results suggest that in mice of the V-strain the responsiveness to androgen 
is smaller than in the SE-strain. The degree of responsiveness might be neo-
natally imprinted, as observed in rats (21). In this respect it is interest-
ing that in males of both the CPB-V and CPB-FT strain, which lack a sex 
difference in hexobarbital metabolism, the 'major urinary protein', the 
hepatic production of which is stimulated by testosterone (22,23) is virtually 
absent in the serum (24). 
ACKNOWLEDGEMENTS. 
The authors wish to thank Miss C.M.M. De Jong, Department of Biochemistry 
II, for performing the testosterone determinations, Dr. H.J.A. Schouten for 
writing a program for the calculations of the kinetic constants, and 
67 
Dr. M.J. Farnham for linguistic correction of the manuscript. 
This work was supported in part by grants from the Netherlands' Foundation 
for Medical Research. 
REFERENCES. 
I. S.Orrenius, B.J. Wilson, C. von Bahr and J.B. Schenkman, in 'Biological 
hydroxylation mechanisms' (G.S. Boyd and R.M.S. Smellie, eds.), Acad. 
Press, New York, 1972, p. 55 
2. G.J. Mannering, in 'Fundamentals of drug metabolism and drug disposition' 
(B.N. LaDu, H.G. Mandel and E.L. Way, eds.), The Williams and Wilkins 
Company, Baltimore, 1971, p. 206 
3. J.B. Schenkman, I. Frey, H. Remmer and R.W. Estabrook, Mol. Pharmacal. 
3, 516 (1967) 
4. T. Niwaguchi and T. !none, Chern. Pharm. Bull, 23, 1300 (1975) 
5. J. Noordhoek, in 'Developmental and genetic aspects of drug and environ-
mental toxicity' (W.A.M. Duncan, ed.), Proc. Eur. Soc. Toxicol., 
Excerpta Medica, Amsterdam, 1975, p. 99 
6. P.L. Gigon, T.E. Gram and J.R. Gillette, Mol, Pharmacal. 5, 109 (1969) 
7. J. Noordhoek, FEES Lett. 24, 255 (1972) 
8. H. Grasdalen, D. BackstrOm, L.E.G. Eriksson, A. Ehrenberg, P. Moldeus, 
C. von Bahr and S. Orrenius, FEES Lett. 60, 294 (1975) 
9. J. Noordhoek, A.P. van den Berg, E.M. Savenije-Chapel and E. Koopman-Kool, 
Biochem. Pharmacal, in press (Chapter VIII of this thesis) 
10. O.H. Lowry, N.J. Rosebrough, A.L. Farrand R.J. Randall, J, Biol. Chern. 
193, 265 (1951) 
11. T. Nash, Biochem. J. 55, 416 (1953) 
12. H.L. Verjans, B.A. Cooke, F.H. de Jong, C.M.M. de Jong and H.J. van der 
Molen, J. Steroid Biochem. 4, 665 (1973) 
13. C.N. Wilkinson, Biochem. J. 80, 324 (1961) 
14. A.P. van den Berg, J. Noordhoek, E.M. Savenije-Chapel and E. Koopman-Kool, 
Biochem. Pharmacal., in press (Chapter VII of this thesis) 
15. A.P. van den Berg, J. Noordhoek, E.M. Savenije-Chapel and E. Koopman-Kool, 
Chem.-Biol, Interact., in press (Chapter V of this thesis) 
16. J.R. Hayes, M.U.K. McBodile and T.C. Campbell, Biochem. Pharmacal. 22, 
1517 (1973) 
17, J.R. Gillette, H. Sasame and B. Stripp, Drug Metab. Disp. 1, 164 (1973) 
18. R.B. Mailman, L.G. Tate, K.E. Muse, L.B. Coons and E. Hodgson, 10, 215 
(1975) 
19. D.A. Haugen, M.J. Coon and D.W. Nebert, J. Biol. Chern. 251, 1817 (1976) 
20. R. Kato, Drug Metab. Rev. 3, 1 (1974) 
21. L.W.K. Chung, G. Raymond and S. Fox, J. Pharmacol. Exp. Ther. 193, 621 
(1975) 
22. Ph. RUrnke and P.J. Thung, Acta Endocrinol. 47, 156 (1964) 
23. J.S. Finlayson, R. Asofsky, M. Potter and c.c. Runner, Science 149, 981 
( 1965) 
24. Chr.L. RUrnke and J. Noordhoek, Arch. int. Pharmacodyn. 182, 399 (1969) 
68 
CHAPTER VII. THE DEVELOPMENT OF SEX DIFFERENCES IN THE DEMETHYLATION OF 
ETHYLMORPHINE AND IN ITS INTERACTION WITH COMPONENTS OF THE 
HEPATIC MICROSOMAL CYTOCHROME P-450 SYSTEM IN MICE. 
SUMMARY. 
The development of sex differences in ethylmorphine N-demethylation and 
several components of the reaction chain were studied in hepatic microsomes 
from mice of the CPB-SE strain between 3 and II weeks of age. 
Sex-specific changes were observed in demethylation rate, type I spectral 
interaction, cytochrome P-450 content, and ethylmorphine-induced stimulation 
of NADPH-cytochrome P-450 reductase activity. These changes occurred mainly 
between the third and seventh weeks and were confined to females. It is 
concluded that the development of the cytochrome P-450 system is repressed 
by androgen during sexual maturation. 
The kinetic constants of demethylation developed differently from the 
ethylmorphine binding constants. Changes in demethylase were mainly restricted 
to Km' whereas the changes in type I binding only involved the maximum 
spectral change. In combination with differences observed between the de-
velopmental patterns of demethylation rate and cytochrome P-450 reductase 
activities, this demonstrated that the reduction of cytochrome P-450-substrate 
complex is not rate-limiting in ethylmorphine demethylation. 
The type I spectral change was correlated with the amount of cytochrome 
P-450 only when a large portion of the cytochrome was considered inactive in 
ethylmorphine binding. It is suggested that immature animals possess a low 
basal level of ethylmorphine binding type I sites, which is elevated selec-
tively in females during sexual maturation. 
INTRODUCTION. 
The develop~ent of hepatic microsomal drug metabolizing enzyme activity 
(cytochrome P-450 system) varies with species and substrate. Nevertheless, 
monooxygenase activity is usually hardly detectable during fetal life (with 
the exception of primates) and increases postnatally to reach a plateau at 
adulthood. Results of investigations in this area have recently been re-
viewed by several authors (1-3). 
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Some substrates (type I substrates, defined by their spectral interaction 
with cytochrome P-450 (4)) show sex-dependent metabolism. These sex differ-
ences appear to occur primarily in rats (see (5) for review). In this species, 
males exhibit higher hydroxylating activity than females. On the basis of the 
results of castration and testosterone treatment, this was attributed to an 
androgenic action (5-7). The development of the sex difference in demethyla-
tion was found to run parallel with the onset of sexual maturity, and was 
mainly the result of an increase in enzyme activity in the male between ap-
proximately 3 and 7 weeks of age. This was observed for aminopyrine (8,9) as 
well as ethylmorphine (10, 11). Studies which included only male rats also 
revealed sudden increases in ethylmorphine demethylation (12,13). 
Some strains of mice also exhibit a sex difference in the metabolism of 
type I substrates (14), which has been the subject of a number of studies in 
our laboratory (15-19). Interestingly, in the CPB-SE strain, metabolism is 
faster in females than in males. Although this difference is opposite to that 
found in rats, it appeared to be abolished by treatment of females with 
testosterone and castration of males, thus suggesting that this sex-depend-
ency is also due to androgenic action. Pomp et al. (20) demonstrated that 
mice were not able to 0- or N-demethylate p-nitroanisol or monomethyl-
p-nitraniline, respectively, at birth. The development of these activities 
was followed for a period of 4 weeks thereafter and found to be completed 
at approximately 3 weeks of age. No specification was given as to the sex 
of the animals. It was therefore of interest to study the demethylation of 
ethylmorphine in the CPB-SE strain during sexual development. 
In a previous investigation (19) the roles of type I binding and NADPH-
cytochrome P-450 reductase were examined in two strains of mice. It had been 
proposed by others (21-23) that type I binding might reflect the formation 
of enzyme-substrate complex, whereas the substrate-induced stimulation of 
NADPH-cytochrome P-450 reductase activity would represent the re.duction of 
this complex by the reductase, which probably constitutes the rate-limiting 
step. Both mouse strains exhibited considerable sex differences in type I 
binding and reductase stimulation, these parameters being highly correlated. 
As demethylation was not sex-dependent in the CPB-V strain, the reduction of 
cytochrome P-450-substrate complex can not be rate-limiting, but this could 
not be excluded in the CPB-SE strain. In order to further elucidate the 
nature of this sex difference the development of NADPH-cytochrome P-450 
reductase activities and cytochrome P-450 were studied as well as the 
kinetic constants of ethylmorphine demethylation and type I binding. 
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MATERIALS AND METHODS. 
Immature male and female mice of the CPB-SE strain (2 weeks old) were 
obtained from the Central Animal Breeding Station TNO, Zeist, The Netherlands. 
The mice of each sex were randomly divided into 5 groups, which were sacri-
ficed when the animals reached the age of 3, 5, 7, 9, and 11 weeks respect-
ively. All animals were kept under similar conditions in Makrolon cages, with 
pinewood shavings, and received standard food pellets (Hope Farms) and water 
ad lib. 
Chemicals. 
---------
Ethylmorphine was obtained from Brocacef; NADP+ (grade I), NADPH (grade I), 
glucose-6-phosphate (disodium salt), and glucose-6-phosphate dehydrogenase 
(grade I) were obtained from Boehringer, and bovine serum albumin from Poviet. 
All other chemicals used were at least reagent grade. 
After starving overnight, the animals were killed by a blow on the head. 
Livers were homogenized in 3 volumes of 0.1 M phosphate buffer (pH 7.4), 
using glass Potter tubes with a Teflon pestle. The homogenate was centrifuged 
for 20 minutes at 9000 g and the microsomal fraction was sedimented from the 
resulting supernatant by centrifuging at 75,000 g for 90 minutes. The pellet 
was suspended in 0.1 M phosphate buffer (pH 7.4). For each determination the 
livers of several animals were pooled. 
Ethylmorphine N-demethylation was assayed by measuring the formation of 
formaldehyde. Microsomes were incubated with ethylmorphine (0.4, 0.5, 0.67, 
1.0, and 2.0 mM) for 10 minutes at 37°C, with shaking, air being freely ad-
mitted, The incubation mixture further contained NADP+ (0.75 ~mol), glucose-
6-phosphate (12.5 ~mol), glucose-6-phosphate dehydrogenase (1 IU), semi-
carbazide (12.5 ~mol), nicotinamide (5 ~mol), MgC1 2 (12.5 ~mol), and micro-
somes, in a total volume of 3 ml. The reaction was initiated by the addition 
of 0.5 ml of microsomal suspension (10 mg protein/ml) and stopped by con-
secutive additions of 0.5 ml 40% Znso 4 and 1 ml saturated Ba(OH) 2 . After 
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centrifugation, 2 ml of the supernatant were mixed with 1 ml double strength 
Nash reagent (24), and incubated at 60°C for 30 minutes, The amount of HCHO 
formed was estimated by determining the absorbance at 415 nm relative to that 
at 500 nm, and subtracting the amount of Nash-positive material formed in the 
appropriate blank. The apparent Michaelis-Menten 
velocity of demethylation (Vmax) were calculated 
Wilkinson (25). 
constant (K ) and maximum 
m 
according to the method of 
Difference spectra were recorded on an Aminco-Chance dual wavelength 
spectrophotometer in the split-beam mode. Cuvettes contained 3 ml of micro-
somal suspension (3 rug protein/ml). After establishing a baseline of equal 
absorbance, ethylmorphine (0.33, 0.4, 0.5, 0.67, 1,0, and 2.0 mM) was added 
to the sample cuvette and the difference spectrum was recorded. The peak-to-
trough difference (385-420 nm) was taken as the magnitude of spectral inter-
action, and expressed in absorbance units. The spectral dissociation constant 
(Ks) and maximum spectral change (6Amax) were calculated according to the 
method of Wilkinson (25). 
NADPH-cytochrome P-450 reductase was assayed under anaerobic conditions 
in a carbon monoxide atmosphere at 30°C essentially as described by Gigon 
et al. (13). The formation of the reduced cytochrome P-450-CO complex was 
recorded as the absorbance change at 450 nm relative to 490 nm, using an 
Aminco DW-2 UV-VIS spectrophotometer in the dual wavelength mode, The reaction 
was initiated by the addition of 50 ~l of NADPH-solution (20 mg/ml) to 2.5 ml 
of a microsomal suspension containing about 1 mg protein/mi. The initial rate 
of reduction was expressed as nmol cytochrome P-450 reduced/min/rug protein 
-1 -! 
using 91 em mM (26) as the value of the absorption coefficient. Reductase 
stimulation (6 d) represents the difference between the rates of reduction 
re 
in the presence and in the absence of ethylmorphine (endogenous or basal 
reduction rate), which were determined in duplicate and triplicate, respect-
ively. Total cytochrome P-450 content was determined by completely reducing 
the cuvette contents with sodium dithionite, 
Microsomal protein was assayed according to the method of Lowry et al. 
(27), using crystalline bovine serum albumin as a standard. 
Two-way analysis of variance was employed to analyze all data for effects 
of age, sex, and interaction (age x sex), the latter representing the degree 
of dissimilarity between the developmental patterns. In the case of signifi-
cant effects of sex, the sex differences at all ages were tested separately 
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against the residual variance. Km values could not be analyzed this way, 
because of a significant difference between the male and female population 
variances. Sex differences were, therefore, tested by Student's t-test or 
Wilcoxon test where appropriate. P<0.05 was taken as the lowest level of 
significance. Additionally, the significance of differences at the p<O.Ol 
level has been indicated. The number of experiments was 4, except in the 
case of 3 week old females, where this number was 3. 
BESULTS. 
The maximum rate of demethylation (Vmax) decreased between 3 and 5 weeks 
in both sexes, and then remained constant (Fig. VII,1). The developmental 
patterns were not significantly different. However, taking all ages together, 
males had a significantly lower (about 20%) Vmax than females (p<O.Ol). 
The apparent Km decreased by a factor of 3, in females, whereas no 
statistically significant change was observed in males. Age-dependent changes 
in Km have also been observed in rats (7,12,28), The sex-dependency of Km 
was rather complicated. At 3 weeks, females had a higher Km, whereas the 
opposite was observed at 11 weeks, when normal, adult values were reached 
(18,29). These developmental patterns of Vmax and Km imply that an increasing 
sex difference is apparent when measured at low substrate concentrations, 
which might be of significance in the in vivo situation. 
The development of the maximum spectral change (6Amax) was highly sex-
dependent (Fig. VII,2). In females, a dramatic increase was observed, 
whereas 6A remained at a constant level in males. At 3 weeks no sex 
max 
difference existed, but at 11 weeks females exhibited a three-fold higher 
6A 
max 
(Fig. 
than males. 6Amax does not correlate with the demethylation rate 
VII,l), which appears to disagree with the concept that the spectral 
interaction reflects the formation of enzyme-substrate complex (21). 
There was no significant effect of age on Ks' neither in females nor in 
males (Fig. VII,2), nor were the developmental patterns significantly 
different. A significant sex difference was found at 9 weeks only. In other 
experiments we have sometimes noticed that adult animals do show a small 
73 
sex difference inKs' females having lower values (18). In this study, also, 
a significant sex difference was found when Ks was tested at all ages simul-
taneously (p<O.OS). Nevertheless, a large discrepancy between the develop-
mental patterns of Km and Ks is apparent. 
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and female mice. * indicates a significant sex difference, 
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The sex difference in cytochrome P-450 content in adult animals appeared 
to be mainly the result of developmental changes occurring in females 
(Fig. VII,3). Between 3 and 11 weeks an increase of 41% was observed. A sig-
nificant sex difference in favour of females did not arise until the age of 
7 weeks. At 3 weeks, even an opposite sex difference was noticed. The cyto-
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chrome P-450 content does not seem to be related to the rate of demethylation, 
which is in agreement with our previous findings, as well as with those ob-
tained in rats by many other authors (9-12,22,30,31). 
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The development of sex differences in 6A and cytochrome P-450 content 
max 
is mainly the result of age-dependent increases occurring in females (Figs. 
VII,2 and VII,3). The maximum spectral change is an expression of the total 
amount of binding sites involved in ethylmorphine binding. If all cytochrome 
P-450 is involved in this binding, then 6Amax and cytochrome P-450 content 
should be related. The data presented, however, show that the relative 
changes in cytochrome P-450 content are much smaller than those 
A better proportionality can be obtained when the increments in 
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liver microsomes from female mice between 3 and 11 weeks of age. 
Values were calculated from the data presented in Figs. VII,L 
and VII,3, by taking the differences between the male and female 
values at all ages and defining the value at 3 weeks as zero level. 
Standard errors were obtained using the weighted mean variances 
of the male and female series of experiments. The line shown 
was obtained by linear regression analysis. 
are calculated at all time intervals, with the situation at 3 weeks as a 
reference level. Furthermore, when the female values are corrected for 
fluctuations occurring in the male, a linear proportionality between 6Amax 
and bP-450 is observed (Fig. VII,4). This suggests that, until the age of 
3 weeks, a low basal level of type I binding activity has developed in both 
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sexes, which does not involve the total amount of cytochrome P-450. There-
after, an additional ethylmorphine binding capacity develops selectively in 
females. This might be due to synthesis of a cytochrome P-450 fraction with 
high specific binding activity, which can be calculated (using Fig. VII,4) to 
be about 7 times higher than that of the cytochrome already present. 
High basal activities of NADPH-cytochrome P-450 reductase were found at 
3 weeks, which subsequently decreased to the same degree in males and females, 
37 and 36% respectively (Fig. VII,5), A sex difference was already apparent 
at 3 weeks and remained constant up to I 1 weeks (male values approximately 
85% of those in females), The development of basal reductase activity re-
sembled, to a certain extent, that of V of ethylmorphine demethylation. 
max 
The decrease which appeared between 5 and 7 weeks, however, was not observed 
with V 
max 
The sex difference in ethylmorphine-induced stimulation of NADPH-cyto-
chrome P-450 reductase activity, observed previously (19), seems to arise 
from developmental changes in both sexes. Reductase stimulation increased 
by 95% in females, whereas a gradual 43% decrease was noticed in males. 
There appears to be no correlation with Vmax values. The concentration of 
ethylmorphine used (1 mM), however, did not produce maximal stimulation. 
The use of still higher concentrations is hampered by the fact that the 
initial rate of reduction becomes too fast to be measured accurately. When 
the demethylation rate is examined at I mM ethylmorphine a developmental 
increase of approx. 50% is observed in females (due to the decreasing Km)' 
whereas hardly any change is noticed in males. Thus reductase stimulation 
does not correlate with the demethylation rate, in contrast to the results 
obtained with rats (1 1,22,23,32). 
The magnitude of spectral interaction in males did not change between 3 
and 11 weeks, whereas a substantial decrease in reductase stimulation was 
noticed (Figs. VII,2 and VII,5). Furthermore, the increases in these para-
meters in females were parallel. Interestingly, howeyer, the sex differences 
developed simultaneously and to the same extent (Table VII, 1). This suggests 
that 6red and ~A are intrinsically related, which would confirm our previous 
observations (19), but it indicates that this relationship is masked by 
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a factor which affects one of these parameters in both sexes to the same 
degree. This points to the decline in basal NADPH-cytochrome P-450 reductase 
activity, which amounted to 36% in males and 37% in females (Fig. VII,5), 
This decline is proportional to the decline in 6red values in males. The 
assumption that 6red was similarly affected in females satisfactorily ex-
plains the discrepancy between the increases in 6red and 6A in this sex, and 
at the same time the highly-correlated development of sex differences in 
these parameters. 
Table VII,l. The development of sex differences in ethylmorphine-
induced stimulation of NADPH-cytochrome P-450 reductase activity 
and magnitude ·of type I spectral interaction. 
age 
(weeks) 
3 
5 
7 
9 
II 
reductase stimulation* 
( males x IOO%) 
females 
112 
71 
48 
38 
33 
• type I spectrum 
( males x 1 OO%) females 
106 
68 
40 
35 
31 
*Values were calculated from the data shown in Figs. VII,L 
and VII,S. 
DISCUSSION. 
The present study demonstrates a sex-dependency in the development of 
ethylmorphine N-demethylation, ethylmorphine binding to cytochrome P-450, 
cytochrome P-450 content and ethylmorphine-induced stimulation of NADPH-
cytochrome P-450 reductase activity in mice. Adult values are reached at 
about 11 weeks of age, thus coinciding with sexual maturation. The time 
course of this development is similar to that found in rats, but the sex 
differences tend towards the opposite direction. We have demonstrated that, 
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in mice, castration of males and testosterone-treatment of females abolish 
the sex differences (17,19). These findings indicate an inhibitory effect of 
androgen, whereas, in rats, the androgen effect is presumed to be stimulatory 
(5). Androgen apparently prevents the stimulation of enzyme activity seen in 
female mice, which is probably the basic developmental pattern in this 
species. The responses to androgen might be enzyme-specific (33-35) as well 
as species-specific (36), as observed with some enzymes involved in steroid 
metabolism. 
The different developmental patterns of the kinetic constants of the de-
methylation reaction and type I binding present a problem concerning the 
mechanism of the reaction. The concept that type I binding represents the 
formation of enzyme-substrate complex, which is subsequently reduced by 
NADPH-cytochrome P-450 reductase in a rate-limiting reaction (21,37), is 
apparently not applicable. In a previous study we observed that, in mice, 
the stimulation of cytochrome P-450 reductase activity by type I substrates 
was correlated with the magnitude of spectral interaction, thus confirming 
results obtained with rats (22,23), although certain discrepancies have been 
reported (I 1). The results presented in Figs. VII,~ and VII,S apparently 
contradict the earlier findings. The data given in Table VII,l and Fig. VII,5, 
however, indicate that this paradox may be explained on the basis of develop-
mental changes in basal reductase activities. These changes might reflect 
changes in the (pseudo first order) rate constant of cytochrome P-450 reduc-
tion, which alter the absolute value of 6 d independently from 6A. The cor-
re 
relation between reductase stimulation and type I binding suggests that 
type I binding represents the formation of a functional cytochrome P-450-
substrate complex. 
Several authors have observed significant correlations between 6red and 
substrate oxidation in rats (11,22,23,32), but other reports have indicated 
that the reductase does not control the rate of substrate oxidation (38-40). 
Previously, we could not exclude this possibility, as any one of the access-
ible and routinely measured parameters (endogenous or basal reduction rate, 
substrate-induced or total reduction rate, or reductase stimulation) might 
not be totally representative of the rate of reduction of the cytochrome 
P-450-substrate complex, formed by type I binding (19). From the present 
results it is evident that cytochrome P-450 reduction is not correlated with 
ethylmorphine demethylation, whichever parameter of reductase activity is 
used. 
If the reductase step is not rate-limiting, changes in K do not necess-
m 
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arily reflect changes inKs' In the case of a reaction mechanism which is not 
completely ordered (as discussed by Gillette et al. (41)) Km may approximate 
the dissociation constant of the oxygenated or the active oxygen cytochrome 
P-450-substrate complex rather thanKs. A changing Km may be indicative of 
conformational changes or of a shift in the rate-limiting step. According to 
the ·most plausible models, however, Vmax should be related 
intermediate forms of cytochrome P-450 reversibly interact 
to 6A . If the 
max 
\Vith the substrate 
and if the unbound forms of the cytochrome are reduced and oxygenated at 
rates which differ considerably from those of the bound intermediates, plots 
of 1/v vs. 1/S will be curves, This curvature may not be detected and may 
lead to Vmax and Km values which are dependent on the substrate range chosen. 
Although in that case these parameters would be ill-defined, it is unlikely 
that this explains the highly diverging 6Amax and Vmax observed during de-
velopment, Hayes et al. (42) have suggested the existence of two demethylases 
with different kinetic constants (in rats). This might introduce a disc rep-
ancy between 6A and v Our results may indicate the presence of two 
max max 
demethylases in female mice, one of which operates at a negligible rate, 
although they are characterized by cytochromes P-450 which have a similar 
ability to form type I complexes and to activate the reductase. This is 
suggestive of ethylmorphine functioning as a (partial) uncoupler of mono-
oxygenase activity (43-45). Further work is needed to resolve these questions. 
An increasing body of evidence suggests the existence of multiple forms 
of cytochrome P-450, which have distinct (but sometimes overlapping) 
specificities with regard to substrate or ligand interaction, and substrate 
hydroxylation (46-53). The demonstration of different classes of type I 
binding sites is of particular interest (48). Our study indicated that type I 
binding of ethylmorphine is restricted to a limited amount of cytochrome 
P-450. This was deduced from the data presented in Figs. VII,3 and VII,4, 
which demonstrate a correlation between the sex-specific increases in the 
extent of spectral interaction (6A ) and cytochrome P-450, and not between 
max 
the absolute values of these parameters. This correlation might indicate 
either specific synthesis of the ethylmorphine-binding cytochrome P-450 
already present in small amounts in immature animals, or generalized syn-
thesis of cytochrome P-450 together with a process of differentiation. The 
latter possibility is supported by the work of Levin et al. (54), who ob-
served a sex-dependent differentiation of rat liver cytochrome P-450 into 
two fractions with different rates of turnover. It might be speculated that, 
in female mice, a type of ethylmorphine-binding cytochrome P-450 develops, 
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which is different with respect to functions other than type I binding (for 
example at the stage of the oxygenated complex), thus accounting for the 
kinetic anomalies discussed above, 
Different levels of tightly-binding endogenous substrates may explain 
differences in type I binding (23,55). We have obtained evidence that this is 
not the case with the observed sex difference (Van den Berget al., to be 
published) (Chapters IX and X). 
ACKNOWLEDGEMENTS. 
The authors wish to thank Dr. R. van Strik for his advice in the sta-
tistical evaluation of the data, Dr. M. Farnham for correcting the manu-
script, and the Netherlands' Foundation for Medical Research for financial 
support. 
REFERENCES. 
I, C.R. Short, D.A. Kinden and R. Stith, Drug Metab. Rev. 5, 1 (1976) 
2, A.H. Neims, M. Warner, P.M. Loughnan and J.V. Aranda, Annu. Rev. Pharmacal. 
Toxicol. 16, 427 (1976) 
3. J.R. Gillette and B. Stripp, Fed. Proc. 34, 172 (1975) 
4. H. Remmer, J.B. Schenkman, R.W. Estabrook, H. Sasame, J.R. Gillette, 
S. Narasimhulu, D.Y. Cooper and 0. Rosenthal, Mol. Pharmacal. 2, 187 
(1966) 
5. R. Kato, Drug Metab. Rev. 3, 1 (1974) 
6, L.W.K. Chung, G. Raymond and S, Fox, J. Pharmacal. Exp. Ther. 193, 621 
(1975) 
7. S, El Defrawy El Masry and G,J, Mannering, Drug Metab, Disp. 2, 279 (1974) 
8. P.Th. Henderson, Biochem. Pharmacal. 20, 1225 (1971) 
9. S.M. McLeod, K.W. Renton and N.R. Eade, J. Pharmacal. Exp. Ther. 183. 489 
(1972) 
10. S. El Defrawy El Masry, G.M. Cohen and G.J. Mannering, Drug Metab. Disp. 
2, 267 (1974) 
11. G.M. Cohen and G.J. Mannering, Drug Metab. Disp. 2, 285 (1974) 
12. T.E. Gram, A.M. Guarino, D.H. Schroeder and J.R. Gillette, Biochem. J. 
113, 681 (1969) 
13. D.D. Shoemaker and M.E. Hamrick, Biochem. Pharmacal. 23, 2325 (1974) 
14. E.S. Vesell, Ann. N.Y. Acad. Sci. 151, 900 (1968) 
15. Chr. L. Rllmke and J. Noordhoek, Arch. int. Pharmacodyn. 182, 399 (1969) 
16. J. Noordhoek and Chr. L. RUmke, Arch. int. Pharmacodyn. 182, 401 (1969) 
17. J. Noordhoek, FEES Lett. 24, 255 (1972) 
18. J. Noordhoek, in 'Developmental and genetic aspects of drug and environ-
mental toxicity', Proc. Eur. Soc. Toxicol. Excerpta Medica, Amsterdam, 
1975, p. 99 
83 
19. A.P. van den Berg, J. Noordhoek, E.M. Savenije-Chapel and E. Kooproan-Kool, 
Chem.-Biol. Interact., in press (Chapter V of this thesis) 
20. H. Pomp, M. Schnoor and K.J. Netter, Dtsch. Med. Wochenschr. 94, 1232 
(I 9 69) 
21. J.B. Schenkroan, H. Remmer and R.W. Estabrook, Mol. Pharmacal. 3, 113 (1967) 
22. P.L. Gigon, T.E. Gram and J.R. Gillette, Mol. Pharmacal. 5, 109 (1969) 
23. H. Diehl, J. Schadel in and V. Ullrich, Hoppe-Seyler's Z. Physiol. Chern. 
351, 1359 (1970) 
24. T. Nash, Biochero. J. 55, 416 (1953) 
25. G.N. Wilkinson, Biochern. J. 80, 324 (1961) 
26. T. Omura and R. Sato, J, Biol. Chern. 239, 2370 (1964) 
27. O.H. Lowry, N.J. Rosebrough, A.L. Farrand R.J. Randall, J. Biol. Chern. 
193, 265 (1951) 
28. J.U. Bell and D.J. Ecobichon, Can. J. Biochem. 53, 433 (1975) 
29. J. Noordhoek, A.P. van den Berg, E.M. Savenije-Chapel and E. Koopman-Kool, 
6th Int. Congress of Pharmacology, Helsinki, 1975 (abstract) 
(Chapter VI of this thesis) 
30. D. MUller, D. FOrster, H. Dietze, R. Langenberg and W, Klinger, Biochern. 
Pharmacal, 22, 905 (1973) 
31. D.S. Davies, P.L. Gigon and J.R. Gillette, Life Sci. 8, 85 (1969) 
32. J.L. Holtzman and B.H. Ruroack, Biochemistry 12, 2309 (1973) 
33. K. Einarsson, J.-R. Gustafsson and R. Stenberg, J. Biol. Chern. 248, 4987 
(1973) 
34, J.-R. Gustafsson and R. Stenberg, J. Biol. Chern. 249, 711 (1974) 
35. J.-R. Gustafsson, M. Ingelman-Sundberg and R. Stenberg, J. Steroid 
Biochem, 6, 643 (1975) 
36. H. Schriefers, A. Eimiller and U. Drews, Hoppe-Seyler's Z. Physiol. Chern, 
357, 95 (1976) 
37. J. Noordhoek, A.P. van den Berg, E.M. Savenije-Chapel and E. Kooprnan-Kool, 
Biochern. Pharmacal., in press (Chapter VIII of this thesis) 
38. R.W. Estabrook, A.G. Hildebrandt, J. Baron, K.J. Netter and K. Leibman, 
Biochem. Biophys. Res. Commun. 42, 132 (1971) 
39. J.A. Thompson and J.L. Holtzman, Drug Metab. Disp. 2, 577 (1974) 
40. T. Matsubara, J. Baron, L.L. Peterson and J.A. Peterson, Arch. Biochem. 
Biophys. 172, 463 (1976) 
41. J. Gillette, H. Sasarne and B. Stripp, Drug Metab. Disp. I, 164 (1973) 
42. J.R. Hayes, M.U.K. McBodile and T.C. Campbell, Biochem. Pharmacal, 22, 
1517 (1973) 
43. V. Ullrich and H. Diehl, Eur, J. Biochem. 20, 509 (1971) 
44. H. Staudt, F. Lichtenberger and V. Ullrich, Eur. J. Biochem. 46, 99 (1974) 
45. A.G. Hildebrandt, M. Tjoe and I. Roots, Biochem. Soc. Trans. 3, 807 (1975) 
46. K. Comai and J.L. Gaylor, J. Biol. Chern. 248, 4947 (1973) 
47. J. Werringloer and R.W. Estabrook, Arch. Biochem. Biophys. 167, 270 (1975) 
48. H. Grasdalen, D. BackstrOm, L.E.G. Eriksson, A. Ehrenberg, P. Moldeus, 
C. von Bahr and S. Orrenius, FEBS Lett. 60, 294 (1975) 
49. R.B. Mailman, L.G. Tate, K.E. Muse, L.B. Coons and E. Hodgson, Chem.-Biol. 
Interact. 10, 215 (1975) 
50. A.F. Welton, F.O. O'Neal, L.C. Chaney and S.D. Aust, J. Biol. Chern. 250, 
5631 (1975) 
51. D. Ryan, A.Y.H. Lu, s. West and W. Levin, J. Biol. Chern. 250, 2157 (1975) 
52. D.A. Haugen, T.A. VanderHoeven and M.J. Coon, J. Biol. Chern. 250, 3567 
(1975) 
53. J.-R. Gustafsson and M. Ingelman-Sundberg, Eur. J. Biochem. 64, 35 (1976) 
54. W. Levin, D. Ryan, R. Kuntzman and A.H. Canney, Mol. Pharmacal. 11, !90 
(1975) 
55. J.B. Schenkman, D.L. Cinti, S. Orrenius, P. Moldeus and R. Kraschnitz, 
Biochemistry 11, 4243 (1972) 
84 
CHAPTER VIII. METABOLISM OF HEXOBARBITAL ENANTIOMERS AND INTERACTION WITH 
CYTOCHROME P-450 IN MALE AND FEMALE MICE AND RATS. 
SUMMARY. 
The metabolism of hexobarbital enantiomers by 9000 g liver supernatant was 
determined in mice and rats. Both male and female mice and rats metabolize 
hexobarbital stereospecifically. In mice the 1-enantiomer is metabolized 
faster, whereas the opposite was observed in rats. The kinetics of metabolism 
and type I binding to cytochrome P-450 of the enantiomers was compared in 
female mice and male rats. In mice Km equaled Ks for type I binding, but in 
rats Km exceeded Ks. This suggests that in mice the type I binding site is the 
active site of the enzyme, whereas in rats this cannot be proved. In female 
rats the 6Amax for type I binding of the enantiomers differs, indicating a 
binding to different cytochrome P-450 subspecies. Comparison of the enhance-
ment of NADPH-cytochrome P-450 reductase activity by the enantiomers with 
their rate of metabolism at the same concentration revealed that in rats the 
reduction of the cytochrome P-450-substrate complex cannot be rate-limiting 
for the total reaction, whereas in mice this cannot be disproved. This would 
explain the apparent discrepancy between the kinetics of type I binding and 
metabolism in rats, which was not found in mice. 
INTRODUCTION. 
Comparison of the kinetic parameters of metabolism and type I binding of 
substrates to cytochrome P-450 can be used to investigate the possibility 
that the type I binding site is the catalytic site of the enzyme. This method 
is valid only if the reduction of the substrate complex is rate-limiting for 
the total reaction. Several authors have compared these parameters in differ-
ent species and sexes (1,2,3). Although in some studies a similarity between 
Km of metabolism and Ks of substrate binding was observed, in many others 
large differences were reported (4) . Investigations conducted in this depart-
ment, using a sex difference in mice for the metabolism of type I substrates 
(5,6), also revealed some discrepancies (7). 
Instead of species and sex differences the use of different substrates 
may further clarify this problem. The ideal compounds for such studies are 
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the enantiomers of chiral substrates, many of which are metabolized stereo-
specifically (8), Up till now investigations with benzphetamine (9) and other 
demethylated substrates (10) failed to give consistent parallels between the 
kinetic constants of metabolism and type I binding. This may be due to cyto-
chrome P-450-catalyzed metabolism of the substrate along pathways other than 
demethylation, which makes demethylation and substrate binding incomparable. 
For our studies we chose hexobarbital as a substrate. In mice (11) and 
rats (12) this drug is converted almost exclusively into its 3-hydroxy metab-
olite, which is further dehydrogenated to 3-keto-hexobarbital. In unpublished 
experiments we found that in 9000 g mouse liver supernatant less than 2% of 
hexobarbital metabolism is due to demethylation. It appears, therefore, that 
only one reaction determines hexobarbital metabolism. Stereoselective metab-
olism of hexobarbital was demonstrated in rats (13-16), mice (15) and humans 
(17), but not in guinea-pigs (18). The kinetics of metabolism and type I 
binding of the enantiomers in untreated animals were compared only in guinea-
pigs, in which no correlation was found (18), 
In the present study the kinetics of metabolism and type I binding of 
hexobarbital enantiomers are compared in male and female mice and rats. In 
addition, the hexobarbital-induced enhancement of NADPH-cytochrome P-450 
reductase activity was investigated. The formation of a cytochrome P-450 
type I substrate complex is thought to be responsible for this enhancement, 
which is, therefore, suggested to be the expression of the reduction of this 
complex (19,20). If this reduction is rate-limiting in the hydroxylation 
reaction, differences in reduction enhancement by the enantiomers should be 
accompanied by similar differences in hydroxylation rate. Furthermore, a re-
lationship between reductase stimulation and the magnitude of the type I 
spectral interaction is to be expected. This was also investigated. 
MATERIALS AND METHODS. 
Animals. 
-------
Male and female Swiss (CPB-SE) mice, at least 10 weeks old, and male and 
female Wistar (WAG) rats (TNO, Zeist) weighing 150-200 g were used. 
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m.p.: 154-155°C, were kindly donated by Prof. Dr. J. Knabe, University of Saar-
land, Saarbrllcken, Germany. Racemic hexobarbital was obtained from the O.P.G., 
Utrecht. All other chemicals and solvents used were of analytical grade purity. 
Hexobarbital metabolism. 
Hexobarbital metabolism was assayed in 9000 g supernatant, which was 
prepared by centrifuging (20 min) a 1:2 (w/v) liver homogenate in 0.1 M Na-K 
phosphate buffer (pH 7.4) containing 0.1 mM EDTA. Enzyme incubations were 
done in the same buffer, containing 0. 75 ~mol NADP, 12.5 ~mol glucose-6-P, 
5 ~mol nicotinamide, 12.5 ~mol MgC1 2 , hexobarbital as indicated and 1 ml 
(mouse) or 0.5 ml (rat) supernatant in a total volume of 3 ml. The incubates 
were shaken in 25 ml bottles at 37°C in air. The reaction was started by 
adding the supernatant to the prewarmed incubation medium and stopped after 
5 min (rats) or 10 min (mice) by addition of 12 ml of heptane containing 
1.5% n-amyl alcohol with shaking. 
Hexobarbital was determined by means of GLC, as UV absorbing metabolites 
may interfere with spectrophotometric determination (21). Hexobarbital was 
extracted from the incubates with 12 ml heptane-amylalcohol containing 0.2 
~mol methohexital as an internal standard, by shaking for 15 sec on a Vortex 
mixer as described by Breimer and Van Rossum (22) . After centrifugation 10 ml 
of the organic layer were vigorously shaken for 5 minutes with 5 ml phosphate 
buffer, pH 11 (23), 4 ml of which were acidified with 0.4 ml 12.5 N HCl and 
shaken for 5 minutes with 20 ml CHC1 3 . The chloroform layer was removed and 
evaporated to dryness. The residue was dissolved in 100 ~1 chloroform and 
1 ~l portions were injected into a Varian 2100 gaschromatograph, using a 
1.8 m x 4 mm column containing 3% OV-17 on 80-100 mesh Chromosorb W (HP). 
The following temperatures were used: injection port: 260°C, oven: 210°C and 
FID detector 300°C. In each series of determinations a standard curve was 
included, which proved to be linear and showed small day-to-day variations. 
Difference spectra and cytochrome P-450 reduction were determined in 
microsomes. 9000 g Supernatant was prepared from a 1:4 (w/v) liver homogenate 
and subsequently centrifuged at 75,000 g for 90 min. The microsomal pellet 
was suspended in 0.1 M phosphate buffer (pH 7.4). 
Spectra were recorded in an Aminco-Chance spectrophotometer in the split-
beam mode. Microsomal suspensions contained 3 mg prot./ml. The difference 
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between maximum and minimum absorbance was taken as the magnitude of spectral 
interaction. 
NADPH-cytochrome P-450 reductase activity was determined at 30°C under 
anaerobic conditions (protein concentration mg/ml), essentially as described 
by Gigon et al. (19). An Aminco DW-2 UV-VIS spectrophotometer was used in the 
dual wavelength mode. Reductase stimulation represents the difference between 
the initial rates of reduction with and without added substrate. Further de-
tails will be provided elsewhere (24) . 
Microsomal protein was estimated according to the method of Lowry (25), 
using bovine serum albumin as a standard. 
Calculations. 
Kinetic constants for metabolisrn (Km' Vmax) and type I binding (Ks' ~Amax) 
were calculated using the method of Wilkinson (26). In some cases more than 
10% of substrate was metabolized. Therefore, the substrate concentrations used 
in the calculations were corrected for substrate disappearance as described 
by Lee and Wilson (27). 
Statistical significance of differences was tested by analysis of variance 
and Student 1 s t-test. 
RESULTS, 
Metabolism in male and female mice. 
9000 g Supernatant of livers from both male and female CPB-SE mice metab-
olizes !-hexobarbital faster than its optical antipode, as can be seen in 
Table VIII,!. Female mice metabolize both enantiomers faster than males, as 
Table VIII, I. Metabolism of hexobarbital enantiomers by 9000 g liver super-
natant (nmoles/min/incubate) of male and female mice (0. 167 mM) and rats 
(0.333 mM) (means:_ SE). 
M i c e R a t s 
male female male female 
d 7.8 + ].2 (7) 14.6 + 0.8 (8) 73.7 + 3.9 (3) 16.9 + 0.8 (4) 
1 13.4 + 1.1 (7) 22.9 + 0.8 (8) 25.8+1.9 (4) 0.91+ 0.40 (3) 
p<O.OOl p<0.001 p<O.OOS p<O.OOI 
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was previously observed for racemic hexobarbital and other type I compounds 
(5,6). This result is in contrast to the work of McCarthy and Stitzel (15), 
who found not the 1- but rather the d-enantiomer to be metabolized faster in 
their mice. 
Because the d-enantiomer of hexobarbital is metabolized very slowly in 
male mice (Table VIII, 1), our method of measuring hexobarbital metabolism by 
dissappearance of substrate does not enable us to determine kinetic constants 
of this reaction in these animals. Similarly, the kinetics of type I binding 
could not be determined in male mice, due to the extremely small difference 
spectra produced by d-hexobarbital. Therefore, only values in females are 
given. Table VIII,2 summarizes the results. The substrate concentrations used 
in metabolic studies were 3, 4.5, 6, 7.5 and 9 m~-l. In binding studies 2, 4, 
6, 8 and 10 mM- 1 hexobarbital were used. Linear Lineweaver-Burk plots were 
obtained for metabolism as well as type I binding of the enantiomers. A sig-
nificant difference (p<0.02) was found for the Km values of the enantiomers, 
calculated with or without corrected substrate concentrations. No difference 
was obtained. K 
s 
was found in Vmax For type I binding an analogous result 
values were different (p<0.005) whereas 6Amax values were not. The values for 
Km' calculated using uncorrected substrate concentrations exceeded the anal-
ogous Ks' but calculation from corrected concentrations gave Km values which 
did not exceed K . 
s 
Table VIII,2. Kinetic constants of metabolism and type I binding of hexo-
barbital enantiomers in female mice and male rats (means~ SE). 
M i c e R a t s 
d 1 d 1 
K (mM) 0.180 + 0.029 o. 092 + 0.009 
m 
K (mM). 0. 112 + 0.022 0.053 + 0.005 
m 
o. 114 + 0.014 0.225 + 0.33 
0.071 + 0.009 o. 193 + 0.026 
K (mM) o. 114 + 0.011 0.073 + 0.004 
s 
0.014 + 0.0004 0.036 + 0.005 
v 38.9 + 2. 3 37.3 + 2.7 95.6 + 5.4 44.3 + 4.0 
max 
v • 35.4 + 2. 1 35.2 + 2.2 90.6 + 4.8 44.0 + 3.3 max 
M 18.0 + o. 7 19.8 + 0.6 24.5 + 0.6 24.6 + 2.0 
max 
*corrected for substrate disappearance. 
n = 12 (Km' Vmax) or 5 (K8 , 6Amax) in rats and 8 in mice. 
Vmax is expressed as nmol/min/incubate and 6Amax as 6A/mg protein. 
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Table VIII,l gives the rate of metabolism of hexobarbital enantiomers in 
male and female rats. In this species the opposite result was obtained from 
that in mice. The d-enantiomer was metabolized faster than its antipode in 
males as well as in females, which is in contrast to the results of Furner 
et al. (13). Male animals metabolized each enantiomer faster than females. 
As can be seen from Table VIII,!, female rats metabolized !-hexobarbital 
very slowly. Therefore, no kinetic studies on hexobarbital metabolism were 
carried out in these animals. Type I binding spectra, however, were of suf-
ficient magnitude to study binding kinetics. Table VIII,2 summarizes kinetic 
constants for metabolism and type I binding obtained in male rats. The con-
centrations used in metabolic studies were 1 .5, 3, 4.5, 6, 7.5, 9 and 20.5 mM-! 
-1 
whereas 10, 50, 100, 150 and 200 mM hexobarbital were used in binding 
studies. Linear Line\veaver-Burk plots were obtained both for metabolism and 
type I binding. The values of K obtained in male rats using our method agree 
m 
with those for racemic hexobarbital reported by Sitar and Mannering (28) and 
Kupfer and Rosenfeld (29), who used product formation instead of substrate 
disappearance for the determination of reaction rates. For the more slowly 
metabolized !-hexobarbital a higher Km (p<O.OOI) and a lower Vmax (p<O.OOI) 
were observed than for the d-enantiomer, as was also reported by McCarthy and 
Stitzel (15). For type I binding a significant parallel difference inKs 
(p<O.Ol) was found, whereas ~A values were similar. The K values were in 
max m 
this case higher than the Ks for the smne enantiomer, even after correction 
for substrate disappearance. In female rats not only Ks (p<O.Ol), but also 
~Amax (p<O.Ol) was different for the enantiomers, indicating that the nature 
of the type I binding sites are different for d- and !-hexobarbital. Hexo-
-1 barbital concentrations of 2, 4, 6, 8 and 10 roM were used in these deter-
minations. 
Due to the rather low enhancements of cytochrome P-450 reduction produced 
by hexobarbital it was not possible to obtain reliable values in some cases 
in concentration regions where differences in the hydroxylation rates of the 
enantiomers are the most prominent. This relates in particular to the male 
mouse, of which no data are presented. In female mice at 1.0 mM no difference 
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Table VIII,3. 
of metabolism, 
in female mice 
female mice 
1.0 mH 
male rats 
0. I mH 
female rats 
0.5 mH 
Enhancement of NADPH-cytochrome P-450 reductase 
and magnitude of spectral interaction of d- and 
and male and female rats (means ~ SE) , 
activity, rate 
1-hexobarbi tal 
reductase rate of type I 
stimulation metabolism spectral change 
d 2.45 + 0.11 ( 14) 31.6 + 1.9 (8) 16.2 + 0.7 (8) 
1 2.33 + 0.11 (14) 33.4 + 2. I (9) 18.5 + 0.6 (8). 
d I. 81 + 0. 14 (5) 53.5 + 2.2 (I 2) 23.5 + 0.9 (5) 
1 I. 80 + 0.13 (4) 15.5 + I. 0 ( 12) 17.4 + 0.6 (5) .. 
d 2.29 + 0. 16 (I 0) 8.0 + 0.3 ( 8) 
1 1. 83 + 0. II (I 0)" 5.5 + 0. 3 (8) .. 
Spectral changes and metabolic rates were derived from the kinetic studies 
presented in Table VIII,2 and are expressed in the units indicated there. 
Reductase stimulation is expressed as nmol cytochrome P-450 reduced/min/mg prot. 
*Significant difference between d and 1, p<O.OS; ** id., p<O.OOl. 
in reductase stimulations produced by the enantiomers could be detected 
(Table VIII,3). However, at this concentration also no significant difference 
in hydroxylation rates was apparent. These findings cannot prove the involve-
ment of cytochrome P-450 complex reduction as a rate-limiting step, but the 
combined data on binding and hydroxylation kinetics and cytochrome P-450 re-
duction leaves this possibility open. 
In male rats d- and 1-hexobarbital (0. 1 mM) enhanced cytochrome P-450 re-
duction to the same extent, although at this concentration the metabolic rates 
differed by a factor of 3.5. In female rats at 0.5 mM a small, but significant 
difference was found in reductase stimulation. In Table VIII,1 it was shown 
that at a concentration of 0.33 mM d-hexobarbital was metabolized about 18 
times faster than the 1-enantiomer. These large discrepancies make it very 
unlikely that in rats the reduction of cytochrome P-450-substrate complex is 
rate-limiting. Furthermore, Table VIII,3 demonstrates statistically significant 
differences between the magnitudes of type I spectra of the enantiomers in all 
cases. This could mean either that reductase stimulation is not as dependent 
on type I binding as is currently believed, or that the initial rate of re-
duction of cytochrome P-450-substrate complex is not only dependent on the 
concentration of this complex. 
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DISCUSSION. 
The present results indicate that, in the Swiss mouse strain we use, 
stereospecific metabolism of hexobarbital takes place. In contrast to the re-
sults of McCarthy and Stitzel (IS) the 1-enantiomer was metabolized faster. 
Apparently strain differences in stereoselectivity exist. The linear Line-
weaver-Burk plots obtained for hexobarbital metabolism in female mice suggest 
a completely ordered system, as discussed by Gillette et al. (30). The 
difference found in K 
m 
correlates with a similar difference in K
5 
for type I 
binding. The similarity of both V and 6A 
max max 
that they interact with the same cytochrome(s) 
of the enantiomers indicates 
P-450, The K values of the 
m 
enantiomers, if corrected for substrate disappearance, did not exceed Ks' as 
was also· observed for dl-hexobarbital (data not given), Furthermore, the rates 
of metabolism and the enhancements of NADPH-cytochrome P-450 reductase activ-
ity at the same concentration did not differ for the enantiomers. This sug-
gests that in female mice the reduction of the cytochrome P-450-substrate 
complex is rate-limiting and, moreover, because Km and Ks values are similar, 
that the type I binding site is the active site of the enzyme. 
In rats, the situation with regard to stereoselectivity and sex difference 
is the opposite of that in mice. In this species the d-enantiomer is metabol-
ized faster and males metabolize both enantiomers faster than females. The 
stereoselectivity is seen in both males and females, whereas Furner et al. (13) 
found it only in males. Their in vivo results, however, clearly demonstrate 
that in females the d-enantiomer is eliminated faster. In male rats we found 
a difference in both 
for the K 
s 
K 
m 
of 
~dV 
max 
for the enantiomers. A similar difference 
type I binding, although, even after correction for was found 
substrate disappearance, Km exceeded K . This difference may be due to a fast 
s . 
product dissociation, which influences Km' but not Ks. Moreover, Ks may be 
concentration range dependent (31) and the difference between Km and Ks might 
be caused by the different concentration ranges used for the determination of 
these constants. The large difference in rates of metabolism of the enantiomers 
was not paralleled by a similar difference in the enhancements of NADPH-cyto-
chrome P-450 reductase activity, measured at the same substrate concentration. 
This indicates that the reduction of the cytochrome P-450-substrate complex 
is not rate-limiting for the total reaction, which would also explain why the 
kinetic constants of type I binding and metabolism are different. 
In female rats only type I binding could be investigated. Here again, the 
faster metabolized enantiomer had a lower Ks' but, in contrast to the results 
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in males, also a higher 6Amax' The latter observation suggests that the 
enantiomers bind to different populations of type I binding sites in female 
rats. Recently Grasdalen et al. (32) demonstrated a heterogeneity of type I 
binding sites in male rats, which may occur in females as well. Moreover, 
Degkwitz et al. (14) and Feller and Lubaway (16) reported bAmax differences 
for d- and !-hexobarbital in phenobarbital-induced male rats, which may also 
be explained by binding to different type I site subspecies. 
Comparing the kinetics of type I binding in female and male rats, a sex 
difference in the composition of cytochrome P-450 is apparent. This is con-
cluded from the sex differences in the respective 6Amax values, which are much 
larger than the sex difference in cytochrome P-450 (data not given), as also 
observed for racemic hexobarbital by Schenkman et al, (1) and by the presence 
of a 6Amax difference for the enantiomers in females, which is absent in males. 
On the basis of other evidence El Defrawy et al. (33) carne to a similar con-
clusion. 
In all experiments significant differences were found between the magni-
tudes of the spectral changes induced by the hexobarbital enantiomers at the 
concentrations used for the reductase stimulation assays. However, only in 
female rats a concomitant, but relatively small difference in reductase stimu-
lation was observed. This apparent discrepancy between type I binding and re-
ductase stimulation seems to be at variance with the concept that by type I 
binding an additional amount of cytochrome P-450 is involved in the first 
phase of reduction, thereby causing an increase in initial reduction rate 
(19,20). In support with this we have observed simultaneous variations of 
type I binding and reductase stimulation in mice, using ethylmorphine as a 
substrate (24). The present results, however, are not necessarily in conflict 
with these findings. For we have also observed, that different substrates, 
which elicit type I spectra of comparable size, can produce diverging re-
ductase stimulations: 
Hexobarbital (dl) 1.0 mM 
Ethylmorphine 1.0 mM 
reductase stim. 
(nmol/min/mg prot.) 
2.46 + 0.15 
6.52 + 0.05 
spectral change 
(6Axt0 3/mg prot.) 
16.9 + 0.4 
17.4 + 0.2 
(means + SE of 4 determinations) 
This suggests that the reductase stimulation is not simply the expression of 
an additional amount of cytochrome P-450 being involved in the first fast 
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phase of reduction. It could very well be that substrates activate similar 
amounts of cytochrome P-450, but that the rate constants of cytochrome P-450-
substrate complex reduction differ. For the hexobarbital enantiomers such 
differences in rate constants could be opposed to differences in amounts of 
complex formed, which occasionally might lead to reductase stimulations of 
similar size. Alternatively, or perhaps additionally, the binding sites for 
reductase stimulation and type I binding might be distinct (although tightly 
coupled) and have different substrate affinities, as suggested by Holtzman and 
Rumack (3). A significant difference in reductase stimulation was found only 
in a case where 6Amax values were different (female rats). This might indicate 
that type I and activation sites are present in equal amounts (situated on the 
same cytochrome P-450 species), but that the binding to the activation sites 
is less or not stereoselective. 
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CHAPTER IX. THE RELATION BETWEEN THE SEX-DEPENDENCY OF TYPE I BINDING OF 
ETHYLMORPHINE AND THE I-BUTANOL-INDUCED SPECTRAL CHANGE IN 
MOUSE LIVER MICROSOMES. 
SUMMARY. 
1. A sex difference in the spectral interaction of ]-butanol with liver 
microsomes from adult mice was observed. In males a profound reverse type I 
spectrum was elicited, whereas only a small spectral change of irregular 
shape was apparent in females. This sex difference is the opposite of that 
observed in the type I binding of ethylmorphine. In immature animals no sex 
difference was found. Testosterone pretreatment of female mice increased the 
size of the !-butanol spectrum concomitantly with a decrease in ethyl-
morphine binding. 
2, Microsomes from males and females did not contain different levels of 
endogenous substrates. Thus, the presence or displacement of such substrates 
does not explain the sex differences in type I and reverse type I binding 
respectively. 
3. !-Butanol was found to interfere with both type II and type I binding. 
It is concluded that the !-butanol-induced spectral change consists of at 
least two components and that the sex difference is due to a sex-dependent 
type I component. 
INTRODUCTION. 
Many compounds give rise to characteristic spectral changes, when added 
to a liver microsomal suspension. This is thought to reflect binding to 
cytochrome P-450 (!). Two main types of difference spectra have been defined: 
type I (peak at 385-390 nm, trough at 420 nm) , caused by binding to a hydro-
phobic part of the cytochrome, and type II (peak at 425-430 nm, trough at 
390-400 nm), caused by direct binding to the heme (2). The difference spectra 
elicited by !-butanol and several other compounds did not fit this classifi-
cation and were called modified type II or reverse type I (2,3). 
In this paper we describe a sex difference in the !-butanol-induced 
spectral change in mouse liver microsomes. Thus far, this spectral change has 
been investigated mostly in male rats. The reverse type I spectral change has 
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been observed, which may reflect the reconversion of the (type I) substrate-
bound form of cytochrome P-450 into the substrate-free form. Several authors 
have tried to confirm this concept, though with varying results (3-6), Lately, 
some evidence has been obtained that the ]-butanol spectrum might represent 
a distinct type of spectral change rather than the displacement of endogenous 
substrates (7-9). 
Previously, we have demonstrated a sex difference in type I binding in 
mice (10), which is opposite to that observed in rats (1 1). Female mice have 
a much larger capacity for binding type I substrates (ethylmorphine, hexo-
barbital) than males as the result of an inhibitory action of androgen (10,12, 
13). The sex difference in the magnitude of the ]-butanol spectrum appeared 
to be the opposite of that found with the type I spectrum, suggesting the 
presence of different levels of endogenous substrates. On the other hand, we 
have obtained evidence that the sex difference in type I binding is caused 
by the existence of different amounts of cytochrome P-450 capable of type I 
binding (13). It was, therefore, of interest to further investigate the nature 
of the !-butanol-induced spectral change in mouse liver microsomes. 
MATERIALS AND METHODS. 
Animals. 
-------
Male and female mice of the CPB-SE strain were obtained from the Central 
Animal Breeding Station TNO, Zeist, The Netherlands. They were kept in 
Makrolon cages with pinewood shavings, received standard food pellets (Hope 
Farms) and tap water ad lib., and were used after they had reached the age 
of 11 weeks, unless stated otherwise. 
1-Butanol (p.a.) was obtained from Merck, ethylmorphine from Brocacef, 
and crystalline bovine serum albumin from Poviet. Testosterone propionate 
was a generous gift from Organon. All other chemicals used were at least 
reagent grade. 
In one experiment female mice were pretreated with testosterone. This was 
carried out by subcutaneous injection of testosterone propionate (2.5 mg in 
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0.1 ml arachis oil/animal) 14, 10, 7, and 3 days prior to the experiments. 
Control animals received an equivalent volume of oil. 
After starving overnight, the animals were killed by a blow on the head. 
Livers were homogenized in 3 volumes of 0.1 M phosphate buffer (pH 7.4), using 
glass Potter tubes with a Teflon pestle. The homogenate was centrifuged for 
20 minutes at 9000 g and the microsomal fraction was sedimented from the re-
sulting supernatant by centrifuging at 75,000 g for 90 minutes. The pellet 
was suspended in 0.1 M phosphate buffer (pH 7.4), For each determination the 
livers of several animals were pooled. 
Extraction of liver microsomes was carried out essentially as described 
by Vore et al. (6). Microsomal suspensions (7-8 mg protein/ml) were quickly 
frozen in liquid nitrogen, and subsequently freeze-dried. A portion of freeze-
dried microsomes, containing about 36 mg protein, was homogenized in 9 ml 
acetone and centrifuged for 5 min at 35,000 g (-20°C). The pellet was re-
suspended in 9 ml of acetone and again centrifuged. A final homogenate in 9 ml 
of acetone was filtered on a BUchner funnel. The filter contents were kept in 
a desiccator in ~ for 30 min at 4°C. The dried powder was homogenized in 
18 ml Na/K-phosphate buffer (0.1 M, pH 7.4) and sonicated for three 5-sec 
intervals, in order to obtain a stable suspension. This sonication did not 
result in any loss of cytochrome P-450. Extraction with ]-butanol was per-
formed by first treating the freeze-dried microsomes with 9 ml of 1-butanol, 
followed by two subsequent extractions with acetone, according to the above 
procedure. As a control, freeze-dried microsomes were directly suspended in 
buffer. 
Difference spectra were recorded using either an Aminco-Chance or an 
Aminco DW-2 UV-VIS spectrophotometer in the split-beam mode. Microsomal suspen-
sions, containing 1-2 mg protein/ml, were equally divided between sample and 
reference cuvettes, and a baseline of zero absorbance was established. 
Substrates were added as indicated in the text. 
The concentration of cytochrome P-450 was estimated by gassing the 
microsomes for 1 minute with carbon monoxide, dividing them between sample 
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and reference cuvettes, and then reducing the contents of the sample cuvette 
by the addition of a few crystals of sodium dithionite. The absorbance differ-
ence between 450 and 490 nm was taken as a measure of the cytochrome P-450 
concentration, using an absorption coefficient of 91 cm- 1roM- 1 (14). 
Microsomal protein was determined according to the method of Lowry et al. 
(15), using crystalline bovine serum albumin as a standard. 
RESULTS, 
Fig. IX, 1 shows typical recordings of the spectral changes induced by 
!-butanol in male and female mice. The male spectrum is characterized by a 
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Fig. IX, 1. !-Butanol-induced difference spectra in liver micro-
somes from male and female mice. Males; - - - - females; 
• • ·· ··· • difference between----- and -. Cytochrome P-450 
contents: males 1.46 nmol/ml; females 1.44 nmol/ml. !-Butanol 
concentration: 66 mM. 
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broad trough around 385-390 nm and a peak at wavelengths varying between 416 
and 420 nm. The female spectrum has a rather anomalous appearance: a slight 
trough around 385 nm and a peak between 410 and 420 nm. The general appear-
ance of the spectra suggests that a different type of absorbance change inter-
feres with that due to cytochrome P-450-substrate interaction, causing the 
absorbance to rise with increasing wavelength. This might represent a solvent 
effect of butanol, causing a change in turbidity of the microsomal suspension 
(it was not reversed by the addition of an equivalent volume of buffer to the 
reference cuvette), When the female spectrum is subtracted from the male 
spectrum, a spectrum is obtained which is the reverse of the type I spectral 
change (Fig. IX,!). 
Both testosterone pretreatment and castration of male and female mice 
have previously been shown to abolish the sex difference in type I binding of 
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Fig. IX,2. Effects of testosterone pretreatment on the !-butanol (A) and 
ethylmorphine (B) induced difference spectra in liver microsomes of female 
mice. Control (oil-treated); ----testosterone-treated. 
Cytochrome P-450 contents: I. 19 (contr.) and 1.23 (test.) nmol/ml. 
Substrate concentrations: 1-butanol, 88 mM; ethylmorphine, 2 mM. 
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ethylmorphine (12). Testosterone pretreatment, in the present study, appeared 
to enlarge the 1-butanol-induced spectral change in females (Fig. IX,2A) 
together with a reduction in the size of the ethylmorphine-induced spectral 
change (Fig. IX,2B). This suggests that these effects are interrelated. 
There was no sex difference in the type I binding capacity of ethyl-
morphine when 3 week old mice were used (13). Table IX, I shows that at 3 weeks 
the !-butanol-induced spectral change in females is slightly larger than that 
observed in males, when the values are calculated on the basis of microsomal 
protein content. When the magnitude of the spectral change is related to the 
cytochrome P-450 content, however, a sex difference is not observed. The 
magnitudes of the spectral changes in immature males and females are equal to 
those observed in adult males. This indicates that the development of the sex 
difference in the 1-butanol-induced spectral change results solely from a 
decrease in the spectral change in females. 
Simply washing the microsomes with }-butanol, in a concentration used for 
the spectral measurements (i.e. 25 ml microsomal suspension containing 
approx. 2 nmol P-450/ml, mixed with 200 ~1 1-butanol, gently stirred for 
15 min, sedimented and resuspended), did not yield significant effects. This 
procedure even tended to slightly decrease the type I spectrum and increase 
the !-butanol spectrum (data not shown). Extraction of freeze-dried micro-
somes with 1-butanol and/or acetone has been shown to increase the type I 
spectral change in male rats (6). Table IX,2 shows that this treatment did 
not significantly increase the ethylmorphine binding spectrum, but decreased 
the !-butanol spectrum. 
The absolute absorption spectra of cytochrome P-450 in microsomes from 
male and female mice were investigated by a direct spectropho~ometric com-
parison (Fig. IX,3), in order to detect a possible sex difference in the 
amount of the substrate-bound form of cytochrome P-450. The amounts of 
cytochrome b 5 were balanced by diluting the microsomes from females by 25%. 
Fortunately, this eliminated the difference in the cytochrome P-450 contents 
almost completely, so that the resulting difference spectrum essentially 
l OJ 
0 
N Table IX, I. The magnitude of the !-butanol-induced spectral change in liver microsomes from immature 
and mature male and female mice. 
6A420_385 ;mg protein ~A420_385 /nmol P-450 
3 weeks adult 3 weeks adult 
--
Males 14.4 + 0.7 (3) 21.18 ~ 1.28 (14)b 19.5~0.7(3) 21.38 + 1.01 (12) 
Females 17.2 + 0.7 (3)d 8.24 + 0.94 (16)a,c 20.0 + 0.9 (3) 6.93 + 0.98 (14)a,c 
Values represent means + SE of the number of experiments indicated in parentheses. 
a Significant effect of-age, p<O.OOI; b id., p<O.OS (Student's t-test), 
c Significant sex difference, p<O.OOI; did., p<O.OS. 
Table IX,2. The effects of organic solvent extraction of freeze-dried liver microsomes from male mice 
on the ethylmorphine- and 1-butanol-induced spectral changes. 
3 mM ethylmorphine 
88 mM 1-butanol 
spectral changes after three 
acetone extractions (n~3) 
control 
5.2 + 0.5 
18.3 + 0.9 
control minus 
extracted 
1.5 + 1.1 
-2.3 + 0.4 lli 
spectral changes after one ]-butanol 
and two acetone extractions (n=2) 
control 
5.0 + 0.8 
17.5 + 0.5 
control minus 
extracted 
2.4 + 0.7 
-4.3 + 0.0 * 
Values are expressed as ~A385 _420 (ethylmorphine) or ~A420_ 385 (1-butanol)/nmol P-450, and represent 
means + SE. *Significant effect of extraction, p<0.05 (paired t-test). 
reflects only differences in the composition of the male and female cytochrome 
P-450 populations. Fig. IX,3 shows a decrease in absorbance with increasing 
wavelength, which is due to a difference in the turbidity of the two prep-
arations, caused by the dilution of one of them. In addition to this only 
a small shoulder seems to be present around 410 nm. 
~ !!.A D.D05 
1 
450 
wovelengt\, (orn) 
Fig. IX,3. Difference between the absolute absorption 
spectra of liver microsomes from male and female mice 
(males minus females). 
The spectrum was obtained essentially according to the 
method used by Kinoshita and Rorie (16) for the deter-
mination of the effect of induction, The cytochrome b 5 
contents of the male and female microsomal preparations 
(approx. 1 mg prot/ml) were estimated by reduction with 
NADH. The cytochrome b5 concentrations were balanced by 
diluting the female preparation. The final cytochrome 
·p-450 concentrations after this balancing were 1.05 
(males) and 1,06 nmol/ml (females). A baseline of zero 
absorbance was established with female microsomes in both 
sample and reference cuvettes. The contents of the refer-
ence cuvette were then replaced by the male microsomal 
preparation, and the difference spectrum was recorded. 
~£!~£~~-~£-~YE~-~-~~~-£YE~-~~-££~E£~g~~-£g_££~_l:~~~~g£~:ig~~£~i-~E~£~E~! 
££~gg~. 
Fig, IX,4A shows that the presence of aniline in sample and reference 
cuvettes diminishes the magnitude of the !-butanol-induced difference 
spectrum in males, and alters the position of the absorbance maximum, 
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indicating the disappearance of a type II component, An analogous effect was 
observed in females, although the resulting spectrum is complex (Fig. IX,4B). 
This indicates either that aniline and ]-butanol compete for type II binding 
sites, or that 1-butanol inhibits aniline binding non-competitively. 
When, in addition, ethylmorphine was added, the final spectra were the 
same in males and females. The female spectrum lost a large type I component, 
whereas the male spectrum was only slightly changed. This indicates that 
]-butanol also interferes with type I binding, which is particularly evident 
in females, ·In Fig. IX,S this interference is further demonstrated by the 
effect of hexobarbital on the female 1-butanol spectrum. The resulting 
spectrum resembles the 1-butanol spectrum observed in males. These results 
suggest that the sex difference in the ]-butanol-induced spectral change may 
be due to sex-dependent type I binding. 
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Fig. IX,4. The effects of aniline and ethylmorphine on the !-butanol-induced 
spectral changes in liver microsomes from male (A) and female (B) mice, 
---- 88 mM ]-butanol in the sample cuvette; - - - - 88 mM 1-butanol + 
3 mM aniline in the sample cuvette and 3 mM aniline in the reference cuvette; 
· ·· • • ·· 88 mM 1-butanol + 3 mM aniline+ 3 mM ethylmorphine in the sample 
cuvette and 3 mM aniline + 3 mM ethylmorphine in the reference cuvette. 
Cytochrome P-450 contents: males 1.28 nmol/ml; females 1.22 nmol/ml. 
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Fig, IX,S. The effect of hexobarbital on the 1-butanol-induced 
spectral change in liver microsomes from female mice. 
88 mM !-butanol in the sample cuvette; - - - - 88 mM 
!-butanol in the sample cuvette and 3 mM hexobarbital in both 
sample and reference cuvettes. Cytochrome P-450 concentration: 
1.10 nmol/ml. 
DISCUSSION. 
If the 1-butanol-induced spectral change represents the displacement of 
endogenous substrates (4), the sex difference in this spectral change, ob-
served in this study (Fig. IX, I), indicates the existence of a high level 
of endogenous substrates in microsomes from male mice as compared with 
females. This may explain the sex difference in the type I binding of ethyl-
morphine and hexobarbital (the binding capacity in males is approximately 
threefold lower than in females), which is due to the unveiling of an 
inhibitory action of androgens during sexual maturation (10,12,13). Fig. IX,2 
shows that testosterone pretreatment, in fact, caused an increase in the 
1-butanol spectrum and a concomitant decrease in the ethylmorphine spectrum. 
Several observations, however, make the role of endogenous substrates 
less obvious. (1) The sex difference in the !-butanol spectrum is due to a 
developmental decrease occurring in females (Table IX,.l). (2) The sex-depend-
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ency of type I binding is due to 6Amax and not to Ks (13) (but the endogenous 
substrates might be bound very tightly). (3) Washing the microsomes from 
male mice with !-butanol had no appreciable effect (the presumably very lipo-
philic compounds, however, might remain with the microsomal membrane rather 
than be removed with the supernatant). (4) Organic solvent extraction of 
freeze-dried microsomes from male mice only slightly decreased the !-butanol 
spectrum, and had no effect on type I binding. 
Convincing evidence that male microsomes do not contain more endogenous 
substrates than females was presented in Fig. IX,3. The binding of endogenous 
type I substrates should result in an increase in the amount of the substrate-
bound form of cytochrome P-450 at the expense of the substrate-free form. 
The recording of a difference spectrum with male and female microsomes 
(balanced with respect to the cytochrome b 5 and cytochrome P-450 contents) 
in sample and reference cuvettes respectively, should, therefore, simply 
yield a type I spectrum. No such spectrum was found, thus indicating that 
male microsomes do not contain more substrate-bound cytochrome P-450 than 
females, if it is present at all. 
The reverse type I spectral change may represent a conformational change 
in cytochrome P-450, due to a loading of the membrane with substrate (17,18). 
Although ]-butanol affects the membrane structure (19,20) and the microsomal 
membrane might have a sex-dependent lipid composition (21) this is not likely 
to explain the sex-dependent ]-butanol spectra. Organic solvent extraction, 
which removes a great deal of the lipid material (6), only slightly decreased 
the spectral change (Table IX,2). 
It has been suggested that ]-butanol interacts directly with the heme-
iron (7-9), due to the nucleophilic OR-group, and thus may interfere with 
the binding of the type II compound aniline. Our results demonstrate that 
!-butanol interferes with type II as well as type I binding. Multiple inter-
action between a substrate and cytochrome P-450 has been often reported 
(22-26). Type I binding of !-butanol, however, has not been observed before. 
Only some 1-alkanols with hydrocarbon chains longer than 5 C-atoms were shown 
to have a type I component in their spectra in male rats (7) and male mice (8) . 
The !-butanol spectra obtained in the presence of aniline together with 
ethylmorphine show the same size in males and females (Fig, IX,4). Type II 
binding is not sex-dependent, at least when related to the cytochrome P-450 
content, as demonstrated with aniline (10). These observations thus indicate 
that the sex difference in the !-butanol-induced spectral cl1ange in the mice 
we investigated is due to a sex-dependent type I binding. This elegantly 
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explains all observed phenomena, and in particular the results presented in 
Table IX,1. Based on the total amount of cytochrome P-450, the size of the 
!-butanol-induced spectrum is the same in male and female immature animals 
and mature males. The low spectral size observed in mature females is due 
to type I binding, which increases selectively in females during sexual 
maturation (13). 
In the accompanying paper it is shown that !-butanol competitively 
inhibits the type I binding of ethylmorphine (Chapter X). 
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CHAPTER X. THE USE OF COMPETITIVE INHIBITION OF SUBSTRATE-BINDING TO 
CYTOCHROME P-450 IN THE DETERMINATION OF SPECTRAL DISSOCIATION 
CONSTANTS FOR SUBSTRATES WITH MULTIPLE TYPES OF BINDING, 
AS ILLUSTRATED WITH 1-BUTANOL, 
SUMMARY. 
A method is described, which allows (a) the detection of competitive 
inhibition of binding to cytochrome P-450 between two substrates which 
elicit the same type of spectral change, and (b) the estimation of disso-
ciation constants for one type of spectral binding of a substrate which 
exhibits multiple interaction with cytochrome P-450. 
This method was used to investigate the interaction of 1-butanol with 
the type I binding site of cytochrome P-450 in liver microsomes from female 
mice, 1-Butanol was found to competitively inhibit the binding of ethyl-
morphine, and has an apparent dissociation constant for type I binding 
of 30 mM. 
INTRODUCTION, 
The spectral interaction of substrates of the microsomal mixed-function 
oxidase with cytochrome P-450 (1) has been defined in terms of the spectral 
dissociation constant (Ks) and maximum spectral interaction (~Amax) (2). 
The spectral changes are determined by means of difference spectroscopy (3). 
Several compounds have been shown to generate different types of spectral 
interaction simultaneously, which leads to composite difference spectra (4-7). 
The presence of a particular component can be demonstrated by the addition 
of a 'modifier' compound, which is known to elicit only one type of spectral 
change, to both sample and reference cuvettes, thus inhibiting the correspond-
ing component of the compound in the sample cuvette, It is shown in this 
paper that, if the inhibition is competitive, the classical equations for 
competitive inhibition do not apply. Suitable equations are formed to deal 
with this situation. In addition, these equations permit the calculation of 
the dissociation constant for one type of spectral interaction of a compound 
which shows multiple interaction with cytochrome P-450. 
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The method described is applied to the type I binding component of 
1-butanol. In the preceding paper, we demonstrated a sex difference in the 
spectral change produced by 1-butanol in mouse liver microsomes. It was 
shown that this spectral change consisted of at least two components and that 
the sex difference was due to a type I component (characterized by a differ-
ence spectrum with a peak at 385 nm and a trough at 420 nm). Previously, we 
have demonstrated a similar sex difference in the binding of the type I 
substrates ethylmorphine and hexobarbital (8-11). In this paper, we demonstrate 
that !-butanol interacts with type I binding sites, as evidenced by a competi-
tive inhibition of ethylmorphine binding. 
MATERIALS AND METHODS. 
Male and female mice of the CPB-SE strain were obtained from the Central 
Animal Breeding Station TNO, Zeist, The Netherlands. They were kept in 
Makrolon cages with pinewood shavings, received standard food pellets (Hope 
Farms) and tap water ad lib., and were used after they had reached the age 
of 11 weeks. 
1-Butanol (p.a.) was obtained from Merck, and ethylmorphine from Brocacef. 
All other chemicals used were at least reagent grade. 
Preparation of liver microsomes and performance of spectral measurements 
are described in the preceding communication (Chapter IX). 
RESULTS. 
Y~!~~~~z-~~-~~~~~~~g£~-~E~£!E£~££E2-~~-~-~~~~£~-~£E_~!~£Yi~a_££~E~£i£~~~ 
i~~i~i£~£g_£f_~ig~igg_~2-£Y!2£~E2~~-~=~~Q. 
The simultaneous binding of two compounds to the same site on cytochrome 
P-450 may be examined, in principle, using the classical method for determining 
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enzyme inhibition patterns, by measuring the spectral changes elicited by 
several concentrations of one substrate in the presence of varying concentra-
tions of the other. The first compound (S) is added to the sample cuvette, 
whereas the second (I) is present in both sample and reference cuvettes. It 
is not usually recognized, however, that double reciprocal plots of spectral 
change vs. substrate concentration obtained in this fashion cannot be inter-
preted in the classical way. The difference spectrum which is actually 
measured is not the spectral change elicited by compoundS. It represents the 
sum of the spectral changes produced by both S and I in the sample cuvette 
minus the spectrum of I alone in the reference cuvette. This subtraction does 
not simply cancel the spectral contribution of I in the sample cuvette, 
because the magnitude of this contribution is diminished by the presence of S. 
The magnitude of the spectral change (6As) elicited by compound S is 
given by 
M 
s 
M .[SJ 
max 
[S] + K 
s 
If a second compound (I) is added (to the sample cuvette only) the observed 
spectral change is determined by two equilibria: 
[E]. [S] [E]. [I] 
( 1) 
K 
s 
and K. 
L 
(2 '3) 
[ES J [EI] 
This spectral change (6Asi) is proportional to the total amount of complex 
famed: 
M 
max 
k([ES] + [EIJ) 
Et represents the total number of binding sites: 
[E) + [ES] + [EI] 
From equations 4, 5 and 6 it can be shown that 
(4) 
(5) 
(6) 
]]] 
M [Et] {E] max 
+ I + I 
M. 
SL 
[ES] + [EI] [ES] + [El] [ES] + [EI] 
[E] 
After insertion of equations 2 and 3, equation 7 is trans fanned to 
M 
max 
+ 
M. [S] 
+ 
[I] 
SL iZ K. 
s L 
M c::;) . [lJ) 
max K K. 
S L 
and M. 
SL [.§_] [J:_] I + + K K. 
s L 
This equation is analogous to the equation describing the simultaneous 
catalytic actions of an enzyme on two different substrates (12a), and does 
not represent a hyperbole. 
(7) 
( 8) 
(9) 
When the compound I is also added to the reference cuvette, the spectral 
shift elicited in this cuvette is given by equation 10. 
M [I] M [I] 
max max K. 
M. L 
L [I] + K. [I] 
L I + K:. 
L 
According to equations 9 and 10 the observed difference spectrum is now 
defined by 
6A . - 6A. 
SL L 
M 
max 
[J:_] 
K. 
L 
+ [I] 
K. 
L 
[~] ) 
;_J:_] 
I + K. 
L 
After simple algebraic manipulation this is simplified to 
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(I 0) 
(I I) 
M .[S] 
max 
M.- M. 
8> L 
[]:_]) + K (1 + [_!]) 2 K. 
(! 2) 
K. s 
L L 
This evidently represents a hyperbole. A double reciprocal plot of spectral 
change in relation to substrate (S) concentration will therefore be linear: 
K 
s [_!] )2 
K. CSJ + 
_I (I + []J) 
K. (I 3) M.- M. 
SL L 
6A 
max 
L 6A 
max 
L 
A series of plots of l/(6A .- 6A.) against 1/{S} at varying inhibitor 
8> L 
concentrations is presented in Fig. X,l. The apparent 
apparent 6Amax depend on the inhibitor concentration, 
from normal inhibition kinetics. 
K, 
6AmClx 
K; 
0.4 
K as well as the 
s 
which is different 
Fig. X, I. Competitive inhibition of spectral interaction with 
cytochrome P-450. 
This figure shows the theoretical pattern of double reciprocal plots 
of the magnitude of the spectral change vs. substrate concentration, 
in the case of two substrates which each competitively inhibit the 
binding of the other to cytochrome P-450, and which both elicit 
the same type of spectral change. Microsomal suspensions are titrated 
with one substrate (S) in the presence of different concentrations 
of the other substrate (I). 6Asi-i represents the size of the spectrum 
observed, when S is added to the sample cuvette only, and I to both 
sample and reference cuvettes. 
I I 3 
The apparent 6Amax is simply given by 
fjA 
max .. 
s~-l. 
fjA ( max 
I + [_J:_l) K. , 
( 14) 
whereas the apparent Ks is obtained from the condition 1/(6Asi 6Ai) 0 (Eq, 13) , 
This yields 
K. can now be , 
the inhibitor 
K (1 + [.!_]) 
s K. , 
(I 5) 
calculated by replotting either l/6A or K .. against 
maxsi-i s1.-1. 
concentration. Such plots are straight lines which intercept 
the abscissa at I = -K .. This procedure is the same as that appropriate for , 
the calculation of K. from the observed K in normal competitive inhibition , s 
kinetics ( 12b) ' but which is not often used because of the availability 
the more convenient Dixon-plot (13), The latter method cannot be used in 
this case, 
of 
In the above calculation it is assumed that both compounds bind to the 
same number of binding sites. In the case of type I binding this might not 
always be true, as different classes of type I binding sites may exist (14). 
!g!~E£~E~~£~-~~-l=£~!~~£1_~i!~_!Q~_£zE~-~-£ig~i~g_£f_~£hzl~2EE~~~g-~g~ 
~~~~~~£~~~-2~-£~~-~i~~££i~!i£~_££~~£~~£_i2E_~~g_i~£~E~££i£~_£f_l=£~!~~21 
~~£~-£~~-£zgg_~-~i!~-i~-~2~~~-1i~~E-~i£E2~2~~~· 
In the preceding paper (Chapter IX) it was indicated that the sex differ-
ence in the composite 1-butanol-induced spectral change is due to a sex-
dependent type I component only, when calculated on the basis of the total 
cytochrome P-450 contents. When the 1-butanol spectrum, obtained with male 
liver microsomes, is subtracted from that obtained with female microsomes, 
a true type I component is, in fact, obtained. Sex-dependent binding has been 
observed, for example, with the type I substrate ethylmorphine (9,10). The 
sex difference was due to a difference in 6Amax (female values are higher 
than the male ones) and not to a difference in Ks. This may also be true for 
]-butanol. 
When the spectral change elicited in males is subtracted from that in 
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females, the relationship between the difference obtained and the substrate 
concentration is still represented by a hyperbole: 
6A .[S) 
max 
[S) + Ks 
M .IS) 
max& 
[S) + K 
s 
A double reciprocal plot is, therefore, linear: 
6A , 
~-u 
K 
s 
[S) 
+ 
M 
max~-O 
(6A -M ).[S) 
max max0 ( 16) 
( I 7) 
If this is applied to the spectral changes elicited by several concentrations 
of !-butanol, Fig. X,2 is obtained. From the intercept on the ordinate the 
value of ~A was calculated to be 12.8 x J0- 3/nmol P-450. This is in 
max0 _0' 
d + · h h 1 f 12 I I 0 I0- 3/nmol P 450 b · d goo agreement Wl.t t e va ue o . + . x - o ta1.ne 
previously for the difference between 
100 
-0.04 -0.02 0.02 
6A 
max 
~ 
0.04 
and LA for ethylmorphine 
maxrJ 
0.06 0.08 0.1 
1/[butanoU (mM)-1 
Fig. X,2. Concentration-dependent difference between the !-butanol-
induced spectral changes in microsomes from male and female mice. 
The size of each spectral change was measured at 385 nm, relative to 
420 nm, these being the wavelengths of the peak and trough of the 
type I difference spectrum, and expressed per nmol P-450. Microsomal 
preparations contained approx. 1.3 nmol P-450/ml. For further 
explanation see the text. 
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binding (9). This is a strong indication that !-butanol occupies the same 
binding sites as ethylmorphine. A dissociation constant of 30 mM is obtained 
from the intercept on the abscissa. 
The influence of ]-butanol on ethylmorphine binding was investigated 
using the method described above. The sample cuvette was titrated with 
ethylmorphine in the presence of different concentrations of ]-butanol in 
sample and reference cuvettes. The data are shown in Fig. X,3. The pattern 
of the double reciprocal plots closely resembles that shown in Fig. X, I, 
thus indicating competitive inhibition between ]-butanol and ethylmorphine. 
[butonoO 
0 
~ 300 ~ 043,8 mM 
' ~
0 
E 
" 
0 
0 200 • N 1 21,9 mM ~ 
00 
M 
"" 
10,9 mM 
<l 
0 mM 
-4 0 I 2 3 
1/ [Ethy I morphine] (mM-1) 
-3 
-2 -I 
Fig. X,3. Effect of !-butanol on type I binding of ethylmorphine 
in liver microsomes from female mice. 
Microsomes were titrated with ethylmorphine in the presence of 
different concentrations of 1-butanol according to the procedure 
given in Fig. X, I. The data points are the means of 4 experiments. 
The apparent K and 6Aruax of ethylmorphine binding at each con-
centration of 1-butanol were calculated according to the method 
of Wilkinson (15). The microsomal preparations contained approx. 
2.4 nmol P-450/ml. 
A replot of the reciprocal of the apparent 6Amax against the !-butanol 
concentration, according to Eq. 14, yielded a Ki of 32 mM (Fig. X,4). A replot 
of the apparent Ks against the !-butanol concentration, according to Eq. 15, 
yielded the same value (not shown) . This value is similar to that obtained 
from Fig. X,2. 
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Fig. X,4. Determination of the (type I) spectral dissociation 
constant of ]-butanol. 
The apparent 6A values obtained from Fig. X,3 were graphically 
related to the ~~Sutanol concentration according to Eq. 14 (see 
the text). The value indicated by K. represents the dissociation 
constant of 1-butanol. J.. 
DISCUSSION. 
It is common practice to examine the mutual effects of different compounds 
on their binding to cytochrome P-450, using spectrophotometric methods. The 
results of such determinations, however, should be interpreted with care. 
If two substrates bind to the same site, thereby eliciting the same type of 
spectral change, the contributions of each substrate to the spectral change 
observed, on simultaneous addition to a microsomal suspension, cannot be 
separated. Any attempt to compensate for the spectral change elicited by the 
'modifier' substrate is bound to fail, i.e. subtraction of this spectral 
change, either by calculation or by means of difference spectroscopy, results 
in spectra which are too small. Similarly, the use of a dual wavelength 
titration yields erroneous results. Jf a classical pattern of competitive 
inhibition is observed using these methods (e.g. 16-18), this may indicate 
competition, but one of the compounds will apparently not itself elicit the 
type of spectral change studied, which is difficult to explain. Only a 
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decrease in ~Amax' in addition to an increase inKs' may indicate the com-
petitive binding of two compounds exhibiting the same type of spectral inter-
action (as observed by Schenkman et al. (19) with phenacetin and hexobarbital). 
The quantitative description of this type of competitive inhibition, 
presented in this paper, allows for the determination of the dissociation 
constant for one type of spectral interaction if a substrate shows multiple 
interaction with cytochrome P-450. Using this method, He have provided 
evidence that ]-butanol binds to the type I binding site of cytochrome P-450, 
thus substantiating the conclusion of the preceding paper (Chapter IX). 
The type I spectral change is usually considered to be inherent in the 
metabolism of a substrate (20), although there might be a few exceptions to 
this rule (e.g. 21). The demonstration of a type I component in the ]-butanol 
spectrum might, therefore, imply that ]-butanol is metabolized by cytochrome 
P-450. Teschke et al. (22) reported that, in rats, !-butanol is partly metab-
olized via the alcohol-oxidizing system, which may involve cytochrome P-450, 
with an apparent Km of 4.9 mM. No binding studies were performed, however. 
As the occurrence of a type I component might be strain-dependent (in addition 
to sex- and species-dependency), it would be interesting to know Hhether a 
type I component was present in the rat strain used. 
An important complication in the determination of Ks-values (as well as 
Km-values) might arise when the substrates studied are very lipophilic, since 
the microsomal membrane might act as a second compartment, a lipid phase, in 
addition to the aqueous phase. Recently Parry et al. (23) have discussed the 
implications of the lipophilicity of substrates which interact with membrane-
embedded enzymes. The occurrence of a biphasic membrane system should be 
evident, in our study, from a non-linear relation between the spectral change 
(which is proportional to the amount of enzyme-substrate complex) and the 
total enzyme concentration. Our experiments, however, were performed with 
microsomal suspensions containing approx. 1-2 mg protein/ml, in which region 
the 1-butanol-induced spectral change is linear with protein concentration 
(unpublished observations), This means that the enzyme concentration is 
relatively low, so that single-compartment kinetics apply. It was demonstrated 
by Parry and coworkers (23) that in such a case dissociation constants do not 
require correction when the binding site faces the aqueous phase. For a 
lipid-faced binding site the observed dissociation constant depends on the 
membrane-water partition coefficient. It has been suggested that the binding 
site is concealed inside a hydrophobic pocket (24,25). In that case the true 
dissociation constant for the type I interaction of !-butanol with cytochrome 
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P-450 might be higher than measured in the present study, as the octanol-
water partition coefficient for ]-butanol is 7.6 (26). 
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CHAPTER XI. 
INTRODUCTION. 
FURTHER EVIDENCE FOR A HETEROGENEITY OF CYTOCHROME P-450 
AS THE CAUSE OF SEX-DEPENDENT TYPE I BINDING. 
Several compounds which elicit a type I spectral change in rat liver 
rnicrosomes have been shown to have spectral dissociation constants in the 
micromolar range. A well-documented compound is the S-adrenoceptor blocking 
drug alprenolol (1,2). Initially, we interpreted the existence of this high-
affinity binding as a support of the concept that tight binding of endogenous 
substrates might occur in microsomes, which could explain the sex difference 
in type I binding of ethylmorphine. As a part of the investigations presented 
in Chapter IX the spectral interaction of testosterone and alprenolol with 
mouse liver microsomes was examined. Both compounds were found to elicit a 
type I spectral change. Although further investigation appeared to be irrel-
evant in the light of the results presented, one finding prompted us to 
extend the study of the binding of alprenolol. The binding of this compound 
did not seem to be sex-dependent. This would provide an indication of a 
heterogeneity of type I binding sites. 
MATERIALS AND METHODS. 
Adult male and female mice of the CPB-SE strain were used. 
Alprenolol was obtained from Astra Chemicals and Pharmaceuticals NV. 
All methods were the same as those described in Chapter IX. 
RESULTS AND DISCUSSION. 
Alprenolol elicited a type I spectral change with mouse liver microsomes, 
but the binding was not sex-dependent. The maximum spectral change was the 
same in both sexes, when related to the cytochrome P-450 content, which is 
in contrast to the results obtained previously with ethylmorphine (Chapters 
V-VI). In Fig. XI, I the double reciprocal plots for alprenolol binding are 
shown. An average line was calculated rather than the average of individual 
lines. ~A was 11.9 x I0-3/nmol P-450 in males and 11.3 x I0-3/nmol P-450 
max 
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Fig. XI, I. Double reciprocal plots of the magnitude of the 
type I spectral change elicited by several concentrations of 
alprenolol in liver microsomes from male and female mice 
(3-4 mg protein/ml), Data points represent means of 6 (females) 
or 5 (males) experiments. 
in females. This is not a significant sex difference, since the standard 
errors of the data points amounted to S-8%. In four of these experiments 
6Amax for ethylmorphine binding was determined in a similar way, in order to 
confirm the sex-dependent binding of ethylmorphine in these microsomes. 
A value of 6.0 x !0-3/nmol P-450 was found in males, whereas this value was 
15.5 x 10-3/nmol P-450 in females. 
In Fig. XI,2 it is shown that the binding of ethylmorphine and alprenolol 
is not fully additive. In females, the spectral change elicited by 100 ~M 
alprenolol is increased by 2 mM ethylmorphine, but not further than to the 
level observed with 2 mM ethylmoprhine alone. Conversely, addition of 
alprenolol did not add to the spectral change elicited by 2 mM ethylmorphine. 
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In males, ethylmorphine did not enhance the type I binding spectrum of 
alprenolol (a slight decrease was, in fact, observed; see below), but 
alprenolol enlarged the spectrum obtained with ethylmorphine to the magnitude 
observed when measured in the absence of ethylmorphine, 
This indicates that, in females, alprenolol is able to bind only to a 
part of the ethylmorphine binding sites, whereas, in males, alprenolol binds 
to all ethylmorphine binding sites plus an additional number of other sites. 
For both substrates the binding affinity is not sex-dependent. The results 
,, 
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Fig. XI,2. Difference spectra observed after cumulative 
addition of 100 ~M alprenolol (alpr.) and 2 mM ethylmorphine 
(EM) in liver microsomes from male and female mice (2-3 
mg protein/ml) , 
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thus present an intriguing pattern of substrate specificity, indicating the 
occurrence of at least three classes of type I binding sites. One class binds 
only ethylmorphine, the second only alprenolol, and the third class binds 
both of them. Grasdalen et al. (3) have observed several classes of type I 
binding sites in male rats, using different substrates. 
In the experiments presented in Fig. XI,2 2 ~~ethylmorphine was added 
after the final addition of 300 wM alprenolol. The absorbance change was 
-3 14.7 x 10 /nmol P-450 in females, which is in good agreement with the value 
of 14~4 x 10-3/ nmol P-450 calculated from the ethylmorphine binding study. 
In males, curiously, the final addition of 300 ~M alprenolol caused the 
spectral change to decrease slightly (which was consistently observed in each 
experiment), and addition of 2 rnM ethylmorphine caused a further decrease to 
about 70% of the value measured using 100 ~M alprenolol. As indicated in 
Fig. XI,2 the addition of ethylmorphine in the presence of 100 ~M alprenolol 
had less effect on the spectral change. In females, concentrations up to 
3 mM alprenolol still caused minor increases. This might indicate that high 
concentrations of alprenolol are deleterious to the type I site in males, or 
that a different type of spectral change arises (type II). The significance 
of this remains to be established. 
The value of 10 ~M for the Ks of alprenolol is not as low as that observed 
in rats. We have found a similar, but smaller difference between mice and rats 
with ethylmorphine and hexobarbital (not shown). Von Bahr et al. (2) indicated 
the presence of two phases of alprenolol binding: a high affinity (Ks = 0.17 wM) 
and a low affinity phase (Ks not given), both with the same binding capacity. 
There might be a low affinity phase in mice (operative at concentrations below 
5 wM), but then its capacity will be much smaller than that of the phase 
presently measured. 
One interesting aspect of high-affinity binding, which is not recognized 
in the literature, may be discussed here. When the apparent dissociation 
constant is determined using substrate concentrations in the micromolar 
range, these concentrations approach the cytochrome P-450 concentrations 
usually employed for these assays, or may be even lower. For example, the 
value of 0.17 ~M determined by Von Bahr et al. (2) was obtained with a micro-
somal preparation containing approx. 2 nmol cytochrome P-450/ml, i.e. 2 ~ 
(not actually stated, but this may be assumed on the basis of other data). 
Although it was calculated that only 13-14% of cytochrome P-450 is involved 
in this binding, the substrate range chosen and the apparent Ks measured are 
lower than the enzyme concentration. In such a case the Michaelis-Menten 
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equation cannot be applied, since the concentration of bound substrate is no 
longer negligible with respect to that of the free substrate. Any linear 
transformation of this equation will yield curves. Nevertheless, a straight 
line was obtained. Similar observations were made with other type I substrates, 
e.g the tricyclic antidepressant drug imipramine (Ks ""0.22 wM) (4) and the 
vitamin n3 metabolite 25-hydroxycholecalciferol (Ks = 0.84 nM) (5). 
nvo explanations may be given for this. (I) Only very small fractions of 
the total cytochrome P-450 population are involved in the binding of these 
substrates (in particular 25-hydroxycholecalciferol), which is interesting 
in view of the heterogeneity of cytochrome P-450, and which would, further-
more, imply that the fraction of 13-14% calculated by Von Bahr et al. (2) is 
overestimated. (2) As discussed in Chapter X, Parry et al. (6) have indicated 
that the apparent Ks may be severely underestimated if the substrate is very 
lipophilic and the binding site is hidden in the lipid phase formed by the 
microsomal membrane. In that case the free substrate concentration represents 
the concentration in the lipid phase, which may be much higher than expected 
on the basis of the total volume of the microsomal suspension, thus exceeding 
the enzyme concentration. 
The fact that 6A values for many substrates, including the so-called 
max 
high-affinity substrates, do not differ greatly, and that often a full or at 
least partial overlap of binding specificity is observed, might indicate 
that all type I binding is associated with an extremely small fraction of 
the cytochrome P-450 content. Since there is some evidence for a binding site 
hidden in the membrane (7~8), however, the fact that the high-affinity 
substrates are lipophilic leaves the second possibility as the more attractive 
one. 
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CHAPTER XII. GENERAL DISCUSSION. 
In this chapter the main aspects of this thesis are summarized and further 
discussed. These aspects include the hormonal basis of the sex-dependency of 
the cytochrome P-450 system, the sex dependency of cytochrome P-450-substrate 
interaction, the heterogeneity of cytochrome P-450, the mechanism of substrate-
induced stimulation of NADPH-cytochrome P-450 reductase activity and the role 
of the reduction of the cytochrome P-450-substrate complex in the hydroxyla-
tion reaction. Finally, possible future developments and clinical aspects 
are discussed. 
It is difficult to interpret the nature of the sex differences in the 
cytochrome P-450-system in terms of hormonal mechanisms. The present study 
allows only very general conclusions in this respect. In mice of the CPB-SE 
strain testosterone pretreatment produces effects in females only, whereas 
castration produces effects in males only. This indicates that the sex differ-
ences arise through androgenic action, In rats, estrogens do not have effects 
of their own, but rather impair the effects of androgens. We have not in-
vestigated this in mice. It has been observed in rats that a sex difference 
exists in the pattern of steroid metabolism. The development of this pattern 
is imprinted by neonatal androgen (Chapter III,4.6). This has also been ob-
served for the metabolism of type I substrates: the responsiveness to 
androgens, which results in a stimulation of metabolic activity during 
sexual maturation, is neonatally imprinted (1). In mice the sex differences 
appeared to arise as a result of developmental changes occurring in females 
(Chapter VII). Taking into account that, in this species, the effects of 
androgen were found to be inhibitory, it might be postulated that the 
testicular androgen produced during sexual maturation impairs a process 
which would occur in its absence. The smaller sex difference in bA 
max 
as well 
as the lack of a sex difference in K 
m 
of ethylmorphine demethylation observed 
in the CPB-V strain, may be assigned to a smaller responsiveness to androgens 
as compared with theSE-strain (Chapter VI). 
The most prominent sex-dependent process in the development of the cyto-
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chrome P-450 system is evidently a change in the type I binding properties 
of cytochrome P-450. The low binding capacity of cytochrome P-450 in males, 
as compared with females, might be the result of tight binding of endogenous 
substrates. These substrates may be steroids, since they appear to have a 
high affinity for cytochrome P-450 (2). It was demonstrated, however, that, 
if endogenous substrate binding is important at all, this does not account 
for the sex-dependent type I binding (Chapter IX). In addition to this, it 
may be mentioned that, in a single experiment, testosterone was found to be 
a type I substrate, which exhibited a similar sex-dependent binding as ethyl-
morphine (apparent Ks approx. 5 ~M), Testosterone could be accumulated (in 
vitro) in the microsomal membrane, but a concentration of 200 ~M was easily 
washed out (by 2 consecutive cycles of centrifuging and resuspending) accord-
ing to what might be expected on the basis of simple partitioning between 
membrane and supernatant. Ethylmorphine binding in centrale male microsomes 
could not be increased by repeated washings. Thus, the mere binding of high 
affinity substrates is not a likely cause of the low level of type I (ethyl-
morphine) binding. Very recently it has been reported that treatment of 
microsomes with charcoal may result in the removal of endogenous substrates 
(3). Preliminary experiments, however, indicated that charcoal treatment 
does not abolish the sex difference in ethylmorphine binding. This sex 
difference is apparently the result of a difference in the very nature of 
the interaction of the substrate with cytochrome P-450, which points to a 
heterogeneity of cytochrome P-450. 
The developmental patterns of cytochrome P-450 in male and female mice 
of the CPB-SE strain indicate a heterogeneity of the cytochrome P-450 popula-
tion. In Chapter VII it was shown that a large portion of cytochrome P-450 
may not be involved in ethylmorphine binding. It can be calculated (using 
Fig. VII,4) that, in male mice, maximally 10% of the total amount of cyto-
chrome P-450 binds ethylmorphine. This is in agreement with the finding 
that high concentrations of type I substrates cause only a slight attenuation 
of the absorbance peak of the absolute spectrum of cytochrome P-450, in 
contrast to the observation that the peak is fully shifted by the binding 
of type II substrates (which bind to the heme) (8). Females have a larger 
capacity for binding ethylmorphine than males, because they possess a larger 
amount of that particular (ethylmorphine-binding) cytochrome P-450. 
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Further evidence for a heterogeneity of cytochrome P-450 was presented 
in Chapter XI. The finding that alprenolol only partly occupies ethylmorphine 
binding sites, indicated a heterogeneity of type I binding sites. The fact 
that alprenolol binds to a fair amount of the ethylmorphine binding sites 
in females, and does not exhibit a sex difference in type I binding in adult 
animals, makes it difficult to understand that the increase in ethylmorphine 
binding capacity in females during sexual maturation would be the result of 
a selective synthesis of ethylmorphine-binding cytochrome P-450 (which was 
suggested by the results in Chapter VII). It would seem more likely that 
the increase in capacity of ethylmorphine binding is due to a modification 
of already existing type I sites. Since the development of alprenolol binding 
was not studied, however, nothing conclusive can be said about this. 
4. ~~~~!Ee!~:i~~~£~~-~!im~le!i~~-~!-~~~K~:£Z!~£~E~m~_K:~~Q_E~~~£!e~~-e£!i~i!Y 
§gg_!t~_E§!~_Qi_E~~~£~iQg_Qf_~Q~_fl!Q£tEQ~~-~=~~Q:~~~~£E~~~-fQ~E!~~· 
The results presented in Chapters V-VIII demonstrated that the stimulation 
of NADPH-cytochrome P-450 reductase activity by type I substrates is closely 
related to the magnitude of the spectral interaction with cytochrome P-450. 
This strongly suggests that type I binding represents the formation of an 
enzyme-substrate complex. The reduction of this complex did not seem to be 
a rate-determining factor in the demethylation of ethylmorphine. It was 
proposed (Chapter V), however, that a true measure of the reduction of the 
cytochrome P-450-substrate complex might not be obtained, since the nature 
of the reductase stimulation is not yet well established. In this regard 
four possibilities can be distinguished. 
I. According to the original hypothesis by Gigon et al. (5) the substrate-
induced reductase stimulation (~red) represents the reduction of a cytochrome 
P-450 in the fast phase of reduction, which was reduced either in the slow 
phase or not at all in the absence of substrate. In the following the con-
tribution of the slow phase to the initial rate of reduction is neglected, 
which is justified on the basis of the rate constants given by several authors 
(6-8). The (initial) basal rate of reduction is represented by kB, in which k 
is the pseudo first order rate constant and B is the amount of cytochrome 
P-450 reduced in the fast phase, This parameter may reflect the reduction of 
cytochrome P-450 bound to endogenous substrates (6), After the addition of 
substrate an extra amount of cytochrome P-450-substrate complex (Bx) is in-
volved in the fast phase. The rate constant of the reduction of this complex 
(k ) may or may not be different from that associated with the basal rate. 
X 
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Thus, the total reduction rate is given by kB + k B . 
X X 6red then becomes 
kB+ kxBx - kB = kxBx. This represents the rate of reduction of cytochrome 
P-450-substrate complex and is directly related to the magnitude of the 
type I spectrum (6A), which is a measure of the number of complexes. 
II. The existence of a fast and a slow phase of reduction may bear no 
relationship to the presence or absence of substrates, but may reflect a 
structural difference in the assembly of cytochrome P-450 and the reductase, 
as proposed by Peterson et al. (8). The substrate binds to all of the cyto-
chrome P-450 involved in the fast phase only and alters the rate constant of 
this phase. The basal reduction rate is kB; the rate in the presence of 
substrate becomes kxB (total reduction rate, neglecting the slow phase, vide 
supra), which directly represents the rate of complex reduction. In that case 
D d = (k - k)B, the stimulation thus being related to the amount of complex. 
re x 
III. This possibility is a variation on case II. Only a portion of the 
fast phase cytochrome P-450 may be involved in the binding of substrate. The 
basal reduction rate equals k(B 1+ B2), B1 and B2 representing subfractions 
of fast phase cytochrome P-450 with different substrate specificities. After 
substrate binding the rate becomes kB 1 + kxB2 , and 6red is given by 
kB 1 + kxB2 - k(B 1+ B2) = (kx- k)B2 . Again 6red is related to the amount of 
complex. But neither 6 d nor the total reduction rate represent the rate of 
re 
reduction of this complex, which is given by kxB2 = k 1B2 + 6red' i.e. 6red 
plus a fraction of the basal reduction rate. 
IV. An extension of cases II and III is obtained by the supposition that 
the substrate may also bind to slow phase cytochrome P-450. This might not 
have an appreciable effect on the initial rate of reduction. In that case 
6red will be related to 6A only if the relative extents of substrate-binding 
linked to each phase do not vary with sex, strain, or treatment, and if the 
reduction rate of the slow phase remains negligible. The rate of complex 
reduction is not well-defined: the rate constant may depend on whether cyto-
chrome P-450 was originally involved in the fast or in the slow phase. This 
case may approach cases II or III, or represent a mixture of cases I and II 
or I and III. 
Summarizing, the rate of cytochrome P-450-substrate complex reduction may 
be 6red (case I), the total reduction rate (case II), or lie between these 
values (cases II and IV), The very consistent finding that 6red is stoichio-
metrically related to the rate of ethylmorphine demethylation in rats (9-11), 
is compatible with the first mechanism. This cannot be reconciled, however, 
with the data obtained by Matsubara(?) and Peterson et al. (8), which require 
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mechanisms II or III, and possibly IV. We found bred to be directly related 
to bA, but, as indicated above, this does not preclude any of the possible 
mechanisms. It only indicates that type I binding and the formation of a 
reducible complex are not separate phenomena. The finding that ethylmorphine 
and hexobarbital form the same number of type I complexes (i.e. they produce 
the same 6A), but that their reductase stimulations are different (Chapter 
VIII), indicates that the rate constant of complex reduction depends on the 
substrate, This makes the role of the type I complex in metabolism (which 
occurs at varying rates depending on the substrate) even more probable. 
The interpretation of cytochrome P-450 reduction data will remain dif-
ficult as long as the actual mechanism of substrate-induced stimulation is 
not known. Nevertheless, the above justifies the conclusion drawn in Chapter 
VII, that the rate of reduction of the cytochrome P-450-substrate complex 
formed by type I binding is not related to the metabolic rate whichever 
mechanism of stimulation is taken into consideration. In the following it is 
discussed, however, that yet another factor may obscure a relationship be-
tween cytochrome P-450-substrate complex reduction and metabolic rate. 
5. ~~E~E~g~~~~EY_~f_£YE~£~E~~~-~:~2Q_~~E~-E~e£~~E-E~_£eEe~YE~£-~£E~~g; 
~-~2E~!~~~i~· 
The discrepancy between the magnitude of the type I spectral change, 6Amax 
(which reflects the formation of cytochrome P-450-substrate complex), and the 
rate of ethylmorphine demethylation, Vmax (Chapters VI and VII), is difficult 
to explain, if it is accepted that the type I complex is the enzyme-substrate 
complex. The fact that a developmental increase in 6Amax is observed without 
a concomitant increase in Vmax' might be explained by a parallel decrease 
of the turnover number, for example due to less optimal conditions, which 
could be indicated by the decreasing Km. This is very unlikely, however, 
since (1) the assay was optimalized on the basis of adult animals, (2) in 
the CPB-V strain a similar 6Amax difference is not accompanied by a sex 
difference in Km' and (3) similar Km-changes have been observed in maturing 
rats (12-14). 
Some interesting observations may form the basis of an attractive hypo-
thesis. It is known that a few substrates are not metabolized, although they 
elicit the type I spectral change and activate the reductase accordingly (15-
18). MOreover, oxygen is introduced into the complex. This inability to be 
metabolized may be due to chemical or sterical hindrance, Thus, it was 
131 
postulated that the substrate activates a part of the cytochrome P-450 
population for the metabolic reaction. Under certain circumstances, however, 
this reaction does not occur: complex formation leads only to the reduction 
of 02 to H20 or H2o2 instead of metabolic conversion of the substrate. It is 
conceivable that the inability to incorporate an oxygen atom into the sub-
strate molecule does not only depend on the nature of the substrate, but also 
on that of the active site of the cytochrome. It might, therefore, be specu-
lated that some types of cytochrome P-450 bind ethylmorphine, but do not 
catalyze its metabolism. This is supported by the finding that after induction 
of rats or guinea-pigs with pregnenolone-16a-carbonitrile, the increase in 
type I binding of ethylmorphine is accompanied by an increase in the H2o2 
production (19). This would explain the enormous discrepancy between V and 
max 
6Amax (Chapter VII). A fraction of the cytochrome P-450 involved in establish-
ing the value of 6Amax does not contribute to Vmax· This may be the ethylmor-
phine binding cytochrome, which develops during sexual maturation in females 
of the CPB-SE strain, since a parallel increase in Vmax is not observed. This 
hypothesis might be tested by the measurement of H2o2 production and 0 2 con-
sumption together with type I binding and ethylmorphine demethylation under 
various conditions, for example in the course of sexual maturation. 
6. ~~~EEEe~""'-~~-~~~-E~!~-~~-~~~~=£l~££~E~~~-~=~~Q_E~~~£~~"~-~g-~~~zl= 
~£EEbig~-~~~~£~Y1~!i£g. 
In Chapter VII it was concluded that the reduction of cytochrome P-450-
substrate complex is not rate-limiting in the demethylation of ethylmorphine, 
since no parameter of reductase activity was related to the demethylation 
rate, However, if a certain amount of type I complexe·s is reduced without 
being further metabolized, the role of the reductase in demethylation should 
be reconsidered, 
Upon examination of the developmental patterns of Vmax and cytochrome 
P-450 reduction, Vmax appeared to show the best correlation with the basal 
reduction rate, although the decrease in reduction rate between 3 and 7 weeks 
was much larger than in Vmax' This is strange, since basal reductase activity 
does not require exogenous substrate. When it is proposed that the same 
amount of cytochrome P-450 is active in demethylation in males and females, 
according to the above hypothesis, the substrate-induced reductase stimulation 
associated with metabolism should be the same in both sexes. In females, this 
6 d (which forms a fraction of the observed 6 d) may be considered equal to 
re re 
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the 6red obtained in males. When this value is added to the observed basal 
reduction rate, the descent of the sum of these reductase activities between 
3 and 7 weeks is not as steep as that of the basal rate alone, thus making 
the resulting reductase pattern very similar to that of V If it is assumed 
max 
that reductase stimulation follows mechanism III (see section 4), it is, there-
fore, conceivable that ethylmorphine binds to a portion of the fast phase 
cytochrome P-450, and that the reduction of the type I complex actually is 
related to V 
max 
Recent investigations have indicated that, in rats, the turnover numbers 
of cytochrome P-450 reduction well exceed those of metabolic reactions, which 
would imply that the reduction is not rate-limiting (7,8). The data presented, 
however, were based on the participation of the complete fast phase of re-
duction in metabolism, which was calculated to relate to approx. 50-75% of 
the total amount of cytochrome P-450. Since there is evidence that type I 
substrates bind to much smaller portions of cytochrome P-450 (see section 3 
and Chapter XI), the actual turnover number of the metabolic reaction may 
be much higher than judged from Vmax on the basis of this large amount of 
cytochrome P-450. The participation of less cytochrome P-450 would, of course, 
imply that the actual value of the turnover number of cytochrome P-450 re-
duction is proportionally higher. But the experimental values of the latter 
parameter may not be correct. The computer program used for the kinetic 
analysis of the reduction progress curve (7,8) was based on the super-
imposition of only two phases, which were resolved into one fast and one 
slow phase. One might wonder how this model would deal with a substrate-
induced activation associated with only a small portion of the fast phase 
cytochrome P-450. 
Conclusive evidence concerning the role of NADPH-cytochrome P-450 re-
ductase in ethylmorphine demethylation and other reactions awaits more in-
formation about the amounts of cytochrome P-450 subspecies involved. 
One of the crucial problems for future research is the heterogeneity of 
cytochrome P-450. Although it is known that factors such as lipophilicity 
and nucleophilicity, or possibly the presence of a certain structural entity 
of the substrate molecule (2), are determinants of the degree of cytochrome 
P-450-substrate interaction, suitable parameters which clearly relate molecu-
lar properties of the substrate to its binding to cytochrome P-450 (sub-
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species) have not yet been developed. Extensive separation and purification 
of different forms of cytochrome P-450 may lead to a better understanding of 
substrate specificity. The use of physical methods (ESR, NMR) may further 
elucidate the nature of the binding sites and the modes of cytochrome P-450-
substrate interaction, including the role of the microsomal membrane in this 
interaction. 
Furthermore it is necessary to establish the requirements for the actual 
metabolism of the substrate after the oxygenated cytochrome P-450-substrate 
complex has been formed. Recently, it has been shown possible to study the 
oxygenation of cytochrome P-450 and two subsequent reactions (formation of 
a second complex and regeneration of the oxidized cytochrome P-450) spectra-
photometrically with a purified preparation of one form of cytochrome P-450 
from phenobarbital-treated rabbit liver microsomes (20). In addition, the 
method introduced by Hrycay and colleagues (21-24) (substrate metabolism by 
means of direct formation of the activated oxygen complex with oxidizing 
agents such as sodium periodate, thus bypassing the reductive steps) may 
prove useful in this respect. 
The results presented in this thesis might give the impression that the 
further study of the sex-dependency of components of the monooxygenase chain 
is rather academic, since there appears to be little or no consequence 
for the metabolism of substrates. This is not true, however, for several 
reasons. 
(1) Sex-dependent type I binding forms one of the many tools to obtain 
information about the heterogeneity of cytochrome P-450, which may help to 
explain functional differences displayed in a different situation. For 
example, the fact that a heterogeneity of cytochrome P-450 with respect to 
both binding and metabolism of several compounds is observed, could suggest 
that the development of a sex-dependent ethylmorphine-binding capacity 
actually reflects the development of a sex-dependent metabolic capacity for 
an endogenous substrate, which fits the active site better than ethylmorphine 
does. 
(2) The fact that ethylmorphine appears to bind to a portion of cytochrome 
P-450 without being metabolized, may not be entirely without consequence. If 
ethylmorphine indeed acts as a partial uncoupler, thus forcing cytochrome 
P-450 to reduce 02 to H2o 2 , this leads to an elevated cellular level of H2o 2 ~ 
which may influence other metabolic processes (as discussed by Hildebrandt 
et al. (19)). Moreover, if the uncoupler is not removed, it may cause the 
excessive consumption of cofactors or oxygen. In this respect it is important 
134 
to note that gluconeogenesis and lipogenesis were shown to be suppressed 
after stimulation of mixed-function oxidase activity (25,26) 
In Chapters I and II it was suggested that the study of the cytochrome 
P-450 system might be of clinical importance. A general rate-limiting step 
in drug metabolism might, for example, be used as a test of drug metabolizing 
capacity in liver biopsy samples. It has become clear, however, that the 
cytochrome P-450 system may be too complicated to provide such a simple 
measure of this capacity. 
A more useful approach seems to be the further study of the factors which 
govern the binding of a particular substrate or class of substrates to a 
particular cytochrome P-450 subspecies (vide supra). The knowledge of the 
relationship between molecular properties and interaction with cytochrome 
P-450 may offer the possibility to predict whether a certain drug will inter-
act with cytochrome P-450, and whether it will compete with other drugs for 
the same cytochrome P-450 or bind to different subspecies. 
Furthermore, it may be of value to investigate the induction of cytochrome 
P-450, and to establish which subspecies is (are) induced by a particular 
compound. The results of such studies may offer the possibility of inducing 
or avoiding the induction of a specific type of metabolic activity. Human 
cytochrome P-450 should be investigated to establish to which extent the 
results obtained with animal studies can be extrapolated to man. 
It may be expected that these fundamental studies will increase the 
understanding of drug-drug interactions and the relationships between molecu-
lar structure and biotransformation. They may further rationalize the de-
velopment of new drugs by providing more detailed criteria for the manipula-
tion of molecular structure. 
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SUMMARY 
In this thesis an investigation into the cytochrome P-450-dependent 
mixed-function oxidase in the endoplasmic reticulum of mouse liver is de-
scribed. This enzyme system possesses various functions, one of which is the 
conversion of lipid-soluble compounds (e.g. many drugs) into products which 
are more readily excreted from the body than the parent compounds. 
From earlier studies it was known that certain strains of mice show a 
sex-dependency in the metabolism of the barbiturate hexobarbital. In male 
mice hexobarbital-anaesthesia lasted longer than in females, and the in vitro 
rate of hexobarbital hydroxylation in males was slower than that observed 
in females. This sex-dependency was used as a tool to investigate the re-
lationships between substrate binding to cytochrome P-450 (type I binding, 
measured as a change in the absorption spectrum of cytochrome P-450), NADPH-
cytochrome P-450 reductase activity and the metabolism of the substrate, in 
view of the existing hypothesis that the reduction of the cytochrome P-450-
substrate complex might be a rate-limiting step in drug metabolism. The 
type I compounds ethylmorphine and hexobarbital were used as model substrates. 
Four introductory chapters, including a general introduction (I), a pres-
entation of the object and framework of the investigations (II), a survey 
of the existing body of knowledge about cytochrome P-450-linked enzyme sys-
tems, with particular reference to the liver (III), and a description of some 
methodological aspects (IV), precede the experimental section. 
In Chapter V it is shown that, in liver microsomes of mice of the CPB-SE 
strain, ethylmorphine demethylation, cytochrome P-450 content, type I binding 
of ethylmorphine, and substrate-induced enhancement of cytochrome P-450 re-
duction show sex differences, which are abolished by testosterone pretreat-
ment and castration. A clear relationship between type I binding and reductase 
stimulation suggested that type I binding reflects the formation of an enzyme-
substrate complex, which is subsequently reduced by NADPH-cytochrome P-450 
reductase. These parameters, however, were not clearly related to the de-
methylation rate, which was particularly evident in the CPB-V strain. 
In Chapter VI the kinetic constants of ethylmorphine demethylation and 
type I binding are examined in the CPB-SE and CPB-V strains. 
Km appeared to be sex-dependent in the CPB-SE strain. In the 
Both V and 
max 
CPB-V strain 
only a very small sex difference in V was found. The maximum spectral 
max 
interaction (~A ) observed in females appeared to be higher than in males 
max 
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in both strains, but in the V-strain the sex difference was smaller than 
in the SE-strain. The effects of testosterone pretreatment and castration 
demonstrated that androgens are responsible for the observed sex differences 
by exerting an inhibitory action in males. Mice of the V-strain appeared to 
be less responsive to androgens than those of the SE-s.train. 
In the SE-strain, the sex differences in 6Arnax' reductase stimulation, 
cytochrome P-450 content and Krn appeared to arise during sexual maturation, 
mainly as the result of developmental changes occurring in females (Chapter 
VII), This suggested that androgens inhibit such a development in males. 
The sex differences in Vmax and basal reductase activity had a more permanent 
character. A discrepancy between the total cytochrome P-450 content and 6Amax 
indicated a heterogeneity of cytochrome P-450: only a small portion of cyto-
chrome P-450 is involved in ethylmorphine binding. The discrepancy between 
6Amax and Vmax in females suggested that the formation of a number of cyto-
chrome P-450-ethylmorphine complexes does not lead to demethylation. The re-
duction of the cytochrome P-450-substrate complex did not seem to be rate-
limiting in ethylmorphine demethylation. 
In Chapter VIII the relationship between the kinetic constants of type I 
binding and metabolism is studied using the optical antipodes of hexobarbital. 
It was found that in mice (in contrast to rats) the Ks was similar to Km' 
suggesting that the type I site is the active site of the enzyme, and that 
the reduction of cytochrome P-450-substrate complex is rate-limiting. This 
was supported by the measurements of reductase activities. Furthermore, it 
was demonstrated that the rate of complex reduction depends on the substrate, 
which leaves the possibility that the rate-limiting character of the reductase 
step depends on the substrate, 
In the remaining chapters the nature of the sex difference in type I 
binding of ethylmorphine is further examined. In Chapter IX the possibility 
is excluded that the sex difference in type I binding of ethylmorphine is 
due to a sex difference in the level of tightly binding endogenous substrates. 
The }-butanol-induced spectral change, which has been attributed to the dis-
placement of endogenous substrates, appeared to be the resultant of different 
superimposed spectral components. The sex-dependency of this spectral change 
is due to sex-dependent type I binding of 1-butanol. 
In Chapter X it is demonstrated that !-butanol competitively inhibits 
ethylmorphine binding. A theoretical evaluation of competitive inhibition 
between two substrates eliciting the same type of spectral change is presented. 
It is shown how the dissociation constant of a substrate which elicits more 
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than one type of spectral interaction with cytochrome P-450, can be calculated, 
This is illustrated with !-butanol. 
Direct evidence for a heterogeneity of cytochrome P-450 as the cause of 
sex-dependent type I binding is presented in Chapter XI. The S- adrenoceptor 
blocking drug alprenolol was shown to be a type I compound, which produced 
the same magnitude of spectral interaction in males and females, It occupies 
all ethylmorphine binding sites in males, but only part of those sites in 
females. 
A general discussion is presented in Chapter XII, in which the roles of 
type I binding and NADPH-cytochrome P-450 reductase in ethylmorphine de-
methylation are further evaluated, The measurement of NADPH-cytochrome P-450 
reductase activities is discussed with regard to the question to what extent 
these activities might be presumed to represent the reduction of the cyto-
chrome P-450-substrate complex. Although the data presented indicate that 
the reduction of the cytochrome P-450-substrate complex is not rate-limiting 
in ethylmorphine demethylation, a rate-limiting role of the reductase cannot 
be excluded, if a number of type I complexes are not involved in the metab-
olism of the substrate (which was indicated in Chapter VII). 
The sex-dependency of the cytochrome P-450 system primarily relates to 
cytochrome P-450 itself, and finds expression in a sex difference in the 
relative amounts of cytochrome P-450 subspecies. Further research should 
provide insight into the factors which determine the binding of a particular 
(type of) substrate to a particular cytochrome P-450, and the factors which 
determine whether the formation of a cytochrome P-450-substrate complex leads 
to metabolism of the substrate or not. This information may improve the 
knowledge of drug-drug interactions and the relationship between chemical 
structure and the biotransformation of drugs. 
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SAMENVATTING 
In dit proefschrift wordt een onderzoek beschreven naar bet cytochroom 
P-450-afhankelijke mixed-function oxidase in bet endoplasroatisch reticulum 
van de muizelever. Dit enzym-systeem bezit een veelheid van funkties, en is 
onder meer betrokken bij de omzetting van vet-oplosbare verbindingen (zeals 
bijvoorbeeld vele farmaka) in produkten die gemakkelijker bet lichaam kunnen 
verlaten dan de oorspronkelijke verbindingen. 
Uit vroegere studies was reeds bekend, dat bepaalde muizenstammen een 
sekse-afhankelijk metabolisme van bet barbituraat hexobarbital vertonen. 
Mannelijke muizen vertoonden een langduriger narkose na toediening van hexo-
barbital dan vrouwelijke, en de in vitro gemeten hydroxyleringssnelheid van 
hexobarbital was in mannetjes lager dan in vrouwtjes, Van deze sekse-
afhankelijkheid is gebruik gemaakt om de relaties tussen substraat-binding 
aan cytochroom P-450 (type I binding, gemeten als verandering van bet 
absorptiespektrum van cytochroom P-450), NADPH-cytochroom P-450 reduktase 
aktiviteit en bet metabolisme van bet substraat te onderzoeken, dit in bet 
licht van de bestaande hypothese, dat de reduktie van bet cytochroom P-450-
substraat kompleks een snelheidsbepalende stap zou kunnen zijn in bet 
metabolisme van farmaka. De type I verbindingen ethylmorfine en hexobarbital 
werden gebruikt als modelsubstraten. 
Vier inleidende hoofdstukken, waaronder een algemene inleiding (I), een 
formulering van doel en opzet van bet onderzoek (II), een overzicht van de 
bestaande kennis omtrent cytochroom P-450-afhankelijke enzym-systemen, toe-
gespitst op de lever (III), en een beschrijving van enkele aspekten van de 
gebruikte methoden (IV), gaan aan het eksperimentele gedeelte vooraf. 
Hoofdstuk V laat zien, dat in levermikrosomen van muizen van de CPB-SE 
stam de demethylering van ethylmorfine, de hoeveelheid cytochroom P-450, de 
type I binding van ethylmorfine en de substraat-geinduceerde versnelling van 
cytochroom P-450 reduktie sekseverschillen vertonen, die worden te niet gedaan 
door testosteron behandeling en kastratie. Een duidelijk verband tussen type I 
binding en reduktase stimulering suggereerde, dat type I binding een weergave 
is van de vorming van een enzym-substraat kompleks, dat vervolgens wordt ge-
reduceerd door NADPH-cytochroom P-450 reduktase. Deze parameters waren echter 
niet duidelijk gerelateerd aan de demethyleringssnelheid, hetgeen vooral 
duidelijk was in de CPB-V s tam. 
In Hoofdstuk VI worden de kinetische konstanten van ethylmorfine demethy-
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lering en type I binding in de CPB-SE en CPB-V 
Km bleken sekse-afhankelijk in de CPB-SE stam. 
stam bestudeerd. Zowel V 
max 
In de V-stam werd alleen een 
als 
zeer klein sekseverschil in Vmax gevonden. De maksimale spektrale interaktie 
(6A ) die in vrouwtjes werd waargenomen, bleek grater te zijn dan die in 
max 
mannetjes in beide stammen, maar in de V-stam was het sekseverschil kleiner 
dan in de SE-stam. De effekten van testosteron behandeling en kastratie 
toonden aan, dat androgenen verantwoordelijk zijn voor de waargenomen sekse-
verschillen door het uitoefenen van het remmende invloed in mannetjes. Muizen 
van de V-stam bleken in mindere mate op androgenen te reageren dan die van 
de SE-stam. 
In de SE-stam bleken de sekseverschillen in 6Amax' reduktase stimulering, 
hoeveelheid cytochroom P-450 en Km te ontstaan tijdens de seksuele ontwikke-
ling, voornamelijk als gevolg van in vrouwtjes optredende veranderingen 
(Hoofdstuk VII). Dit suggereerde, dat in mannetjes dergelijke veranderingen 
door androgenen worden tegengegaan. De sekseverschillen in Vmax en basale 
reduktase aktiviteit hadden een meer permanent karakter. Ret afwezig zijn van 
een verband tussen de totale hoeveelheid cytochroom P-450 en 6~ax duidde op 
een heterogeniteit van het cytochroom P-450: slechts een klein gedeelte van 
het cytochroom P-450 is betrokken bij de binding van ethylmorfine. Ret ont-
breken van een relatie tussen 6Amax en Vmax in vrouwtjes suggereerde, dat de 
vorming van een aantal cytochroom P-450-ethylmorfine kompleksen niet tot 
demethylering leidt. De reduktie van het cytochroom P-450-substraat kompleks 
scheen niet snelheidsbepalend te zijn in de demethylering van ethylmorfine. 
In Hoofdstuk VIII wordt het verband tussen de kinetische konstanten van 
type I binding en metabolisme bestudeerd aan de hand van de optische anti-
paden van hexobarbital. In tegenstelling tot ratten bleken muizen een gelijke 
Ks en Km te vertonen, wat er op wijst, dat de type I plaats het aktief centrum 
is voor de hydroxyleringsreaktie, en dat de reduktie van bet cytochroom P-450-
substraat kompleks snelheidsbepalend is, Deze opvatting werd gesteund door de 
meting van reduktase aktiviteiten. Voorts werd aangetoond, dat de reduktie-
snelheid van het kompleks afhankelijk is van het substraat, wat de mogelijk-
heid openlaat, dat bet snelheidsbepalend karakter van de reduktie stap 
substraat-afhankelijk is. 
In de resterende hoofdstukken wordt de aard van het sekseverschil in type I 
binding van ethylmorfine verder onderzocht. In Hoofdstuk IX wordt de mogelijk-
heid uitgesloten, dat bet sekseverschil in type I binding van ethylmorfine te 
wijten is aan een sekseverschil in de hoeveelheid sterk gebonden endogene 
substraten. De spektrale verandering die door 1-butanol wordt teweeggebracht, 
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en die is toegeschreven aan een verdringing van endogene substraten, bleek de 
resultante te zijn van verschillende gesuperponeerde spektrale komponenten. 
De sekse-afbankelijkbeid van deze spektrale verandering is bet resultaat van 
sekse-afbankelijke type I binding van !-butanol. 
In Hoofdstuk X wordt aangetoond, dat 1-butanol de binding van etbylmorfine 
kompetitief remt. Een tbeoretiscbe beschrijving van de kompetitieve inhibitie 
tussen twee substraten die hetzelfde type spektrale verandering te zien geven, 
wordt gegeven. Een berekeningsmetbode wordt ontwikkeld voor de dissociatie-
konstante van een substraat dat meer dan een type spektrale interaktie ver-
toont. Dit wordt toegelicht aan de hand van ]-butanol. 
Een direkt bewijs voor een heterogeniteit van cytochroom P-450 als oor-
zaak van sekse-afhankelijke type I binding wordt geleverd in Hoofdstuk XI. 
Alprenolol, een S-sympathicolyticum, bleek een type I verbinding te zijn, die 
in mannetjes en vrouwtjes dezelfde mate van spektrale verandering teweegbrengt. 
In mannetjes bezet bet alle ethylmorfine bindings plaatsen, maar in vrouwtjes 
wordt slecbts een gedeelte biervan bezet. 
Een algemene diskussie wordt geboden in Hoofdstuk XII, waarin de rol van 
type I binding en NADPH-cytochroom P-450-reduktase in de demethylering van 
ethylmorfine verder wordt getoetst. De bepaling van NADPH-cytocbrooro P-450 
reduktase aktiviteiten wordt besproken in bet licht van de vraag, in boeverre 
deze verondersteld kunnen worden de reduktie van bet cytochroom P-450-
substraat kompleks te vertegenwoordigen. Hoewel de reduktie van dit kompleks 
niet snelheidsbepalend kan zijn, als men afgaat op de konkrete resultaten, 
kan dit niet worden uitgesloten als een aantal type I kompleksen niet be-
trokken is bij bet metabolisme van bet substraat. Voor dit laatste werd een 
aanwijzing gevonden in Hoofdstuk VII. 
De sekse-afhankelijkbeid van bet cytocbroom P-450 systeem betreft in de 
eerste plaats bet cytochroom P-450 zelf, en komt tot uitdrukking in een 
sekseverschil in de verhouding van de hoeveelheden van verschillende soorten 
cytochroom P-450. Verder onderzoek moet inzicbt bieden in de faktoren die de 
binding van een bepaald (soort) substraat aan een bepaald cytocbroom P-450 
bepalen, en de faktoren die bepalen of de vorming van een cytochroom P-450-
substraat kompleks al of niet leidt tot bet metabolisme van bet substraat. 
Deze informatie kan leiden tot een beter begrip van de interakties tussen 
verschillende farmaka en de relatie tussen chemische struktuur en bio-
transformatie. 
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